Document:

Exhibit 4.17

 

Confidential Treatment Requested by Mediwound Ltd.

	AWARD/CONTRACT	1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700)	RATING	PAGE  OF PAGES	 
	1	2	 
	
2. CONTRACT (Proc. Inst. Ident.) NO.

HHSO100201800023C

	
3. EFFECTIVE DATE

09/30/2018

	4. REQUISITION/PURCHASE REQUEST/PROJECT NO.	 
	5. ISSUED BY                                                              CODE	ASPR-BARDA	6. ADMINISTERED BY (If other than Item 5)                  CODE	ASPR-BARDA02	 
	
 

ASPR-BARDA

200 Independence Ave., S.W.

 Room 640–G

Washington DC 20201

 

 

	
 

US DEPT OF HEALTH & HUMAN SERVICES

ASST SEC OF PREPAREDNESS & RESPONSE

ACQ MANAGEMENT, CONTRACTS, & GRANTS

 O’NEILL HOUSE OFFICE BUILDING

Washington DC 20515

 

	 
	
7. NAME AND ADDRESS OF CONTRACTOR (No., Street, City, Country, State and ZIP Code)

 

MEDIWOUND LTD 1477616

MEDIWOUND LTD            42 HAYARKON

42 HAYARKON

YAVNE      00812

	
8. DELIVERY

 

FOB ORIGIN                   X OTHER (See below)

	 
	
9. DISCOUNT FOR PROMPT PAYMENT

 

 

 

 

	 
	
10. SUBMIT INVOICES

(4 copies unless otherwise specified) TO THE ADDRESS SHOWN IN

	ITEM	 
	CODE    1477616	FACILITY CODE	 
	11. SHIP TO/MARK FOR                                            CODE	 	12. PAYMENT WILL BE MADE BY                             CODE	PSC	 
	 	
PSC

Program Support Center

 7700 Wisconsin Ave

Bethesda MD 20814

 

 

	 
	
13. AUTHORITY FOR USING OTHER THAN FULL AND OPEN COMPETITION:

☐10 U.S.C. 2304 (c) (                      )          ☐41 U.S.C. 253 (c) (                      )

	
14. ACCOUNTING AND APPROPRIATION DATA

See Schedule

	 
	
15A. ITEM NO

	
15B. SUPPLIES/SERVICES

	
15C. QUANTITY

	
15D.

 UNIT

	
15E. UNIT PRICE

	
15F. AMOUNT

	 
	 	
 

Continued

	 	 	 	 	 
	15G. TOTAL AMOUNT OF CONTRACT         	$11,942,818	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

16. TABLE OF CONTENTS

	(X)	SEC.	DESCRIPTION	PAGE(S)	(X)	SEC.	DESCRIPTION	PAGE (S)
	PART I - THE SCHEDULE	PART II - CONTRACT CLAUSES
	 	A	SOLICITATION/CONTRACT FORM	 	 	I	CONTRACT CLAUSES	 
	 	B	SUPPLIES OR SERVICES AND PRICES/COSTS	 	PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACH.
	 	C	DESCRIPTION/SPECS./WORK   STATEMENT	 	 	J	LIST OF ATTACHMENTS	 
	 	D	PACKAGING AND MARKING	 	PART IV - REPRESENTATIONS AND INSTRUCTIONS
	 	E	INSPECTION AND ACCEPTANCE	 	 	K	REPRESENTATIONS, CERTIFICATIONS AND OTHER STATEMENTS OF OFFERORS	 
	 	F	DELIVERIES OR PERFORMANCE	 
	 	G	CONTRACT ADMINISTRATION DATA	 	 	L	INSTRS., CONDS., AND NOTICES TO OFFERORS	 
	 	H	SPECIAL CONTRACT REQUIREMENTS	 	 	M	EVALUATION FACTORS FOR AWARD	 

CONTRACTING OFFICER WILL COMPLETE ITEM 17 (SEALED-BID OR NEGOTIATED PROCUREMENT) OR 18 (SEALED-BID PROCUREMENT) AS APPLICABLE

	 	 	 	 
	
17. ☐CONTRACTOR’ S NEGOTIATED AGREEMENT (Contractor is required to sign this document and return__________copies to issuing office.) Contractor agrees to furnish and deliver all items or perform all the services set forth or otherwise identified above and on any continuation sheets for the consideration stated herein. The rights and obligations of the parties to this contract shall be subject to and governed by the following documents: (a) this award/contract, (b) the solicitation, if any, and (c) such provisions, representations, certifications, and specifications, as are attached or incorporated by reference herein. (Attachments are listed herein.)

	
18. ☒ SEALED-BID AWARD (Contractor is not required to sign this document.) Your bid on Solicitation Number       _________________________________________,

including the additions or changes made by you which additions or changes are set forth in full above, is hereby accepted as to the items listed above and on any continuation sheets. This award consummates the contract which consists of the following documents: (a) the Government’s solicitation and your bid, and (b) this award/contract. No further contractual document is necessary. (Block 18 should be checked only when awarding a sealed-bid contract.)

 

1

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

 

 

	 	 

 

Confidential Treatment Requested by Mediwound Ltd.

	19A. NAME AND TITLE OF SIGNER (Type or print)	
20A. NAME OF CONTRACTING OFFICER

JONATHAN F. GONZALEZ

	
19B. NAME OF CONTRACTOR

 

BY

(Signature of person authorized to sign)                                          

 

	19C. DATE SIGNED	
20B. UNITED STATES OF AMERICA

 

BY

(Signature of the Contracting Officer)                                         

 

	20C. DATE SIGNED
	 	 	 	 

	AUTHORIZED FOR LOCAL REPRODUCTION	 	STANDARD FORM 26 (Rev. 5/2011)
	Previous edition is NOT usable	 	Prescribed by GSA - FAR (48 CFR) 53.214(a)
	 	 	 ☐	☐
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

2

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

CONTRACT TABLE OF CONTENTS

 

	PART I – THE SCHEDULE	4
	 	 
	SECTION B – SUPPLIES OR SERVICES AND PRICE/COSTS	4
	 	 
	SECTION C – DESCRIPTIONS/SPECIFICATIONS/WORK STATEMENT	10
	 	 
	SECTION D – PACKAGING, MARKING, & SHIPPING	13
	 	 
	SECTION E – INSPECTION AND ACCEPTANCE	14
	 	 
	SECTION F – DELIVERIES OR PERFORMANCE	16
	 	 
	SECTION G – CONTRACT ADMINISTRATION DATA	32
	 	 
	SECTION H – SPECIAL CONTRACT REQUIREMENTS	39
	 	 
	PART II – CONTRACT CLAUSES	60
	 	 
	SECTION I – CONTRACT CLAUSES	60
	 	 
	PART III – LIST OF DOCUMENTS, EXHIBITS, AND OTHER ATTACHMENTS	67
	 	 
	SECTION J – LIST OF ATTACHMENTS	67
	 	 
	PART IV – REPRESENTATIONS AND INSTRUCTIONS	66
	 	 
	SECTION K – REPRESENTATIONS, CERTIFICATIONS, AND OTHER STATEMENTS	66

 

3

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

PART I – THE SCHEDULE

 

SECTION B – SUPPLIES OR SERVICES AND PRICES/COSTS 

 

B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

 

The Pandemic and All Hazards Preparedness Act (PAHPA) of 2006 established the Biomedical Advanced Research and Development Authority (BARDA) and was reauthorized under the PAHPA of 2013 to support development and acquisition of medical countermeasure (MCMs) to prevent or treat the medical consequences of chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza (PI), and emerging infectious diseases (EID). These MCMs include vaccines, therapeutics, diagnostics, and medical devices. Additionally, BARDA is entrusted to foster innovation of technologies that enable better manufacturing, testing, and utilization of these medical countermeasures.

 

This contract is for a potential 8-year product development plan to achieve the licensing of NexoBrid as a MCM for Sulfur Mustard (SM) injury. The existing BARDA MCM development program for NexoBrid for thermal burns has generated significant nonclinical and human clinical safety data. These data, as well as the manufacturing information for a currently approved human therapeutic commercial indication can be leveraged to obtain approval of the MCM indication for NexoBrid under the FDA Animal Rule.

 

MediWound considers NexoBrid as a proposed removal agent for tissue damaged by sulfur mustard which addresses unmet needs by being as effective as surgery, yet selective, non-invasive, and not pre-treatment diagnosis dependent. The use of NexoBrid resolves the first stage of wound bed preparation in the comprehensive wound care process. Additionally, NexoBrid facilitates the second stage of non-surgical or surgical wound closure by enabling earlier, direct visual assessment of the wound bed and by reducing surgical needs (e.g., extent of surgical excisional debridement) which is an integral, substantial, demanding part of the surgical wound closure process.

 

Work performed during the base period and during each option period constitutes an independent, non-severable discrete work segment that cannot be subdivided for separate performance and is necessary to support R&D tasks related to the development of the product/service. Each work segment constitutes an entire job (discrete requirement) which shall contain multiple R&D activities that when reviewed in total shall constitute a non-severable requirement. Each non-severable work segment will be fully funded from an appropriation source that is current at the time the work under such segment will begin.

 

The Government has determined a Bona Fide Need for each non-severable discrete work segment which will conclude upon the completion of a defined task or defined tasks that provide(s) independent merit and value to the Government. The Contractor’s success in completing the required tasks under the work segments must be demonstrated through the Deliverables and Milestones specified under Article F of this contract. As set forth in the Contract WBS Milestones/Deliverables and Technical Deliverables chart under Article F of this contract, the GO/NO GO Contract Milestones and Decision Gates will constitute the basis for the Government’s decision, at its sole discretion, to exercise any follow-on option period(s).

 

The base and option period segments under Contract Line Item (CLIN) 0001 are event driven work segments rather than time driven CLINs. The funds for each independent, non-severable discrete work segment (requirement), regardless of duration, shall only be used for the scope of work covered in each discrete work segment (i.e., the base period work segment and each option work segment). The periods of performance listed under each of the CLINs under Article B.2 and Article B.3 below are estimated time periods. Those individual time periods may be extended to complete the tasks required under each work segment. It is possible that more than one option period (requirement), may be awarded at one time and that individual CLINs may overlap and/or proceed concurrently.

 

4

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

B.2 BASE PERIOD

 

		1.	[***].

 

		2.	[***].

 

	 	3.	[***] $11,942,818. The Government will not be responsible for any contractor-incurred costs that exceed this amount unless a modification to the contract that expressly increases this amount is signed by the Contracting Officer.

 

	 	4.	The Contractor shall maintain records of all contract costs and such records shall be subject to FAR 52.215-2 (Oct 2010), Audit and Records – Negotiation, and Health and Human Services Acquisition Regulation (HHSAR) 352.242-74, Final Decisions on Audit Findings, incorporated by reference into the contract in SECTION I.

 

	 	5.	[***].

 

	CLIN	Period of 

 Performance	Supplies/Services	
Estimated  

Cost

	Fixed Fee 	Estimated  

 Total 
	0001	
[***]

	
Select method of SM exposure for wound depth (mini-pig), Efficacy studies (mini-pig), and IND submission and regulatory support.

	[***]	[***]	$11,942,818

 

		6.	The Government shall withhold payment of fee as necessary to protect the Government’s interest as set forth in Federal Acquisition Regulation (FAR) 52.216-8 Fixed Fee (June 2011).

 

B.3. OPTION PERIODS

 

B.3.1 COST REIMBURSMENT OPTIONS

 

		a.	The contract includes optional, cost plus fixed-fee reimbursement CLINs 0002, 0003, 0004, and 0005. The Government may exercise Option Periods in accordance with FAR 52.217-9 Option to Extend the Term of the Contract (March 2000), as set forth in Section I of the contract.

 

		b.	Unless the government exercises its option pursuant to the option clause contained in ARTICLE I.2, the contract consists only of the Base Work segment specified in the Statement of Work as defined in SECTONS C and F, for the price set forth in ARTICLE B.2 of the contract.

 

		c.	The Government may modify the contract unilaterally and require the contractor to provide supplies and services for Option Periods listed below, in accordance with FAR 52.217-9.

 

		d.	If the Government decides to exercise an option(s), the Government will provide the Contractor a preliminary written notice of its intent as referenced in the clause. Specific information regarding the time frame for this notice is set forth in the OPTION CLAUSE Article in SECTION G of this contract. The estimated cost of the contract will be increased as set forth below:

 

	Option	CLIN	 Period of 

 Performance	
Supplies/Services 

	Estimated 

  Cost	Fixed Fee 	
Estimated

 Total 

	1	0002	[***]	Option 1 Period:  Mini-pig pivotal study and BLA Submission	[***]	[***]	[***]
	2	0003	[***]	
Option 2 Period: Hairless guinea pig POC Animal Study and regulatory support.

 

	[***]	[***]	[***]
	3	0004	[***]	Option 3 Period:  Hairless Guinea Pig Pivotal Study and additional BLA update and regulatory support.	[***]	[***]	[***]
	4	0005	[***]	Option 4 Period:  [***]	[***]	[***]	[***]
	 	 	TOTALS	Only option years	[***]	[***]	[***]
	 	 	TOTALS 	Base + options	[***]	[***]	[***]

 

5

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

B.4. LIMITATIONS APPLICABLE TO DIRECT COSTS

 

		a.	Items Unallowable Unless Otherwise Provided

 

Notwithstanding the clauses and unless authorized in writing by the Contracting Officer or set forth in the Statement of Work, the cost of the following items or activities shall be unallowable as direct costs:

 

		1)	Acquisition, by purchase or lease, of any interest in real property;

 

		2)	Special rearrangement or alteration of facilities;

 

		3)	Accountable Government Property (see the HHS Contracting Guide for Control for Government Property incorporated by Section G.10. of this contract);

 

			Note: this includes the lease or purchase of any item of general purpose office furniture or office equipment regardless of dollar value.

 

		4)	Purchase or lease of scientific instruments or equipment over $10,000 except for instruments and equipment specifically included in the Statement of Work;

 

		5)	Travel to attend general scientific meetings/conferences;

 

		6)	Printing Costs (as defined in the Government Printing and Binding Regulations);

 

		7)	Overtime (premium) compensation

 

		8)	Entering into certain types of subcontracting arrangements (See Section B.5(c) for specific obligations). Note that most consulting agreements require CO’s written consent.

 

		9)	Foreign Travel (see Subparagraph b.3);

 

		10)	Patient care costs (see Section J-List of Attachments);

 

		11)	Light Refreshment and Meal Expenditures - Requests to use contract funds to provide light refreshments and/or meals to either federal or nonfederal employees must be submitted to the Contracting Officer’s Representative (COR), with a copy to the Contracting Officer, at least six (6) weeks in advance of the event and are subject to “HHS Policy on Promoting Efficient Spending: Use of Appropriate Funding for Conferences and Meetings, Food and Promotional Items and Printing and Publications.” The request shall contain the following information: (a) name, date, and location of the event at which the light refreshments and/or meals will be provide; (b) a brief description of the purpose of the event; (c) a cost breakdown of the estimated light refreshments and/or meals costs; (d) the number of nonfederal and federal attendees receiving light refreshments and/or meals; and (e) if the event will be held at a government facility.

 

6

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		b.	Travel Costs

 

		1)	Total expenditures for travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance of this contract during the Base Period (CLIN 0001) shall not exceed $39,995 without the prior written approval of the Contracting Officer. The Contractor shall notify the Contracting Officer in writing when travel expenditures have exceeded 80% of the base period travel expenses. Costs must be consistent with Federal Acquisition Regulations (FAR) 52.247-63 – Preference for U.S. Air Flag carriers.

 

		2)	Subject to the annual dollar limitation specified under B.4.b.1. above, the Contactor shall invoice and be reimbursed for all travel costs in accordance with Federal Acquisition Regulation (FAR) 31.2 – Contracts with Commercial Organizations, Sub-Section 31.205- 46, Travel Costs.

 

		3)	If foreign travel is necessary, a Contracting Officer Authorization (COA) will be required. Expenditures for foreign travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance of this contract shall not exceed the amount specified in each approved COA, without the prior written approval of the Contracting Officer.

 

Requests for foreign travel must be submitted at least four weeks in advance and shall contain the following:

 

		●	Meeting(s) and place(s) to be visited, with costs and dates; name(s) and title(s) of Contractor personnel to travel and their functions in the contract project;

		●	Contract purposes to be served by the travel;

		●	How travel of Contractor personnel will benefit and contribute to accomplishing the contract project, or will otherwise justify the expenditure of BARDA contract funds;

		●	How such advantages justify the costs for travel and absence from the project of more than one person if such are suggested; and

		●	What additional functions may be performed by the travelers to accomplish other purposes of the contract and thus further benefit the project.

 

B.5. ADVANCE UNDERSTANDINGS

 

		a.	Person-in-Plant

 

With seven (7) days advance notice to the Contractor in writing from the Contracting Officer, the Government may place a man-in-plant in the Contractor’s or Subcontractor’s facility, who shall be subject to the Contractor’s or Subcontractor’s policies and procedures regarding security and facility access at all times while in the Contractor’s or Subcontractor’s facility. The Government’s representative shall be provided reasonable access, during normal business hours, of the production areas being utilized in performance on the Contract. As determined by federal law, no Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not authorized by law, any information coming to him in the course of employment or official duties, while stationed in a contractor or subcontractor plant.

 

7

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

  An article substantially similar to this Person-in-Plant article shall be incorporated into any subcontract for experimental or manufacturing work.

 

		b.	Security

 

No security plan is required at this point for this effort. It is anticipated that a security waiver will be approved.

 

		c.	Subcontracts

 

Prior written consent from the Contracting Officer in the form of Contracting Officer Authorization (COA) is required for any subcontract that:

 

		●	Is of the cost-reimbursement type and exceeds $150,000; or

		●	Is of the fixed price type and exceeds $150,000 or 5% of the contract, whichever is less.

 

The Contracting Officer shall request appropriate supporting documentation in order to review and determine authorization, pursuant with FAR Clause 52.244-2, Subcontracts. After receiving written consent of the subcontract by the Contracting Officer, the Contractor shall provide a copy of the signed, executed subcontract and consulting agreement to the Contracting Officer within ten (10) calendar days.

 

Note: Consulting services are treated as subcontracts and subject to the ‘consent to subcontract’ provisions set forth in this Section.

 

		d.	Overtime Compensation

 

No overtime (premium) compensation is authorized under the subject contract.

 

		e.	Sharing of contract deliverables within United States Government (USG)

 

In an effort to build a robust medical countermeasure pipeline through increased collaboration, the Government may share technical deliverables with Government entities responsible for Medical Countermeasure Development. In accordance with recommendations from the Public Health Emergency Medical Countermeasure Enterprise Review, agreements established in the Integrated Portfolio Advisory Committee (PAC) Charter, and agreements between BARDA and the Department of Defense, the National Institutes of Health, the Centers for Disease Control, and the Food and Drug Administration, BARDA may share technical deliverables and test results created in the performance of this Contract with colleagues within the Integrated Portfolio. This advance understanding does not authorize the Government to share financial information outside of the United States Government. The Contractor is advised to review the terms of FAR 52.227-14, Rights in Data – General, regarding the government’s rights to deliverables submitted during performance as well as the government’s rights to data contained within those deliverables.

 

8

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		f.	Approval of Human and Animal Protocols

 

The Contractor shall submit all human and animal protocols and human informed consent documents as referenced under this Contract to the COR for review and approval prior to seeking other approvals (Institutional Review Board, Human Use Committee, Institutional Animal Care and Use Committee). The Government requires no fewer than eight (8) business days to perform a review. The Contractor shall take this review time into account and submit protocols as early as possible to avoid delays. The Government’s comments and feedback shall be addressed prior to approval. The COR will review and provide approval of protocols. Human informed consents shall also be submitted and reviewed with any human protocol.

 

		g.	Rights in Data

 

The contract will incorporate the FAR Clause 52.227-14, Rights in Data—General. The Contractor is advised to review the terms of FAR 52.227-14, Rights in Data, regarding the government’s rights to deliverables submitted during performance as well as the government’s rights to data contained within those deliverables.

 

		h.	Invoice Submission during end of Fiscal Year

 

The government will not accept invoices for processing from Sep 6th through Oct 5th because of end of year fiscal requirements. Any invoices received from September 6th through October 5th will be canceled and returned to the Contractor for resubmission beginning on October 6th.

 

9

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

 

C.1. STATEMENT OF WORK 

 

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government as needed to perform the Statement of Work attached to this contract as Attachment 1 (Section J-List of Attachments).

 

C.2. REPORTING REQUIREMENTS 

 

Refer to Section F.2 for specific instructions regarding Reporting Requirements.

 

C.3. PROJECT MEETING CONFERENCE CALLS

 

A conference call between the Contract Officer, the Contracting Officer’s Representative (COR) and designees and the Contractor’s Project Leader/delegate and designees shall occur bi-weekly or as otherwise mutually agreed upon by the Government and the Contractor or determined by the Contracting Officer. During this call the Contractor’s Project Leader/delegate and designees will discuss the activities since the last call, any problems that have arisen and the activities planned until the next call takes place. The Contractor’s Project Leader/delegate may choose to include other key personnel on the conference call to give detailed updates on specific projects or this may be requested by the Contracting Officer’s Representative. Electronic copy of conference call meeting minutes/summaries shall be provided via e-mail to the CO, COR, and uploaded in eRoom by the Contractor within five (5) business days after the conference call is held.

 

C.4. PROJECT MEETINGS  

 

The Contractor shall participate in Project Meetings to coordinate the performance of the contract, as requested by the COR.  These meetings may include face-to-face meetings with BARDA and AMCG in Washington, D.C. and at work sites of the Contractor and its subcontractors. Such meetings may include, but are not limited to, meetings of the Contractor (and subcontractors invited by the Contractor) to discuss study designs, site visits to the Contractor’s and subcontractor’s facilities, and meetings with the Contractor and HHS officials to discuss the technical, regulatory, and ethical aspects of the program. The Contractor must provide data, reports, and presentations to groups of outside experts (subject to appropriate protections for Contractor confidential or proprietary data) and Government personnel as required by the COR in order to facilitate review of contract activities.

 

		a.	Kickoff Meeting

 

The Contractor and Government shall conduct a kickoff meeting within 45 calendar days after contract award to review HHS procedures, processes and expectations. Contractor shall provide an itinerary/agenda no later than 5 business days before meeting. Minutes from the kickoff meeting must be provided within 10 business days of the event.

 

		b.	Quarterly and Ad-Hoc Meetings

 

At the discretion of the CO or COR, the Contractor shall participate in Project Meetings to coordinate the performance of the contract, as requested by the Contracting Officer’s Representative.  These meetings may be conducted via teleconferences or face-to-face meetings in Washington, D.C. or at work sites of the Contractor and its subcontractors. Such meetings may include, but are not limited to, meetings of the Contractor (and subcontractors invited by the Contractor) to discuss study designs, site visits to the Contractor’s and subcontractor’s facilities, and meetings with the Contractor and HHS officials to discuss the technical, regulatory, and ethical aspects of the program. The Contractor must provide data, reports, and presentations to groups of outside experts (subject to appropriate protections for Contractor’s confidential or proprietary data) and Government personnel as required by the Contracting Officer’s Representative, giving reasonable prior notice of such requirement to Contractor, in order to facilitate review of contract activities.

10

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Contractor shall provide itinerary/agenda at least 5 business days in advance of face-to-face meeting.

 

		c.	Face-to-Face Project Review Meetings

 

The Contractor shall, at a time to be determined later, present a comprehensive review of contract progress to date annually in a face-to-face meeting in Washington, DC. The Contractor will be responsible for updating the BARDA program on technical progress under the Statement of Work. Presentation must be delivered seven (7) business days prior to the scheduled meeting.

 

C.5 RISK MANAGEMENT

 

The Contractor shall establish and maintain an active, enterprise-wide risk management system as well as a specific risk management plan that includes the SOPs governing risk management, a description of the risk management activities required to oversee the project across its range of scope, and the processes for reviewing completed risk mitigations. The Contractor shall complete risk management documentation for the program as applicable, such as:

 

		1.	Preliminary hazard analyses as necessary for each product component

		2.	Design, user, and process FMEA plans

		3.	Risk control plans to verify the proposed mitigations

 

C.6 REGULATORY ACTIVITIES

 

The Contractor shall submit to the COR for review and acceptance, pre-submission documents and all proposed regulatory filing documents.

 

The Contractor shall provide the COR the opportunity to review and comment upon any draft documents, including draft pre-submission packages, and meeting requests, to be submitted to the FDA or other regulatory agency. The Contractor shall provide the COR with five (5) business days for review and comments. An acceptable version shall be provided to the COR prior to FDA submission.

 

The Contractor shall provide the COR initial draft minutes and final draft minutes of any - meeting with the FDA and other regulatory agencies.

 

The Contractor shall communicate the dates and times of any meeting with the FDA and other regulatory agencies to the COR and ensure participation for appropriate COR and BARDA SMEs staff to attend the meetings.

 

The Contractor shall forward Standard Operating Procedures (SOPs) upon request from Contracting Officer’s Representative /Contracting Officer.

 

The Contractor shall support FDA audits. Within thirty (30) calendar days of an FDA audit of Contractor or subcontractor facilities, the Contractor shall provide copies of the audit findings, final report, and a plan for addressing areas of nonconformance to FDA regulations and guidance for GLP, GMP or GCP guidelines as identified in the final audit report.

 

11

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

C.7 QUALITY

 

The Contractor shall establish and maintain a Quality Management System with sufficient content to include but not limited to the elements contained in the Code of Federal Regulations Title 21 Part 820.

 

The Contractor shall establish routine internal reviews, documentation, and evidence of the ability to maintain, and adhere to the Code of Federal Regulations Title 21 Part 820.

 

The Contractor shall contract for an independent audit of its system quality system adherence, resolve any issues noted by the auditor, and provide the audit findings and resolutions to the Government.

 

12

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION D – PACKAGING, MARKING, AND SHIPPING

 

All deliverables required under this contract shall be packaged, marked and shipped in accordance with Government specifications and Section F. At a minimum, all deliverables shall be marked with the contract number and Contractor name. The Contractor shall guarantee that all required materials shall be delivered in immediate usable and acceptable condition

 

Unless otherwise specified by the CO, delivery of reports to be furnished to the Government under this contract (including invoices) shall be delivered to the CO and COR electronically along with a concurrent email notification to the CO and COR (as defined in Section F.3. Electronic Submission) summarizing the electronic delivery.

 

13

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION E – INSPECTION AND ACCEPTANCE

 

E.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)

 

This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/FAR/ . HHSAR Clauses at: http://www.hhs.gov/policies/hhsar/subpart352.html.

 

	FAR Clause	Title and Date	 

  

FAR 52.246-3, Inspection of Supplies – Cost-Reimbursement (May 2001)

FAR 52.246-5, Inspection of Services - Cost-Reimbursement (April 1984)

FAR 52.246-8, Inspection of Research and Development – Cost Reimbursement (May 2001)

FAR 52.246-9, Inspection of Research and Development (Short Form) (April 1984)

FAR 52.246-16, Responsibility for Supplies (April 1984)

 

E.2. DESIGNATION OF GOVERNMENT PERSONNEL

 

For the purpose of this Section E, the designated Contracting Officer’s Representative (COR) is the authorized representative of the Contracting Officer. The COR will assist in resolving technical issues that arise during performance. The COR however is not authorized to change any contract terms or authorize any changes in the Statement of Work or modify or extend the period of performance, or authorize reimbursement of any costs incurred during performance.

 

E.3. INSPECTION, ACCEPTANCE AND CONTRACT MONITORING

 

Inspection and acceptance of the product, services, and documentation called for herein shall be accomplished by the Contracting Officer or a duly authorized representative. Delivery, technical inspection and acceptance will be take place at a location designated by the Contracting Officer or at:

 

Office of the Assistant Secretary for Preparedness and Response

Biomedical Advanced Research and Development Authority

O’Neill House Office Building

Washington, DC 20515

 

		a.	Site Visits and Inspections

 

At the discretion of the Government and independent of activities conducted by the Contractor, with 48 hours’ notice to the Contractor, the Government reserves the right to conduct site visits and inspections related to this Contract on an as needed basis during normal business hours, including collection of product samples and intermediates held at the location of the Contractor, or its subcontractor. All costs reasonably incurred by the Contractor and subcontractor for such visit and/or inspection shall be allowable costs subject to the Allowable cost requirements in FAR Subpart 31.2. The Contractor shall coordinate these visits and shall have the opportunity to accompany the Government on any such visits. Under time-sensitive or critical situations, the Government reserves the right to suspend the 48 hour notice to the Contractor. The areas included under the site visit could include, but are not limited to: security, regulatory and quality systems, manufacturing processes and cGMP/GLP/GCP compliance related to activities funded under this Contract.

 

14

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

If the Government, Contractor, or other party identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and provide a report to the Government for review and acceptance:

 

		●	If issues are identified during the audit, the Contractor shall submit a report to the CO and COR within five (5) business days detailing the finding and corrective action(s) of the audit.

		●	COR and CO will review the report and provide a response to the Contractor within ten (10) business days.

		●	Once corrective action is completed, the Contractor will provide a final report to the CO and COR.

 

15

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION F – DELIVERIES OR PERFORMANCE

 

F.1. ESTIMATED PERIOD OF PERFORMANCE

 

The estimated period of performance for this contract shall be consistent with the dates set forth in the Base Period in Section B.2. If the Government exercises the Options Period(s) pursuant to the Option Clause in Section I.3 of the contract, the period of performance shall be increased as shown in the table in Section B.3.

 

F.2. DELIVERABLES

 

Successful performance of the final contract shall be deemed to occur upon completion of performance of the work set forth in the Statement of Work dated 02 September 2018, set forth in Section J - List of Attachments of this contract and upon delivery and acceptance, as required by the Statement of Work, by the COR, of each of the deliverables described in Section C, Section F, and Section J.

 

All deliverables and reporting documents listed within this Section shall be delivered electronically (as defined in Section F.3 Electronic Submission) to the CO, CS, and the COR unless otherwise specified by the CO.

 

Unless otherwise specified by the CO, the deliverables identified in this Section F shall also be delivered electronically to the designated eRoom along with a concurrent email notification sent to the CO, CS, COR, and Alternate COR stating delivery has been made.

 

All paper/hardcopy documents/reports submitted under this contract shall be printed or copied, double-sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in accordance with FAR 4.302(b). Hard copies of deliverables and reports furnished to the Government under the resultant Contract (including invoices) shall be addressed as follows:

 

HHS/ASPR/AMCG:

 

ATTN: Jonathan Gonzalez (Contracting Officer)

U.S. Department of Health & Human Services

Office of the Assistant Secretary for Preparedness and Response

Office of Acquisition Management, Contracts, and Grants (AMCG)

O’Neill House Office Building

Room Number: 22J12

Washington, DC 20515 

Email: Jonathan.Gonzalez@hhs.gov

 

HHS/ASPR/BARDA:

 

ATTN: Efrain E Garcia, Ph.D. (COR)

U.S. Department of Health & Human Services

Office of the Assistant Secretary for Preparedness and Response

Biomedical Advanced Research & Development Authority (BARDA)

O’Neill House Office Building

Room Number: 24E25

Washington, DC 20515

Email: Efrain,garcia@hhs.gov

 

16

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

Contract Data Requirements List (CDRLs)

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	
01

 

	Kickoff Meeting	
The Contractor shall complete a Kickoff meeting after contract award

 

	
● Within 45 calendar days after contract award.  

● Materials: Contractor shall provide itinerary and agenda to CO and COR at least 5 business days in advance of meeting. CO approves and the COR distributes itinerary and agenda within 3 business days. 

● Due out: Contractor provides meeting minutes to CO and COR within 5 business days after the meeting. The CO and COR reviews, comments, and the CO approves minutes within 10 business days of the event. 

	02	Quarterly Meetings	At the discretion of the government the Contractor shall hold recurring teleconference or face-to-face Project Review Meetings up to four per year either in Washington D.C or at work sites of the Contractor or subcontractors. Face-to-face meetings shall alternate between Washington DC and Contractor, sub-contractor sites. The meetings will be used to discuss contract progress in relation to the Program Management deliverables described below as well as study designs, technical, regulatory, and ethical aspects of the program.	
●  Materials: Contractor shall provide itinerary and agenda to CO and COR at least 5 business days in advance of site visit. The COR approves and distributes itinerary and agenda within 3 business days. 

● Due out: Contractor provides meeting minutes to the CO and the COR within 5 business days after the meeting. The CO and COR reviews, comments, and the CO approves minutes within 10 business days.

	03	Biweekly Teleconference Meetings	The Contractor shall participate in teleconferences every two weeks with the CO and the COR to discuss the performance of the contract.	
● Materials: Contractor provides agenda to the CO and COR no later than 2 business days in advance of meeting. The COR approves and distributes agenda prior to meeting. 

● Due out: Contractor provides meeting minutes to the CO and COR within 5 business days following the meeting. The CO and COR reviews, comments, and the COR approves minutes within 10 business days following the meeting. 

 

17

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	
04 (Monthly)

05 (Annual)

 

	Monthly & Annual Technical Progress Reports	
The Monthly and Annual Technical Progress report shall address each of the below items and be cross-referenced to the Work Breakdown Structure (WBS), Statement of Work (SOW), Integrated Master Schedule (IMS), and Contract Performance Report (CPR). 

1. An Executive Summary highlighting the progress, issues and relevant manufacturing, non-clinical, clinical and regulatory activities. The Executive Summary should highlight only critical issues for that reporting period and resolution approach; limited to 2-3 pages.

2. Progress in meeting contract milestones – broken out by subtasks within each milestone, overall project assessment, problems encountered and recommended solutions. The reports shall detail the planned and actual progress during the period covered, explaining occurrences of any differences between the two and the corrective steps. 

3. The reports shall also include a three-month rolling forecast of the key planned activities, referencing the WBS/IMS.

4. A tracking log of progress on regulatory submissions with the FDA number, description of submission, date of submission, status of submission and next steps.

5. Estimated and Actual Expenses.

6. This report shall also contain a narrative or table detailing whether there is a significant discrepancy (>10%) at this time between the % of work completed and the cumulative costs incurred to date. Monthly and actual expenses should be broken down to the appropriate WBS level. This section of the report should also contain estimates for the Subcontractors’ expenses from the previous month if the Subcontractor did not submit a bill in the previous month. If the subcontractor(s) was not working or did not incur any costs in the previous month, then a statement to this effect should be included in this report for those respective subcontractors. 

	
● Due: Monthly Reports shall be submitted on the 25th day of the month after the end of each month with an Annual Report submitted on the 30th calendar day of the final month of each contract year for the previous twelve calendar months.  

● When the 25th or 30th falls on a weekend or a US Holiday, the reports will be due the next business day. 

● Monthly progress reports are not required for the periods when the Annual Report(s) and Final Report are due. The CO and the COR will review the monthly reports and provide feedback within 5 business days of receiving the report. The CO approves acceptance of monthly and annual reports.  

 

18

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	06	Risk Management Plan	The Contractor shall provide a Risk Management Plan that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy will capture how the corrective action will reduce impacts on cost, schedule and performance.	
● Due: Within 90 days of contract award. 

● Due out: Contractor provides updated Risk Management Plan in Monthly Progress Report. The COR shall provide Contractor with written comments in response submitted plan. Contractor must address, in writing, all commercially reasonable concerns raised by the COR within 20 business days of Contractor’s receipt of COR’s concerns for CO approval.  

	07	Deviation Notification and Mitigation Strategy	Process for changing IMS activities associated with cost and schedule as baselined at the PMBR. Contractor shall notify BARDA of significant changes the IMS defined as increases in cost above 5% or schedule slippage of more than 30 days, which would require a PoP extension. Contractor shall provide a high-level management strategy for risk mitigation.	
● Due: As needed.

	08	Go/No-Go Decision Gate Presentation	Contractor shall provide a presentation detailing technical progress made towards completion of Go/No-Go decision gate milestones following a prescribed template provided by BARDA prior to the In-Process Review (IPR).	
● Materials: Contractor shall provide presentation materials to the CO and COR 10 business days prior to the IPR. Contractor shall submit written justification of progress towards satisfying Go/No-Go criteria. After reviewing, the CO and COR will provide a written response within 10 business days. 

	
09

 

	
Incident Report

 

	
Contractor shall communicate and document all critical programmatic concerns, risks, or potential risks with the CO and COR.

 

	
● Due: Within 48 hours of activity or incident or within 24 hours for a security activity or incident via email or telephone, with written follow-up to the CO and COR. Additional updates due within 48 hours of additional developments. 

● Due out: Contractor shall submit, within 5 business days, a Corrective Action Plan (if deemed necessary by either party) to address any potential issues. If corrective action is deemed necessary, Contractor must address in writing, its consideration of concerns raised by the CO, within 5 business days of receiving such concerns in writing. 

 

19

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	10	
Draft and Final Reports for Clinical,Non-Clinical, and Human Factors Studies 

(if applicable)

 

	Contractor shall provide Draft and Final Clinical/Non-Clinical and Human Factors Study Reports to the CO and COR for review and comment.	
● Draft - within 45 calendar days after completion of analysis and at least 15 business days prior to submission to FDA. Subcontractor prepared reports received by the Contractor shall be submitted to the CO and COR for review and comment no later than 5 business days after receipt by Contractor. The CO shall provide written comments to the Draft Final Report for Clinical and Non-Clinical Studies within 15 business days after the submission. 

● Final - due 30 calendar days after receiving comments on the Draft Final Report for Clinical and Non-Clinical Studies. If corrective action is recommended, Contractor must address, in writing, all reasonable concerns raised by the CO in writing. Contractor shall consider revising reports to address CO’s recommendations prior to FDA submission. 

● Final FDA submissions shall be provided to the CO and COR concurrently or no later than 5 business days after submission to the FDA. 

	11	Standard Operating Procedures	The Contractor shall make internal and, to the extent possible, subcontractor Standard Operating Procedures (SOPs) available for review electronically.	Upon request from the CO.
	12	FDA Correspondence	The Contractor shall memorialize any correspondence between Contractor and FDA and submit to the CO and COR. All documents shall be duly marked as either “Draft” or “Final”.	
● Due: Contractor shall provide written summary of any FDA correspondence within 5 business days of correspondence.

 

20

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	13	FDA Meetings	The Contractor shall forward the dates and times of any meeting with the FDA to the CO and COR and make arrangements for appropriate Government staff to attend the FDA meetings. Government staff shall include up to a maximum of four people (COR, CO and up to 2 subject matter experts).	
● Contractor shall schedule upcoming FDA meetings, so at a minimum the CO, COR, and RQA persons from BARDA can attend. Additionally, a pre-meeting needs to be held with BARDA to review slides and discuss meeting strategies.  

● Contractor shall notify the CO and COR of upcoming FDA meeting within 24 hours of scheduling. 

● The Contractor shall forward initial Contractor and FDA-issued draft minutes and final minutes of any meeting with the FDA to the CO and COR within 5 business days of receipt. All documents shall be duly marked as either “Draft” or “Final”. 

	14	FDA Submissions	The Contractor shall provide the CO and COR the opportunity to review and comment upon all draft submissions before submission to the FDA. Contractor shall provide the CO and COR with an electronic copy of the final FDA submission. All documents shall be duly marked as either “Draft” or “Final”.	
● Due: Contractor shall submit draft FDA submissions to the CO and COR at least 15 business days prior to FDA submission. The CO and COR will provide feedback to Contractor within 10 business days of receipt. 

● Due out: If corrective action is recommended, the Contractor must address, in writing, its consideration of all concerns raised by the CO.  

● The Contractor shall consider revising their documents to address CO’s concerns and/or recommendations prior to FDA submission. 

● Final FDA submissions shall be submitted to the CO and COR concurrently or no later than 5 calendar day of its submission to CDER. 

	15	FDA Audits	In the event of an FDA inspection which occurs as a result of this contract and for the product, or for any other FDA inspection that has the reasonable potential to impact the performance of this contract, the Contractor shall provide the Government with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR). The Contractor shall provide the COR and CO with copies of the plan for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines as identified in the audit report, status updates during the plans execution and a copy of all final responses to the FDA. The Contractor shall also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or for this product. The Contractor shall make arrangements for BARDA representative(s) to be present during the final debrief by the regulatory inspector.	
● Contractor shall notify the CO and COR within 10 business days of a scheduled FDA audit or within 24 hours of an ad hoc site visit/audit if the FDA does not provide advanced notice. 

● Contractor shall provide copies of any FDA audit report received from subcontractors that occur as a result of this contract or for this product within 5 business days of receiving correspondence from the FDA or third party. 

● Within 10 business days of audit report, Contractor shall provide CO with a plan for addressing areas of nonconformance, if any are identified.  

 

21

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	16	QA Audit Reports	The COR reserves the right to participate in QA audits. Upon completion of the audit/site visit the Contractor shall provide a report capturing the findings, results and next steps in proceeding with the subcontractor. If action is requested of the subcontractor, detailed concerns for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to the CO and COR. The Contractor shall provide responses from the subcontractors to address these concerns and plans for corrective action execution.	
● Contractor shall notify the CO and COR 10 days in advance of upcoming, ongoing, or recent audits/site visits of subcontractors as part of weekly communications. 

● Contractor shall notify the CO and COR within 5 business days of report completion. 

	17	BARDA Audit	Contractor shall accommodate periodic or ad hoc site visits by the CO and COR. If the CO, COR, Contractor, or other parties identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and provide a report to the CO and COR.	
● If issues are identified during the audit, Contractor shall submit a report to the CO and COR detailing the finding and corrective action(s) within 10 business days of the audit.  

● Due out: The CO and COR will review the report and provide a response to the Contractor with 10 business days. Once corrective action is completed, the Contractor will provide a final report to the CO and COR. 

	18	Technical Documents	Upon request, Contractor shall provide CO and COR with deliverables from the following contract funded activities: process Development Reports, Assay Qualification Plan/Report, Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, SOPs, Master Production Records, Certificate of Analysis, Clinical Studies Data or Reports. The CO and COR reserve the right to request within the PoP a non-proprietary technical document for distribution within the Government.	
● Contractor shall provide technical document within 10 business days of COR’s request. Contractor can request additional time on an as needed basis. 

● If corrective action is recommended by the COR, the Contractor must address, in writing, concerns raised by the COR to the COR and CO in writing. 

 

22

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	19	Raw Data or Data Analysis	Contractor shall provide raw data or data analysis to the CO and COR upon request.	
● Contractor shall provide data or data analysis to the CO and COR within 20 business days of request.

	20	Publications	Any manuscript or scientific meeting abstract containing data generated under this contract must be submitted to the CO and COR for review prior to submission.  	
● Contractor must submit all manuscript or scientific meeting abstract to the CO and COR within 30 days for manuscripts and 15 days for abstracts. 

● Contractor must address in writing all concerns raised by the CO and COR in writing.  

● Final submissions shall be submitted to the CO and COR concurrently or no later than five (5) calendar days after its submission. 

	21	Press Releases	Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases.	
● With the exception of ad-hoc press releases required by applicable law or regulations, Contractor shall ensure that the CO and COR has received and approved an advanced copy of any draft press release to this contract not less than 2 business days prior to the issuance of the press release. The CO shall reply with comments within 1 business day of receipt of the draft press release. Should no comments be forthcoming from the CO by end of the 1st business day, Contractor will be permitted to issue the press release 

● If corrective action is required, the Contractor agrees to accurately and factually represent the work conducted under this contract in all press releases.  

●  Any final press releases shall be submitted to the CO and COR no later than 1 (one) calendar day prior to its release.  

	22	
Integrated Master Schedule (IMS)

 

	
The Contractor shall provide an IMS including WBS, critical path milestones, and Earned Value Management Plan.

 

	
● Due: Contractor shall provide the draft IMS within 90 days of contract award with final due 8 months after award and updated monthly as part of the Monthly Progress Report. 

● Contractor must address, in writing, all concerns raised by the COR in writing and provide response to the CO and COR.  

 

23

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	23	Draft and Final Technical Progress Report	
A Draft Final Technical Progress Report containing a summation of the work performed and the results obtained for the entire contract PoP. The draft report shall be duly marked as ‘Draft’.

 

The Final Technical Progress Report incorporating feedback received from the CO and COR and containing a summation of the work performed and the results obtained for the entire contract PoP. The final report shall document the results of the entire contract. This report shall be in sufficient detail to fully describe the progress achieved under all milestones. The final report shall be duly marked as ‘Final’.

 

	
● Due: Contractor shall provide a draft Technical Progress Report 75 calendar days before the end of the PoP and the Final Technical Progress Report on or before the completion date of the PoP. 

● Subcontractor prepared reports received by the Contractor shall be submitted to the CO and COR for review and comment no later than 5 business days after receipt by the Contractor. 

● Due out: the CO shall provide feedback on draft report within 15 calendar days of receipt, which the Contractor shall consider incorporating into the Final Report. 

● Contractor shall submit, with the Final Technical Progress Report, a summary (not to exceed 200 words) of salient results achieved during the performance of the contract.  

	
24

 

	
Draft and Final Study Protocols

 

	
Contractor shall provide all Draft and Final Study Protocols to the COR for evaluation. (The CO and COR reserves the right to request within the period of performance a non-proprietary Study Protocol for distribution within the Government

 

	
● The Contractor will submit all proposed protocols to the CO and COR at least 10 business days prior to study start. If corrective action is required, the Contractor must address in writing all concerns raised by the CO and COR to the satisfaction of the COR before study execution and provide the CO and COR a revised draft protocol that addresses the CO’s comments and requested changes. 

● After receiving the revised Study Protocol that satisfies the COR, the CO will approve the revised Study Protocol and will provide a written approval to the Contractor that provides authorization to the Contractor to execute the specific study. 

● Contractor shall not proceed with any study protocol until the COR gives its approval and the Contractor has provided the CO and COR with a final and approved Study Protocol. 

 

24

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CDRL#	Deliverable	Description	Reporting Procedures and Due Dates
	
25

 

	
Clinical Study Status Update (if applicable)

 

	
Contractor shall provide COR with a status update of clinical studies that are actively enrolling patients to include by study site: cumulative enrollment; new enrollments; screen failures; patients dropped from study; AE and SAEs; activation or inactivation of study sites; investigator appointments or changes; and status of IRB/IEC review/approval/renewal. Contractor will provide proposed format for the COR’s review and approval.

 

	
● Update will be submitted by e-mail or other electronic format to be provided by the COR by the end of the 25th business day of each new month. 

● When the 25th falls on a weekend or US Holiday, the update will be due the next business day. 

● Updates, to the extent they are available, will be presented during biweekly teleconferences. 

● If no changes have occurred since the prior update only a simple statement that there is no new data is required. 

  

NOTE: Pursuant to the Trade Secrets Act, 18 U.S.C. § 1905, no Government personnel shall publish or, disclose to any non-Government entity any Contractor data marked according to FAR 52.227-14 that qualifies as trade secrets or other confidential information unless permitted to do so by law or regulation.

 

GO/NO GO Milestones and Technical Deliverables

 

	Milestone	Go Criteria	No-Go Criteria	WBS # 	Due Date
	Initiate Option 1 CLIN 0002:  (Pivotal efficacy studies in mini pigs and BLA submission)
	POC Efficacy Study: Mini-Pig (Gottingen)	
Efficacy demonstrated in POC studies in minipigs.

 

	Efficacy was not demonstrated in POC studies in minipigs.	
1.3.2.4

 

	[***]
	End of Phase 2 Meeting with FDA	FDA accepts minipigs as valid model for Animal Rule approval.	FDA does not accept minipigs as valid model for Animal Rule approval.	1.5.1.4	[***]
	Initiate Option 2 CLIN 0003: (Proof of Concept Studies in Hairless Guinea Pig Model (POC))
	POC Efficacy Study: Mini-Pig (Gottingen)	
Efficacy demonstrated in POC studies in minipigs.

 

	Efficacy was not demonstrated in POC studies in minipigs.	
1.3.2.4

 

	[***]
	End of Phase 2 Meeting with FDA	FDA requires the hairless guinea pig model in addition to the minipig model.	FDA does not require an extra model.	1.5.1.4	[***]
	Initiate Option 3 CLIN 0004:  (Pivotal Efficacy Study in Hairless guinea pig, BLA Submission update).
	POC Efficacy Study: Hairless guinea pig	Efficacy demonstrated in hairless guinea pig model.	Failure to demonstrate efficacy in the hairless guinea pig model.	3.3.2.3	[***]
	Initiate Option 4 CLIN 0005: ([***])
	[***]	[***] 	Failure to demonstrate efficacy in minipigs 	1.3.2.1	[***]
	[***]	
[***] 

	Failure to demonstrate efficacy in minipigs 	1.3.2.2	[***]

 

25

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	CLIN / Deliverable	Deliverable	Due Date
	CLIN 0001	Base Period	[***]
	1	Integrated Product Development Plan (IPDP)	[***]
	2	Base Period Subcontractor Management Plan	[***]
	3	Risk mitigation plan 	[***]
	4	EVMS implementation plan and first monthly report	[***]
	5	[***]	[***]
	6	[***]	[***]
	7	PIND and other RA Meetings/ requests for review at each development milestone.	[***]
	8	Bioanalytical Methods Development: Mini-Pig (Gottingen)	[***]
	9	IND preparation and submission 	[***]
	10	[***]	[***]
	11	PK Studies: Mini-Pig (Gottingen)	[***]
	12	[***]	[***]
	13	[***]	[***]
	14	[***]	[***]
	15	POC Efficacy Study: Mini-Pig (Gottingen)	[***]
	16	End of Phase 2 Meeting	[***]
	CLIN 0002	Option One	[***]
	1	Pre-BLA gap analysis by SMEs.	[***]
	2	[***]	[***]
	3	[***]	[***]
	4	Pivotal Efficacy Studies: Mini-Pig (Gottingen)	[***]
	5	Pre-BLA meeting	[***]
	6	Plan for MCI Support	[***]
	7	Preparation and Submission of BLA	[***]
	CLIN 0003	Option Two	[***]
	1	[***]	[***]
	2	[***]	[***]
	3	Bioanalytical Methods Development: Hairless guinea pig	[***]
	4	PK Studies: Hairless guinea pig	[***]
	5	[***]	[***]
	6	POC Efficacy Study: Hairless guinea pig	[***]
	7	End of Phase 2 Meeting	[***]
	CLIN 0004	Option Three	[***]
	1	Pivotal Efficacy Study: Hairless guinea pig	[***]
	2	Regulatory - Gap Analysis	[***]
	3	Pre-BLA Meeting	[***]
	4	[***]	[***]
	5	Submit BLA. Respond to FDA feedback and update BLA as needed (additional updates for second animal model)	[***]
	CLIN 0005	Option Four	[***]
	1	[***]	[***]
	2	[***]	[***]
	3	[***]	[***]

 

26

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Detailed Description of Select Contract Deliverables

 

		A.	Monthly and Annual Progress Reports

 

In addition to those reports required by the other terms of this contract, the Contractor shall prepare and submit the following reports in the manner stated below and in accordance with this Section F of this contract, and in the Statement of Work, attached to this contract (see Section J-List of Attachments).

 

		i.	Monthly Progress Report

 

This report shall include a description of the activities during the reporting period, and the activities planned for the ensuing reporting period. The first reporting period consists of the first full month of performance plus any fractional part of the initial month. Thereafter, the reporting period shall consist of each calendar month.

 

The Contractor shall submit a Monthly Progress Report according to the dates set forth in the summary table (“Summary of Contract Deliverables”) under this Section. The progress report shall conform to the requirements set forth in the Deliverables Chart in Section F of this contract.

 

The format should include:

 

		●	A cover page that includes the contract number and title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and e-mail address; and the date of submission; 

		●	SECTION I – EXECUTIVE SUMMARY

		●	SECTION II - PROGRESS

		●	SECTION II Part A: OVERALL PROGRESS - A description of overall progress. 

		●	SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE - A description of all meetings, conference calls, etc. that have taken place during the reporting period. Include progress on administration and management issues (e.g., evaluating, and managing subcontractor performance, and personnel changes).

		●	SECTION II Part C: TECHNICAL PROGRESS - For each activity related to Gantt chart, document the results of work completed and cost incurred during the period covered in relation to proposed progress, effort and budget. The report shall be in sufficient detail to explain comprehensively the results achieved. The description shall include pertinent data and/or graphs in sufficient detail to explain any significant results achieved and preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the contract. The report shall include a description of problems encountered and proposed corrective action; differences between planned and actual progress, why the differences have occurred and what corrective actions are planned; preliminary conclusions resulting from analysis and scientific evaluation of data accumulated to date under the project.

		●	SECTION II Part D: PROPOSED WORK - A summary of work proposed related to Gantt chart for the next reporting period and preprints/reprints of papers and abstracts. 

		●	SECTION III: Estimated and Actual Expenses.

a. This Section of the report shall contain a narrative or table detailing whether there is a significant discrepancy (>10%) at this time between the % of work completed and the cumulative costs incurred to date. Monthly and actual expenses should be broken down to the appropriate WBS level. 

b. This Section of the report should also contain estimates for the Subcontractors’ expenses from the previous month if the Subcontractor did not submit a bill in the previous month. If the subcontractor(s) was not working or did not incur any costs in the previous month, then a statement to this effect should be included in this report for those respective subcontractors. 

 

27

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

A Monthly Progress Report will not be required in the same month that the Annual Progress Report is submitted.

 

		ii.	Annual Progress Report

 

This report shall include a summation of the results of the entire contract work for the period covered. Monthly Progress Reports shall not be submitted in the same month when an Annual Progress Report is due. Furthermore, an Annual Progress Report will not be required for the period when the Final Report is due. The first Annual Progress Report shall be submitted in accordance with the date set forth in the table (“Summary of Contract Deliverables”) under Section F.2. of this contract. The progress report shall conform to the requirements set forth in the Deliverables Chart in Section F of this contract.

 

Each Annual Progress Report shall include:

 

		●	A Cover page that includes the contract number and title; the type of report and period that it covers; the Contractor’s name, address, telephone number, fax number, and email address; and the date of submission;

		●	SECTION I: EXECUTIVE SUMMARY - A brief overview of the work completed, and the major accomplishments achieved during the reporting period.

		●	SECTION II: PROGRESS

		●	SECTION II Part A: OVERALL PROGRESS - A description of overall progress.

		●	SECTION II Part B: MANAGEMENT AND ADMINISTRATIVE UPDATE -

A high level summary of critical meetings, etc. that have taken place during the reporting period. Include progress on administration and management to critical factors of the project (e.g. regulatory compliance

audits and key personnel changes).

		●	SECTION II Part C: TECHNICAL PROGRESS - A detailed description of the work performed structured to follow the activities and decision gates outlined at the Integrated Baseline Review and as described in the Integrated Master Schedule. The Report should include a description of any problems (technical or financial) that occurred or were identified during the reporting period, and how these problems were resolved.

		●	SECTION II Part D: PROPOSED WORK - A summary of work proposed for the next year period to include an updated Gantt Chart.

 

Contractor also should include the following in the Annual Progress Report:

 

		1.	Copies of manuscripts (published and unpublished), abstracts, and any protocols or methods developed specifically under the contract during the reporting period; and

		2.	A summary of any Subject Inventions per the requirements under FAR Clause 52.227-11.

 

28

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		iii.	Draft Final Report and Final Report

 

These reports are to include a summation of the work performed and results obtained for the entire contract period of performance. This report shall be in sufficient detail to describe comprehensively the results achieved. The Draft Final Report and Final Report shall be submitted in accordance with the Deliverables Chart in Section F of the contract. An Annual Progress Report will not be required for the period when the Final Report is due. The Draft Final Report and the Final Report shall be submitted in accordance with the dates set forth in the table (“Summary of Contract Deliverables”) under SECTION F.2. of this contract. The report shall conform to the following format:

 

		1.	Cover page to include the contract number, contract title, performance period covered, Contractor’s name and address, telephone number, fax number, email address and submission date.

		2.	SECTION I: EXECUTIVE SUMMARY - Summarize the purpose and scope of the contract effort including a summary of the major accomplishments relative to the specific activities set forth in the Statement of Work.

		3.	SECTION II: RESULTS - A detailed description of the work performed related to WBS and Gantt chart, the results obtained, and the impact of the results on the scientific and/or public health community including a listing of all manuscripts (published and in preparation) and abstracts presented during the entire period of performance and a summary of all inventions.

 

Draft Final Report: The Contractor is required to submit the Draft Final Report to the Contracting Officer’s Representative and Contracting Officer. The Contracting Officer’s Representative and Contracting Officer will review the Draft Final Report and provide the Contractor with comments in accordance with the dates set forth in Section F.2. of the contract.

 

Final Report: The Contractor will deliver the final version of the Final Report on or before the completion date of the contract. The final version shall include or address the COR’s and CO’s written comments on the draft report. Final Report shall be submitted on or before the completion date of the contract.

 

		iv.	Summary of Salient Results

 

The Contractor shall submit, with the Final Report, a summary of salient results achieved during the performance of the contract.

 

		v.	Audit Reports

 

Within thirty (30) calendar days of an audit related to conformance to FDA regulations and guidance, including adherence to GLP, GMP, GCP guidelines, the Contractor shall provide copies of the audit report (so long as received from the FDA) and a plan for addressing areas of nonconformance to FDA regulations and guidelines for GLP, GMP, or GCP guidelines as identified in the final audit report and as related to activities funded under this contract.

 

		vi.	Periodic Document Review

 

Upon request, Contractor shall provide CO and COR with the following contract funded documents as specified below but not limited to: Process Development Reports; Assay Qualification Plan/Report, Assay Validation Plan/Report, Assay Technology Transfer Report, Batch Records, Contractor/Subcontractor Standard Operating Procedures (SOP’s), Master Production Records, Certificate of Analysis, Clinical Studies Data or Reports. The CO and COR reserve the right to request within the Period of Performance a non-proprietary technical document for distribution within the Government. Contractor shall provide technical document within 10 business days of CO or COR request. Contractor can request additional time on an as needed basis. If edits are recommended, the Contractor must address, in writing, concerns raised by BARDA in writing.

 

29

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		vii.	Risk Management Plan

 

The Contractor shall provide a Risk Management Plan that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy will capture how the corrective action will reduce impacts on cost, schedule and performance. 

		●	Due within 180 days of contract award

		●	Contractor provides updated Risk Management Plan in Monthly Progress Report

		●	The COR shall provide Contractor with a written list of concerns in response plan submitted

 

Contractor must address, in writing, all concerns raised by COR within 20 business days of Contractor’s receipt of COR’s concerns.

 

		B.	Deliverables Arising from FDA Correspondence

 

		i.	FDA Meetings

 

The Contractor shall forward the dates and times of any meeting with the FDA to BARDA and make arrangements for appropriate BARDA staff to attend the FDA meetings. BARDA staff shall include up to a maximum of four people (COR, CO and up to 2 subject matter experts).

 

		●	Contractor shall notify BARDA of upcoming FDA meeting within 24 hours of scheduling.

		●	The Contractor shall forward initial Contractor and FDA-issued draft minutes and final minutes of any meeting with the FDA to the CO and COR within 5 business days of receipt. All documents shall be duly marked as either “Draft” or “Final.”

 

		ii.	FDA Submissions

 

The Contractor shall provide the COR all documents submitted to the FDA. 

Contractor shall provide the COR with an electronic copy of the final FDA submission. All documents shall be duly marked as either “Draft” or “Final.”

 

		●	If draft documents are submitted to the COR for review, the COR will provide feedback to Contractor within 10 business days of receipt.

		●	If BARDA reviews draft documents, the Contractor shall revise their documents to address BARDA’s written concerns and/or recommendations prior to FDA submission.

		●	Final FDA submissions shall be submitted to the CO and COR concurrently or no later than 5 calendar days of their submission to FDA.

 

30

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		iii.	FDA Audits

 

In the event of an FDA inspection which occurs as a result of this contract and for the product, or for any other FDA inspection that has the reasonable potential to impact the performance of this contract, the Contractor shall provide the CO and COR with an exact copy (non-redacted) of the FDA Form 483 and the Establishment Inspection Report (EIR) within five (5) business days after the Contractors receipt of those documents. The Contractor shall provide the COR and CO with copies of the plan for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines as identified in the audit report, status updates during the plans execution and a copy of all final responses to the FDA. The Contractor shall also provide redacted copies of any FDA audits received from subcontractors that occur as a result of this contract or for this product. The Contractor shall make arrangements for BARDA representative(s) to be present during the final debrief by the regulatory inspector.

 

		●	Contractor shall notify CO and COR within 10 business days of a scheduled FDA audit or within 24 hours of an ad hoc site visit/audit if the FDA does not provide advanced notice.

		●	Contractor shall provide copies of any FDA audit report received from subcontractors that occur as a result of this contract or for this product within 5 business days of receiving correspondence from the FDA, Subcontractor, or third party.

		●	Within 15 business days of audit report, Contractor shall provide CO with a plan for addressing areas of nonconformance, if any are identified.

 

		iv.	Other FDA Correspondence

 

The Contractor shall memorialize any correspondence between Contractor and FDA as related to activities funded under this contract and submit to BARDA. All documents shall be duly marked as either “Draft” or “Final.” Contractor shall provide written summary of any FDA correspondence within 5 business days of correspondence.

 

F.3. ELECTRONIC SUBMISSION

 

For electronic delivery, the Contractor shall upload documents to the appropriate folder on https://eroom.bardatools.hhs.gov/eRoom (“eRoom”) which is the designated Government file sharing system. The Government shall provide two contractor representatives authorized log in access to the file share program. Each representative must complete a mandatory training provided by the Government prior to gaining user access. A notification email should be sent to the CO and COR upon electronic delivery of any documents.

 

F.4. SUBJECT INVENTION REPORTING REQUIREMENT

 

All reports and documentation required by FAR Clause 52.227-11, Patent Rights-Ownership by the Contractor, including, but not limited to, the invention disclosure report, the confirmatory license, and the Government support certification, one copy of an annual utilization report, and a copy of the final invention statement, shall be submitted to the Contracting Officer. A final invention statement (see FAR 27.303 (b)(2)(ii)) shall be submitted to the Contracting Officer on the expiration date of the contract.

 

Reports and documentation submitted to the Contracting Officer shall be sent to the address set forth in Section G – Contract Administration Data.

 

If no invention is disclosed or no activity has occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to the Contracting Officer at the address listed above.

 

F.5.       FEDERAL ACQUISITION REGULATION CLAUSES INCORPORATED BY REFERENCE 

 

This contract incorporates the following clause(s) by reference, with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text available. The full text of each clause may be accessed electronically at this address: http://www.acquisition.gov/comp/far/index.html.

 

FAR 52.242-15, Stop Work Order (August 1989), Alternate 1 (April 1984)

 

31

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION G - CONTRACT ADMINISTRATION DATA

 

G.1. CONTRACTING OFFICER

 

The following Contracting Officers (CO) will represent the Government for the purpose of this contract:

 

Jonathan Gonzalez (Contracting Officer) 

U.S. Department of Health & Human Services 

Office of the Assistant Secretary for Preparedness and Response 

Office of Acquisition Management, Contracts, and Grants (AMCG) 

O’Neill House Office Building 

Room Number: 22J12 

Washington, DC 20515 

202-401-4685 (Office) 

Jonathan.Gonzalez@hhs.gov

 

		1)	The Contracting Officer is the only individual who can legally commit the Government to the expenditure of public funds. No person other than the Contracting Officer can make any changes to the terms, conditions, general provisions, or other stipulations of this contract.

		2)	The Contracting Officer is the only person with the authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to (1) direct or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize reimburse to the Contractor of any costs incurred during the performance of this contract; (5) otherwise change any terms and conditions of this contract.

		3)	No information other than that which may be contained in an authorized modification to this contract, duly issued by the Contracting Officer, which may be received from any person employed by the US Government, other otherwise, shall be considered grounds for deviation from any stipulation of this contract.

		4)	The Government may unilaterally change its CO designation, after which it will notify the Contractor in writing of such change.

 

G.2. CONTRACTING OFFICER’S REPRESENTATIVE (COR)

 

The following Contracting Officer’s Representative (COR) will represent the Government for the purpose of this contract:

 

ATTN: Efrain Garcia (COR) 

U.S. Department of Health & Human Services 

Office of the Assistant Secretary for Preparedness and Response 

Biomedical Advanced Research & Development Authority (BARDA) 

O’Neill House Office Building 

Room Number: 

Washington, DC 20515 

Email: Efrain.Garcia@hhs.gov

 

The COR is responsible for:

 

		1)	Monitoring the Contractor’s technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements;

		2)	Assisting the Contracting Officer in interpreting the statement of work and any other technical performance requirements;

		3)	Performing technical evaluation as required;

		4)	Performing technical inspections and acceptances required by this contract; and

		5)	Assisting in the resolution of technical problems encountered during performance. The Government may unilaterally change it’s COR designation, after which it will notify Contractor in writing of such change.

 

32

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

G.3. KEY PERSONNEL

 

Pursuant to the Key Personnel clause incorporated in Section I of this contract, the following individuals are considered to be essential to the work being performed hereunder:

 

	Name	Title
	Gal Cohen	President and CEO
	Sharon Malka	Chief Financial & Operation Officer
	Lior Rosenberg	Chief Medical Officer
	Ety Klinger	Chief R&D Officer
	Andrey Kon	Plant Manager
	Eilon Asculai	VP R&D
	Smadar Nestor	Director Regulatory Affairs
	Nimrod Leuw	Director of QA/QC
	Elanite Caspi	R&D Project Manager

 

The key personnel specified in this contract are considered to be essential to work performance. At least 30 days prior to diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) and qualifications of the individual proposed as a substitute to permit evaluation by the Government of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the contractor or Government. At a minimum, the key personnel should include the project manager, principal investigator, radiation biologist, quality control manager, quality assurance director, regulatory lead, and manufacturing lead.

 

G.4. CONTRACT FINANCIAL REPORT

 

		a.	Financial reports on the attached Financial Report of Individual Project/Contract shall be submitted by the Contractor to the CO with a copy to the COR in accordance with the instructions for completing this form, which accompany the form, in an original and one electronic copy, not later than the 30th business day after the close of the reporting period. The line entries for subdivisions of work and elements of cost (expenditure categories), which shall be reported within the total contract, are discussed in paragraph e., below. Subsequent changes and/or additions in the line entries shall be made in writing.

 

		b.	Unless otherwise stated in the instructions for completing this form, all columns A through J, shall be completed for each report submitted.

 

		c.	The first financial report shall cover the period consisting of the first full three calendar months following the date of the contract, in addition to any fractional part of the initial month. Thereafter, reports will be on a quarterly basis.

 

		d.	The Contracting Officer may require the Contractor to submit detailed support for costs contained in one or more interim financial reports. This clause does not supersede the record retention requirements in FAR Part 4.7.

 

		e.	The listing of expenditure categories to be reported is incorporated as a part of this contract and can be found under Section J entitled, “Financial Report of Individual Project/Contract,”.

 

33

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		f.	Monthly invoices must include the cumulative total expenses to date, adjusted (as applicable) to show any amounts suspended by the Government.

 

		g.	Contractor invoices/financial reports shall conform to the form, format, and content requirements of the instructions for Invoice/Financing requests and Contract Financial Reporting, and be sent to the following points of contact:

 

	CO	COR	PSC
	
Jonathan Gonzalez (Contracting Officer) 

HHS/ASPR/BARDA/CMA 

O’Neill House Office Building 

Room Number: 22J12 

Washington, DC 20515 

Email: Jonathan.Gonzalez@hhs.gov

	
Efrain Garcia 

COR 

HHS/ASPR/BARDA 

O’Neill House Office Building 

Room Number: 

Washington, DC 20515 

202-205-3817 (Office) 

Efrain.Garcia@hhs.gov

 

	
PSC_Invoices@psc.hhs.gov

 

&

 

“e-Room”

 

 

The Contractor agrees to immediately notify the CO in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10%) of the estimated costs for the base period or any option period(s) (See estimated costs under Section B) and the reasons for the variance. These requirements are in addition to the specified requirements of FAR Clause 52.232-20, Limitation of Cost that is incorporated by reference under Section I.1 which states;

 

Limitation of Cost (Apr 1984)

 

●         The parties estimate that performance of this contract, exclusive of any fee, will not cost the Government more than (1) the estimated cost specified in the Schedule or, (2) if this is a cost-sharing contract, the Government’s share of the estimated cost specified in the Schedule. The Contractor agrees to use its best efforts to perform the work specified in the Schedule and all obligations under this contract within the estimated cost, which, if this is a cost-sharing contract, includes both the Government’s and the Contractor’s share of the cost.

 

●         The Contractor shall notify the Contracting Officer in writing whenever it has reason to believe that—

 

●         The costs the Contractor expects to incur under this contract in the next 60 days, when added to all costs previously incurred, will exceed 75 percent of the estimated cost specified in the Schedule; or

 

●         The total cost for the performance of this contract, exclusive of any fee, will be either greater or substantially less than had been previously estimated.

 

●         As part of the notification, the Contractor shall provide the Contracting Officer a revised estimate of the total cost of performing this contract.

 

●        Except as required by other provisions of this contract, specifically citing and stated to be an exception to this clause—

 

34

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

●        The Government is not obligated to reimburse the Contractor for costs incurred in excess of (i) the estimated cost specified in the Schedule or, (ii) if this is a cost-sharing contract, the estimated cost to the Government specified in the Schedule; and

 

●        The Contractor is not obligated to continue performance under this contract (including actions under the Termination clause of this contract) or otherwise incur costs in excess of the estimated cost specified in the Schedule, until the Contracting Officer (i) notifies the Contractor in writing that the estimated cost has been increased and (ii) provides a revised estimated total cost of performing this contract. If this is a cost-sharing contract, the increase shall be allocated in accordance with the formula specified in the Schedule.

 

●        No notice, communication, or representation in any form other than that specified in paragraph (d)(2) of this clause, or from any person other than the Contracting Officer, shall affect this contract’s estimated cost to the Government. In the absence of the specified notice, the Government is not obligated to reimburse the Contractor for any costs in excess of the estimated cost or, if this is a cost-sharing contract, for any costs in excess of the estimated cost to the Government specified in the Schedule, whether those excess costs were incurred during the course of the contract or as a result of termination.

 

●        If the estimated cost specified in the Schedule is increased, any costs the Contractor incurs before the increase that are in excess of the previously estimated cost shall be allowable to the same extent as if incurred afterward, unless the Contracting Officer issues a termination or other notice directing that the increase is solely to cover termination or other specified expenses.

 

●        Change orders shall not be considered an authorization to exceed the estimated cost to the Government specified in the Schedule, unless they contain a statement increasing the estimated cost.

 

●        If this contract is terminated or the estimated cost is not increased, the Government and the Contractor shall negotiate an equitable distribution of all property produced or purchased under the contract, based upon the share of costs incurred by each.

 

		h.	The Contractor shall submit an electronic copy of the payment request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment via e-mail to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF). Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor’s name, contract number, and unique invoice number.

 

		i.	An electronic copy of the payment request shall be uploaded into the designated eRoom (as defined in Section F.3 ELECTRONIC SUBMISSION) and an e-mail notification of the upload will be provided to the CO and COR.

 

		j.	All invoice submissions shall be in accordance with FAR Clause 52.232-25, Prompt Payment (Jan 2017).

 

		k.	Invoices - Cost and Personnel Reporting, and Variances from the Negotiated Budget.

 

The Contractor agrees to provide a detailed breakdown on invoices of the following cost categories:

 

		1.	Direct Labor - List individuals by name, title/position, hourly/annual rate, level of effort (actual hours or % of effort), and amount claimed.

		2.	Fringe Benefits - Cite rate and amount

		3.	Overhead - Cite rate and amount

 

35

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		4.	Materials & Supplies - Include detailed breakdown when total amount is over

$10,000. 

		5.	Travel - Identify travelers, dates, destination, purpose of trip, and total breaking out amounts for transportation (plane, car etc), lodging, M&IE. Cite COA, if appropriate. List separately, domestic travel, general scientific meeting travel, and foreign travel.

		6.	Consultant Fees - Identify individuals, amounts and activities. Cite appropriate COA

		7.	Subcontracts - Attach subcontractor invoice(s). Cite appropriate COA

		8.	Equipment - Cite authorization and amount. Cite appropriate COA

		9.	Other Direct Costs - Include detailed breakdown when total amount is over

$10,000. 

		10.	G&A - Cite rate and amount.

		11.	Total Cost (and applicable cost-shared ratio)

		12.	Fixed Fee (if applicable)

		13.	Total Cost Plus Fixed Fee

 

Additional instructions and an invoice template are provided in Section J-List of Attachments, Invoice/Financing Request Instructions and Contract Financial Reporting Instructions for Cost- Reimbursement Contracts. All invoices must be signed by a representative of the contractor authorized to certify listed charges are accurate and comply with government regulations. Invoices shall be signed and submitted electronically (in accordance with Section F.3 Electronic Submission).

 

If applicable, the Contractor shall convert any foreign currency amount(s) in the monthly invoice to U.S. dollars each month, on the 1st of the month, using the foreign exchange rate index published on www.federalreserve.gov. Payment of invoices is subject to the U.S. dollar limits within the Total Costs of CLIN 0001 in Section B of the contract.

 

The Government shall use electronic funds transfer to the maximum extent possible when making payments under this contract. FAR 52.232-33, Payment by Electronic Funds Transfer–System for Award Management, in Section I requires the Contractor to designate in writing a financial institution for receipt of electronic funds transfer payments.

 

G.5. REIMBURSEMENT OF COST

 

The Government shall reimburse the Contractor the cost determined by the Contracting Officer to be allowable (hereinafter referred to as allowable cost) in accordance with FAR Clause 52.216-7, Allowable Cost and Payment incorporated by reference in Section I, Contract Clauses, of this contract, and FAR Subpart 31.2. Examples of allowable costs include, but are not limited to, the following:

 

		a)	All direct materials and supplies that are used in performing the work provided for under the contract, including those purchased for subcontracts and purchase orders.

 

		b)	All direct labor, including supervisory, that is properly chargeable directly to the contract, plus fringe benefits.

 

		c)	All other items of cost budgeted for and accepted in the negotiation of this basic contract or modifications thereto.

 

36

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		d)	Travel costs including per diem or actual subsistence for personnel while in an actual travel status in direct performance of the work and services required under this contract subject to the following:

 

		(i)	Air travel shall be by the most direct route using “air coach” or “air tourist” (less than first class) unless it is clearly unreasonable or impractical (e.g., not available for reasons other than avoidable delay in making reservations, would require circuitous routing or entail additional expense offsetting the savings on fare, or would not make necessary connections).

 

		(ii)	Rail travel shall be by the most direct route, first class with lower berth or nearest equivalent.

 

		(iii)	Costs incurred for lodging, meals, and incidental expenses shall be considered reasonable and allowable to the extent that they do not exceed on a daily basis the per diem rates set forth in the Federal Travel Regulation (FTR).

 

		(iv)	Travel via privately owned automobile shall be reimbursed at not more than the current General Services Administration (GSA) FTR established mileage rate.

 

G.6. INDIRECT COST RATES

 

The following Contractor established provisional billing rates are incorporated into the contract, and will be utilized for billing purposes during the Base Period (CLIN 0001) and total estimated cost plus fixed fee Option Periods (CLINs 0002, 0003, 0004, and 0005) ONLY if exercised by the CO pending the establishment of final indirect cost rates for each fiscal year or until revised by the CO in accordance with the provisions of FAR 42.705-1. FAR clause 52.216-7 will be utilized for billing purposes during both the Base Period (CLIN 0001) and total estimated cost plus fixed fee Option Periods (CLINs 0002, 0003, 0004, and 0005) ONLY if exercised by the CO.

 

	MediWound Ltd.
	Rate Type	Rate	Ceiling Rate	Allocation Base
	[***]	[***]	[***]	[***]
	[***]	[***]	[***]	[***]

 

The Indirect Cost Ceilings are established for the Base Period (CLIN 0001) and total estimated cost plus fixed fee Option Periods (CLINs 0002, 0003, 0004, and 0005) ONLY if exercised by the CO.  The Contractor cannot seek reimbursement in excess of the Indirect Cost Ceilings.

 

Use of the above provisional rates does not change any cost ceilings, contract obligations, or specific allowance or disallowance provided for in the contract.

 

Final rate proposals must be sent to the CO, within 6 months subsequent to the fiscal year end. (See also FAR Clause 52.216-7 incorporated herein).

 

G.7. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

 

Contractor Performance Evaluations

 

Interim and final evaluations of Contractor performance will be prepared on this contract in accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at the time of completion of work. In addition to the final evaluation, an interim evaluation shall be submitted annually.

 

Interim and final evaluations will be provided to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the matter will be referred to an individual one level above the Contracting Officer whose decision will be final.

 

Copies of the evaluations, Contractor responses, and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.

 

37

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Electronic Access to Contractor Performance Evaluations

 

Contractors that have Internet capability may access evaluations through a secure Web site for review and comment by completing the registration form that can be obtained at the following address:

 

http://www.cpars.csd.disa.mil/cparsmain.htm

 

The registration process requires the Contractor to identify an individual that will serve as a primary contact and who will be authorized access to the evaluation for review and comment. In addition, the Contractor will be required to identify an alternate contact that will be responsible for notifying the cognizant contracting official in the event the primary contact is unavailable to process the evaluation within the required 30-day time frame.

 

G.8. CONTRACT COMMUNICATIONS/CORRESPONDENCE (JULY 1999)

 

The Contractor shall identify all correspondence, reports, and other data pertinent to this contract by imprinting the contract number from Page 1 of the contract.

 

G.9. GOVERNMENT PROPERTY

 

In addition to the requirements of the Government Property clause incorporated in Section I of this contract, the Contractor shall comply with the provisions of HHS Publication, “HHS Contracting Guide for Control of Government Property,” which is incorporated into this contract by reference. This document can be accessed at:

 

http://www.hhs.gov/hhsmanuals/ (HHS Logistics Management Manual)

 

Among other issues, this publication provides a summary of the Contractor’s responsibilities regarding purchasing authorizations and inventory and reporting requirements under the contract.

 

Notwithstanding the provisions outlined in the HHS Publication, “HHS Contracting Guide for Control of Government Property,” which is incorporated in this contract in paragraph 1. above, the Contractor shall use the form entitled, “Report of Government Owned, Contractor Held Property” for submitting summary reports required under this contract, as directed by the Contracting Officer or his/her designee. This form is attached to this contract (see Section J- List of Attachments). Title will vest in the Government for equipment purchased as a direct cost.

 

38

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SECTION H - SPECIAL CONTRACT REQUIREMENTS

 

The Contractor, depending upon the nature of the work, is responsible for following the provisions below in conducting its own work under this contract. The Contractor also is responsible for incorporating these provisions into any subcontract awarded, if applicable to the specific nature of the work in the subcontract. Accordingly, those provisions shall be flowed-down as applicable.

 

H.1 CLINICAL AND NON-CLINICAL TERMS OF AWARD

 

BARDA has a responsibility to obtain documentation concerning mechanisms and procedures that are in place to protect the safety of participants and animals in BARDA funded clinical trials and non-clinical studies. Therefore, the Contractor shall develop a protocol for each clinical trial and non-clinical study funded under this contract and submit all such protocols and protocol amendments to the Contracting Officer’s Representative (COR) for evaluation and comment.

 

Approval by the COR is required before work under a protocol may begin. The COR comments will be forwarded to the Contractor at least (10) business days prior to the start of any study under the protocol. The Contractor must address, in writing, all concerns (e.g. study design, safety, regulatory, ethical, and conflict of interest) noted by the COR.

 

If the draft protocols are to be submitted to the FDA, the COR review shall occur before submission, pursuant to the terms set forth by Section F.2 of this contract. The Contractor shall revise their protocols to address BARDA’s concerns and recommendations prior to FDA submission. The Contractor must provide BARDA with a copy of FDA submissions, within the time frame set forth by Section F.2 of this contract.

 

Execution of clinical and non-clinical studies requires written authorization from the Government. The Government will provide written authorization to the Contractor upon either 1) receiving documentation in which all COR comments have been satisfactorily addressed; or 2) receiving documentation that the FDA has reviewed and commented on the protocol.

 

The Government shall have unlimited rights to all protocols, data resulting from execution of these protocols, and final reports funded by BARDA under this contract, as set forth in the FAR clauses referenced in PART II of this contract. The Government reserves the right to request that the Contractor provide any contract deliverable in a non-proprietary form to ensure the Government has the ability to review and distribute the deliverables as the Government deems necessary. Important information regarding performing human subject research is available at http://www3.niaid.nih.gov/healthscience/clinicalstudies/.

 

Any updates to technical reports are to be addressed in the Monthly and Annual Progress Reports. The Contractor shall advise the Contracting Officer’s Representative or designee in writing and via electronic communication in a timely manner of any issues potentially affecting contract performance.

 

		1.	Non-Clinical Terms of Award

 

These Non-Clinical Terms of Award detail an agreement between the Biomedical Advanced Research and Development Authority (BARDA) and the Contractor; they apply to all grants and contracts that involve non-clinical research.

 

		a.	Safety and Monitoring Issues

 

		i.	PHS Policy on Humane Care and use of Laboratory Animals

 

Within 30 days of award and then with the annual progress report, the Contractor must submit to BARDA a copy of the current Institutional Animal Care and Use Committees (IACUC) documentation of continuing review and approval and the Office of Laboratory Animal Welfare (OLAW) federal wide assurance number for the institution or site.

 

39

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

If other institutions are involved in the research (e.g., a multicenter trial or study), each institution’s IACUC must review and approve the protocol. They must also provide BARDA initial and annual documentation of continuing review and approval and federal wide assurance number.

 

The Contractor must ensure that the application, as well as all protocols, is reviewed by the performing institution’s IACUC.

 

To help ensure the safety of animals used in BARDA-funded studies, the Contractor must provide BARDA copies of documents related to all major changes in the status of ongoing protocols, including the following:

 

		●	All amendments or changes to the protocol, identified by protocol version number, date, or both and date it is valid.

 

		●	All material changes in IACUC policies and procedures, identified by version number, date, and all required signatories (if applicable).

 

		●	Termination or temporary suspension of the study(ies) for regulatory issues.

 

		●	Termination or temporary suspension of the protocol.

 

		●	Any change that is made in the specific IACUC approval for the indicated study(ies).

 

		●	Any other problems or issues that could affect the scientific integrity of the study(ies), i.e., fraud, misrepresentation, misappropriation of funds, etc.

 

Contractor must notify BARDA of any of the above changes within five (5) working days from the time the Contractor becomes aware of such changes by email or fax, followed by a letter signed by the institutional business official, detailing notification of the change of status to the local IACUC and a copy of any responses from the IACUC.

 

If a non-clinical protocol has been reviewed by an institutional biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 

		ii.	Non-Clinical Data and Safety Monitoring Requirements

 

BARDA strongly recommends continued safety monitoring for all non-clinical studies of investigational drugs, devices, or biologics. FDA expects non- clinical studies to include safety in addition to efficacy. The Contractor should consider evaluation of clinical relevant safety markers in the pivotal and non- pivotal, non-clinical studies. In preparation for clinical trials of licensed or not yet licensed products, it is imperative that BARDA- sponsored studies of any type measure the risk and safety parameters that are elicited and provide a safety profile from the studies for future human risk assessment.

 

40

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

A risk is minimal where the probability and magnitude of harm or discomfort anticipated in the proposed research are not greater than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For example, the risk of drawing a small amount of blood from a healthy subject for research purposes is no greater than the risk of doing so as part of a routine physical examination (45 CFR 46.102(i)).

 

The COR will work with the Contractor on decisions regarding the type and extent of safety data accrual to be employed before the start of efficacy or safety studies.

 

The Contractor shall inform the CO and COR of any upcoming site visits and/or audits of CRO facilities funded under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of CRO’s as BARDA deems necessary, provided reasonable prior notice is given to the Contractor.

 

		b.	BARDA Review Process before Non-Clinical study Execution Begins

 

BARDA is under the same policy-driven assurances as NIH in that it has a responsibility to ensure that mechanisms and procedures are in place to protect the safety and welfare of animals used in BARDA-funded non-clinical trials. Therefore, before study execution, the Contractor must provide the following (as applicable) for review and comment by the COR:

 

		●	IACUC approved (signed) non-clinical research protocol identified by version number, date, or both, including details of study design, euthanasia criteria, proposed interventions, and exclusion criteria.

 

		●	For non-pivotal mouse studies, the Contractor will provide an annual animal care and use protocol.

 

		●	Documentation of IACUC approval, including OLAW federal wide number, IACUC registration number, and IACUC name.

 

		●	Contractor should reduce the number of animals required for a study using power of statistics.

 

		●	Plans for the management of side effects, rules for interventions and euthanasia criteria.

 

		●	Procedures for assessing and collecting safety data were appropriate.

 

		●	If a study is contracted through Contract Research Organizations (CROs), work orders and service agreements the Contractor shall assure an integrated safety documentation plan is in place for the study site, pharmacy service records on the dosing material to be used and excipients, and laboratory services (including histopathology).

 

		●	Documentation that the Contractor and all required staff responsible for the conduct of the research have received training in the protection and handling of animals, or that the CRO has the required documentation.

 

		●	Purchasing of animals and/or other supplies for non-clinical studies funded in part or in whole by BARDA requires written approval by the Contracting Officer in accordance with the contract. The Contractor must have the ability to return/re-sell animals, at purchase price, to distributor or a third party, in the event that the Contracting Officer Authorization is not granted.

 

41

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		●	Provide justification for whether studies require good laboratory practice (GLP) conditions.

 

		●	Provide justification for whether studies will be classified as non-pivotal or pivotal studies.

 

Documentation of each of the above items shall be submitted to the COR for evaluation and comment in conjunction with the protocol. Execution of non-clinical studies requires written authorization from the Contracting Officer in accordance with this Section of the contract.

 

		c.	References

 

Public Health Service Policy on Humane Care and Use of Laboratory Animals: 

http://grants.nih.gov/grants/olaw/InvestigatorsNeed2Know.pdf

 

USDA Animal Welfare Act:

http://awic.nal.usda.gov/nal_display/index.php?info_center=3&tax_level=3&tax_su bject=182&topic_id=1118&level3_id=6735&level4_id=0&level5_id=0&placement_d efault=0

 

		2.	Clinical Terms of Award

 

These Clinical Terms of Award detail an agreement between the Government and the Contractor; they apply to all grants and contracts that involve clinical research.

 

BARDA shall have unlimited rights to all protocols, data generated from the execution of these protocols, and final reports, funded by BARDA under this contract, as defined in Rights in Data Clause in FAR 52.227-14. BARDA reserves the right to request that the Contractor provide any contract deliverable that is produced in the performance of this contract without any restrictive legends to ensure BARDA has the ability to review and distribute the deliverables, as BARDA deems necessary.

 

		a.	Safety and Monitoring Issues

 

		i.	Institutional Review Board or Independent Ethics Committee Approval

 

Within 30 days of award and then with the annual progress report, the Contractor must submit to the COR a copy of the current IRB-or IEC-approved informed consent document, documentation of continuing review and approval and the OHRP federal wide assurance number for the institution or site.

 

If other institutions are involved in the research (e.g., a multicenter clinical trial or study), each institution’s IRB or IEC must review and approve the protocol. They must also provide BARDA initial and annual documentation of continuing review and approval, including the current approved informed consent document and federal wide number.

 

The Contractor must ensure that the application as well as all protocols is reviewed by their IRB or IEC.

 

42

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

To help ensure the safety of participants enrolled in BARDA-funded studies, the Contractor must provide the COR copies of documents related to all major changes in the status of ongoing protocols, including the following:

 

		●	All amendments or changes to the protocol, identified by protocol version number, date, or both and dates it is valid.

 

		●	All changes in informed consent documents, identified by version number, dates, or both and dates it is valid.

 

		●	Termination or temporary suspension of patient accrual.

 

		●	Termination or temporary suspension of the protocol.

 

		●	Any change in IRB approval.

 

		●	Any other problems or issues that could affect the participants in the studies.

 

The Contractor must notify the COR and CO of any of the above changes within five (5) working days by email or fax, followed by a letter signed by the institutional business official, detailing notification of the change of status to the local IRB and a copy of any responses from the IRB or IEC.

 

If a clinical protocol has been reviewed by an institutional biosafety committee (IBC) or the NIH Recombinant DNA Advisory Committee (RAC), the Contractor must provide information about the initial and ongoing review and approval, if any. See the NIH Guidelines for Research Involving Recombinant DNA Molecules.

 

		ii.	Data and Safety Monitoring Requirements

 

BARDA strongly recommends independent safety monitoring for clinical trials of investigational drugs, devices, or biologics; clinical trial of licensed products; and clinical research of any type involving more than minimal risk to volunteers. Independent monitoring can take a variety of forms. Phase III clinical trials must be reviewed by an independent data and safety monitoring board (DSMB); other trials may require DSMB oversight as well. The Contractor shall inform BARDA of any upcoming site visits and/or audits of CRO facilities funded under this effort. BARDA reserves the right to accompany the Contractor on site visits and/or audits of CROs as BARDA deems necessary.

 

A risk is minimal where the probability and magnitude of harm or discomfort anticipated in the proposed research and not greater than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. For examples, the risk of drawing a small amount of blood from a healthy individual for research purposes is no greater than the risk of doing so as part of a routine physical examination (45 CFR 46.102I).

 

Final decisions regarding the type of monitoring to be used must be made jointly by BARDA and the Contractor before enrollment starts. Discussions with the responsible BARDA Project Officer regarding appropriate safety monitoring and approval of the final monitoring plan by BARDA must occur before patient enrollment begins and may include discussions about the appointment of one of the following.

 

43

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		▪	Independent Safety Monitor – a physician or other appropriate expert who is independent of the study and available in real time to review and recommend appropriate action regarding adverse events and other safety issues.

 

		▪	Independent Monitoring Committee (IMC) or Safety Monitoring Committee (SMC) – a small group of independent investigators and biostatisticians who review data from a particular study.

 

		▪	Data and Safety Monitoring Board – an independent committee charged with reviewing safety and trial progress and providing advice with respect to study continuation, modification, and termination. The Contractor may be required to use an established BARDA DSMB or to organize an independent DSMB. All phase III clinical trials must be reviewed by a DSMB; other trials may require DSMB oversight as well. Please refer to: NIAID Principles for Use of a Data and Safety Monitoring Board (DSMB) For Oversight of Clinical Trials Policy

 

When a monitor or monitoring board is organized, a description of it, its charter or operating procedures (including a proposed meeting schedule and plan for review of adverse events), and roster and curriculum vitae from all members must be submitted to and approved by the COR before enrollment starts. The Contractor will also ensure that the monitors and board members report any conflicts of interest and the Contractor will maintain a record of this. The Contractor will share conflict of interest reports with the CO and COR.

 

Additionally, the Contractor must submit written summaries of all reviews conducted by the monitoring group to the BARDA within thirty (30) days of reviews or meetings.

 

		iii.	BARDA Protocol Review Process Before Patient Enrollment Begins The COR has a responsibility to ensure that mechanisms and procedures are in place to protect the safety of participants in BARDA-supported clinical trials. Therefore, before patient accrual or participant enrollment, the Contractor must ensure the following (as applicable) are in place at each participating institution, prior to patient accrual or enrollment:

 

		●	IRB- or IEC-approved clinical research protocol identified by version number, date, or both, including details of study design, proposed interventions, patient eligibility, and exclusion criteria.

		●	Documentation of IRB or IEC approval, including OHRP federal wide number, IRB or IEC registration number, and IRB and IEC name.

		●	IRB- or IEC- approved informed consent document, identified by version number, date, or both and dates it is valid.

		●	Plans for the management of side effects.

		●	Procedures for assessing and reporting adverse events.

		●	Plans for data and safety monitoring (see above) and monitoring of the clinical study site, pharmacy, and laboratory.

		●	Documentation that the Contractor and all study staff responsible for the design or conduct of the research have received training in the protection of human subjects.

 

Documentation to demonstrate that each of the above items are in place shall be submitted to the COR) for evaluation and comment in conjunction with the protocol. Execution of clinical studies requires written authorization from the COR in accordance with this Section of this contract.

 

44

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		iv.	Investigational New drug or Investigational Device Exemption Requirements

 

Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

 

Exceptions must be granted in writing by FDA. If the proposed clinical trial will be performed under an IND or IDE, the Contractor must provide BARDA with the name and institution of the IND or IDE sponsor, the date the IND or IDE was filed with FDA, the FDA IND or IDE number, any written comments from FDA, and the written responses to those comments.

 

Unless FDA notifies Contractor otherwise, The Contractor must wait thirty (30) calendar days from FDA receipt of an initial IND or IDE application before initiating a clinical trial.

 

The Contractor must notify BARDA if the FDA places the study on clinical hold and provide BARDA any written comments from FDA, written responses to the comments, and documentation in writing that the hold has been lifted. The Contractor must not use grant or contract funds during a clinical hold to fund clinical studies that are on hold. The Contractor must not enter into any new financial obligations related to clinical activities for the clinical trial on clinical hold.

 

		v.	Required Time-Sensitive Notification

 

Under an IND or IDE, the sponsor must provide FDA safety reports of serious adverse events. Under these Clinical Terms of Award, the Contractor must submit copies to the responsible Contracting Officer’s Representative (COR) as follows:

 

		i.	Expedited safety report of unexpected or life-threatening experience or death:

A copy of any report of unexpected or life-threatening experience or death associated with the use of an IND drug, which must be reported to FDA by telephone or fax as soon as possible but no later than seven (7) days after the IND sponsor’s receipt of the information, must be submitted to the COR within 24 hours of FDA notification.

 

		ii.	Expedited safety reports of serious and unexpected adverse experiences: A copy of any report of unexpected and serious adverse experience associated with use of an IND drug or any finding from tests in laboratory animals that suggests a significant risk for human subjects, which must be reported in writing to FDA as soon as possible but no later than 15 days after the IND sponsor’s receipt of the information, must be submitted to the COR within 24 hours of FDA notification. For medical devices, adverse events should be reported under the MedWatch (MDR) program with reporting timelines of 5 days for serious adverse events or 30 days for reportable events.

 

		iii.	IDE reports of unanticipated adverse device effect:

 

A copy of any reports of unanticipated adverse device effect submitted to FDA must be submitted to the COR within 24 hours of FDA notification.

 

45

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		iv.	Expedited safety reports: Sent to the COR concurrently with the report to FDA.

 

		v.	Other adverse events documented during the course of the trial should be included in the annual IND or IDE report and reported to BARDA annually.

 

In case of problems or issues, the Contracting Officer’s Representative will contact the Contractor within ten (10) business days by email or fax, followed within thirty (30) calendar days by an official letter to the Contractor’s Project Manager, with a copy to the institutions’ office of sponsored programs, listing issues and appropriate actions to be discussed.

 

		vi.	Safety reporting for research not performed under an IND or IDE.

 

Final decisions regarding ongoing safety reporting requirements for research not performed under an IND or IDE must be made jointly by the Contracting Officer’s Representative and the Contractor.

 

H.2. PROTECTION OF HUMAN SUBJECTS, HHSAR 352.270-4(b) (December 2015)

 

		a.	The Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall be protected in accordance with 45 CFR Part 46 and with the Contractor’s current federal wide Assurance of Compliance on file with the Office for Human Research Protections (OHRP), Department of Health and Human Services. The Contractor further agrees to provide certification at least annually that the Institutional Review Board has reviewed and approved the procedures, which involve human subjects in accordance with 45 CFR Part 46 and the Assurance of Compliance.

 

		b.	The Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under this contract and shall ensure that work is conducted in a proper manner and as safely as is feasible. The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under this contract. The Contractor shall not deem anything in this contract to constitute the Contractor or any subcontractor, agent or employee of the Contractor, or any other person, organization, institution, or group of any kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this contract and will discharge its obligations, duties, and undertakings and the work pursuant thereto, whether requiring professional judgment or otherwise, as an independent contractor without imputing liability on the part of the Government for the acts of the Contractor or its employees.

 

		c.	Contractors involving other agencies or institutions in activities considered to be engaged in research involving human subjects must ensure that such other agencies or institutions obtain their own FWA if they are routinely engaged in research involving human subjects or ensure that such agencies or institutions are covered by the Contractors’ FW’ via designation as agents of the institution of via individual investigator agreements (see OHRP website at: http//:www.hhs.gov/ohrp/policy/guidanceonalternativeofwa.pdf).

 

		d.	If at any time during the performance of this contract, the Contractor is not in compliance with any of the requirements and/or standards stated in paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. The Contracting Officer may communicate the notice of suspension by telephone with confirmation in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may, after consultation with OHRP, terminate this contract in whole or in part.

 

46

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

H.3. HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE)

 

The acquisition and supply of all human specimen material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable Federal, State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise, will be offered to any person to influence their donation of human material.

 

The Contractor shall provide written documentation that all human materials obtained as a result of research involving human subjects conducted under this contract, by collaborating sites, or by subcontractors identified under this contract, were obtained with prior approval by the Office for Human Research Protections (OHRP) of an Assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all collaborating sites without OHRP- approved Assurances, whether domestic or foreign, and compliance must be ensured by the Contractor.

 

Provision by the Contractor to the Contracting Officer of a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263(formerly Optional Form 310), certifying IRB review and approval of the protocol from which the human materials were obtained constitutes the written documentation required. The human subject certification can be met by submission of a self-designated form provided that it contains the information required by the “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263 (formerly Optional Form 310).

 

H.4. RESEARCH INVOLVING HUMAN FETAL TISSUE

 

All research involving human fetal tissue shall be conducted in accordance with the Public Health Service Act, 42 U.S.C. 289g-1 and 289g-2. Implementing regulations and guidance for conducting research on human fetal tissue may be found at 45 CFR 46, Subpart B and http://grants1.nih.gov/grants/guide/notice-files/not93-235.html and any subsequent revisions to this NIH Guide to Grants and Contracts (“Guide”) Notice.

 

The Contractor shall make available, for audit by the Secretary, HHS, the physician statements and informed consents required by 42 USC 289g-1(b) and (c), or ensure HHS access to those records, if maintained by an entity other than the Contractor.

 

H.5. CARE OF LIVE VERTEBRATE ANIMALS, HHSAR 352.270-5 (Dec 2015)

 

		a.	Before undertaking performance of any contract involving animal-related activities where the species is regulated by USDA, the Contractor shall register with the Secretary of Agriculture of the United States in accordance with 7 U.S.C. 2136 and 9 CFR Sections 2.25 through 2.28. The Contractor shall furnish evidence of the registration to the Contracting Officer.

 

		b.	The Contractor shall acquire vertebrate animals used in research from a dealer licensed by the Secretary of Agriculture under 7 U.S.C. 2133 and 9 CFR Sections 2.1-2.11, or from a source that is exempt from licensing under those Sections.

 

		c.	The Contractor agrees that the care, use and intended use of any live vertebrate animals in the performance of this contract shall conform with the Public Health Service (PHS) Policy on Humane Care of Use of Laboratory Animals (PHS Policy), the current Animal Welfare Assurance, the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC) and the pertinent laws and regulations of the United States Department of Agriculture (see 7 U.S.C. 2131 et seq. and 9 CFR Subchapter A, Parts 1-4). In case of conflict between standards, the more stringent standard shall govern.

 

47

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		d.	If at any time during performance of this contract, the Contracting Officer determines, in consultation with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), that the Contractor is not in compliance with any of the requirements and standards stated in paragraphs (a) through (c) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may, in consultation with OLAW, NIH, terminate this contract in whole or in part, and the Contractor’s name may be removed from the list of those contractors with approved Assurances.

 

Note: The Contractor may request registration of its facility and a current listing of licensed dealers from the Regional Office of the Animal and Plant Health Inspection Service (APHIS), USDA, for the region in which its research facility is located. The location of the appropriate APHIS Regional Office, as well as information concerning this program may be obtained by contacting the Animal Care Staff, USDA/APHIS, 4700 River Road, Riverdale, Maryland 20737 (E- mail: ace@aphis.usda.gov; W eb site: (http://www.aphis.usda.gov/animal_welfare).

 

H.6. ANIMAL WELFARE

 

All research involving live, vertebrate animals shall be conducted in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals. This policy may be accessed at: http://grants1.nih.gov/grants/olaw/references/phspol.htm

 

H.7. INFORMATION ON COMPLIANCE WITH ANIMAL CARE REQUIREMENTS

 

Registration with the U. S. Dept. of Agriculture (USDA) is required to use regulated species of animals for biomedical purposes. USDA is responsible for the enforcement of the Animal Welfare Act (7 U.S.C. 2131 et. seq.), http://www.nal.usda.gov/awic/legislat/awa.htm.

 

The Public Health Service (PHS) Policy is administered by the Office of Laboratory Animal Welfare (OLAW) http://grants2.nih.gov/grants/olaw/olaw.htm. An essential requirement of the PHS Policy http://grants2.nih.gov/grants/olaw/references/phspol.htm is that every institution using live vertebrate animals must obtain an approved assurance from OLAW before they can receive funding from any component of the U. S. Public Health Service.

 

The PHS Policy requires that Assured institutions base their programs of animal care and use on the Guide for the Care and Use of Laboratory Animals http://www.nap.edu/readingroom/books/labrats/ and that they comply with the regulations (9 CFR, Subchapter A)http://www.nal.usda.gov/awic/legislat/usdaleg1.htm issued by the U.S. Department of Agriculture (USDA) under the Animal Welfare Act. The Guide may differ from USDA regulations in some respects. Compliance with the USDA regulations is an absolute requirement of this Policy.

 

The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) http://www.aaalac.org is a professional organization that inspects and evaluates programs of animal care for institutions at their request. Those that meet the high standards are given the accredited status. As of the 2002 revision of the PHS Policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC Accreditation is not required to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool. They also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published by the Federated of Animal Science Societies http://www.fass.org.

 

H.8. REQUIREMENTS FOR ADEQUATE ASSURANCE OF PROTECTION OF VERTEBRATE ANIMAL SUBJECTS

 

The PHS Policy on Humane Care and Use of Laboratory Animals requires that applicant organizations proposing to use vertebrate animals file a written Animal Welfare Assurance with the Office for Laboratory Animal Welfare (OLAW), establishing appropriate policies and procedures to ensure the humane care and use of live vertebrate animals involved in research activities supported by the PHS. The PHS Policy stipulates that an applicant organization, whether domestic or foreign, bears responsibility for the humane care and use of animals in PHS- supported research activities. Also, the PHS policy defines “animal” as “any live, vertebrate animal used, or intended for use, in research, research training, experimentation, biological testing or for related purposes.” This Policy implements and supplements the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training, and requires that institutions use the Guide for the Care and Use of Laboratory Animals as a basis for developing and implementing an institutional animal care and use program. This Policy does not affect applicable State or local laws or regulations that impose more stringent standards for the care and use of laboratory animals. All institutions are required to comply, as applicable, with the Animal Welfare Act as amended (7 USC 2131 et. seq.) and other Federal statutes and regulations relating to animals. These documents are available from the Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD 20892, (301) 496-7163. See: http://grants.nih.gov/grants/OLAW/olaw.htm

 

48

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

No PHS supported work for research involving vertebrate animals will be conducted by an organization, unless that organization is operating in accordance with an approved Animal Welfare Assurance and provides verification that the Institutional Animal Care and Use Committee (IACUC) has reviewed and approved the proposed activity in accordance with the PHS policy. Applications may be referred by the PHS back to the institution for further review in the case of apparent or potential violations of the PHS Policy. No award to an individual will be made unless that individual is affiliated with an assured organization that accepts responsibility for compliance with the PHS Policy. Foreign applicant organizations applying for PHS awards for activities involving vertebrate animals are required to comply with PHS Policy or provide evidence that acceptable standards for the humane care and use of animals will be met. Foreign applicant organizations are not required to submit IACUC approval, but should provide information that is satisfactory to the Government to provide assurances for the humane care of such animals.

 

H.9. APPROVAL OF REQUIRED ASSURANCE BY OLAW

 

Under governing regulations, federal funds which are administered by the Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority (BARDA) shall not be expended by the Contractor for research involving live vertebrate animals, nor shall live vertebrate animals be involved in research activities by the Contractor under this award unless a satisfactory assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 is submitted within 30 days of the date of this award and approved by the Office of Laboratory Animal Welfare (OLAW). Each performance site (if any) must also assure compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28 with the following restriction: Only activities which do not directly involve live vertebrate animals (i.e. are clearly severable and independent from those activities that do involve live vertebrate animals) may be conducted by the Contractor or individual performance sites pending OLAW approval of their respective assurance of compliance with 7 U.S.C. 2316 and 9 CFR Sections 2.25-2.28. Additional information regarding OLAW may be obtained via the Internet at http://grants2.nih.gov/grants/olaw/references/phspol.htm

 

H.10. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

 

Anyone who becomes aware of the existence or apparent existence of fraud, waste and abuse in BARDA funded programs should report such matters to the HHS Inspector General’s Office in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS (1-800- 447-8477). All telephone calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is:

 

Office of Inspector General

Department of Health and Human Services TIPS HOTLINE

P.O. Box 23489 Washington, D.C. 20026

 

49

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

H.11. PROHIBITION ON CONTRACTOR INVOLVEMENT WITH TERRORIST ACTIVITIES

 

The Contractor acknowledges that U.S. Executive Orders and Laws, including but not limited to 13224 and P.L. 107-56, prohibit transactions with, and the provision of resources and support to, individuals and organizations associated with terrorism. It is the legal responsibility of the Contractor to ensure compliance with these Executive Orders and Laws. This clause must be included in all subcontracts issued under this contract.

 

H.12. IDENTIFICATION AND DISPOSITION OF DATA

 

The Contractor will be required to provide certain data generated under this contract to the Department of Health and Human Services (DHHS). DHHS reserves the right to review any other data determined by DHHS to be relevant to this contract. The Contractor shall keep copies of all data required by the Food and Drug Administration (FDA) relevant to this contract for the time specified by the FDA.

 

H.13. EXPORT CONTROL NOTIFICATION

 

Contractors are responsible for ensuring compliance with all export control laws and regulations that may be applicable to the export of and foreign access to their proposed technologies. Contractors may consult with the Department of State with any questions regarding the International Traffic in Arms Regulation (ITAR) (22 CRF Parts 120-130) and /or the Department of Commerce regarding the Export Administration Regulations (15 CRF Parts 730-774).

 

H.14. CONFLICT OF INTEREST

 

The Contractor represents and warrants that, to the best of the Contractor’s knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, as defined in FAR 2.101 and Subpart 9.5, and that the Contractor has disclosed all such relevant information. Prior to commencement of any work, the Contractor agrees to notify the Contracting Officer promptly that, to the best of its knowledge and belief, no actual or potential conflict of interest exists or to identify to the Contracting Officer any actual or potential conflict of interest the firm may have. In emergency situations, however, work may begin but notification shall be made within five (5) working days. The Contractor agrees that if an actual or potential organizational conflict of interest is identified during performance, the Contractor shall promptly make a full disclosure in writing to the Contracting Officer. This disclosure shall include a description of actions which the Contractor has taken or proposes to take, after consultation with the Contracting Officer, to avoid, mitigate, or neutralize the actual or potential conflict of interest. The Contractor shall continue performance until notified by the Contracting Officer of any contrary action to be taken. Remedies include termination of this contract for convenience, in whole or in part, if the Contracting Officer deems such termination necessary to avoid an organizational conflict of interest. If the Contractor was aware of a potential organizational conflict of interest prior to award or discovered an actual or potential conflict after award and did not disclose it or misrepresented relevant information to the Contracting Officer, the Government may terminate the contract for default, debar the Contractor from Government contracting, or pursue such other remedies as may be permitted by law or this contract.

 

H.15. INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF INTEREST

 

The Contractor shall comply with the requirements of 45 CFR Part 94, Responsible Prospective Contractors, which promotes objectivity in research by establishing standards to ensure that Investigators (defined as the project director or principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research funded under BARDA contracts, or proposed for such funding, which may include, for example, collaborators or consultants) will not be biased by any Investigator financial conflicts of interest.

 

If the failure of an Investigator to comply with an Institution’s financial conflicts of interest policy or a financial conflict of interest management plan appears to have biased the design, conduct, or reporting of the BARDA-funded research, the Contractor must promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will consider the situation and, as necessary, take appropriate action or refer the matter to the Contractor for further action, which may include directions to the Contractor on how to maintain appropriate objectivity in the BARDA-funded research project.

 

50

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

The Contracting Officer and/or HHS may inquire at any time before, during, or after award into any Investigator disclosure of financial interests, and the Contractor’s review of, and response to, such disclosure, regardless of whether the disclosure resulted in the Contractor’s determination of a financial conflict of interests. The Contracting Officer may require submission of the records or review them on site. On the basis of this review of records or other information that may be available, the Contracting Officer may decide that a particular financial conflict of interest will bias the objectivity of the BARDA-funded research to such an extent that further corrective action is needed or that the Institution has not managed the financial conflict of interest in accordance with 45 CFR Part 94. The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.

 

If the Contracting Officer determines that BARDA-funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an Investigator with a financial conflict of interest that was not disclosed managed or reported the Contractor shall require the Investigator involved to disclose the financial conflict of interest in each public presentation of the results of the research and to request an addendum to previously published presentations.

 

The Contractor shall comply with the requirements of 45 CFR Part 94, Responsible Prospective

 

Contractors, which promotes objectivity in research by establishing standards to ensure that investigators (defined as the principal investigator and any other person who is responsible for the design, conduct, or reporting of research funded under BARDA contracts) will not be biased by any conflicting financial interest. 45 CFR Part 94 is available at the following Web site: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=cc7504e541bc62939c52389e9afc27d5&rgn=div5&view=text&node=45:1.0.1.1.51&idno=45

 

As required by 45 CFR Part 94, the Contractor shall, at a minimum:

 

		52.	Maintain a written, enforceable policy on conflict of interest that complies with 45 CFR Part 94 and inform each investigator of the policy, the investigator’s reporting responsibilities, and the applicable regulations. The Contractor must take reasonable steps to ensure that investigators working as collaborators or subcontractors comply with the regulations.

 

		52.	Designate an official(s) to solicit and review financial disclosure statements from each investigator participating in BARDA-funded research. Based on established guidelines consistent with the regulations, the designated official(s) must determine whether a conflict of interest exists, and if so, determine what actions should be taken to manage, reduce, or eliminate such conflict. A conflict of interest exists when the designated official(s) reasonably determines that a Significant Financial Interest could directly and significantly affect the design, conduct, or reporting of the BARDA-funded research. The Contractor may require the management of other conflicting financial interests in addition to those described in this paragraph, as it deems appropriate. Examples of conditions or restrictions that might be imposed to manage actual or potential conflicts of interests are included in 45 CFR Part 94, under Management of Conflicting Interests.

 

		52.	Require all financial disclosures to be updated during the period of the award, either on an annual basis or as new reportable Significant Financial Interests are obtained.

 

		52.	Maintain records, identifiable to each award, of all financial disclosures and all actions taken by the Contractor with respect to each conflicting interest 3 years after final payment or, where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract Records Retention.

 

		52.	Establish adequate enforcement mechanisms and provide for sanctions where appropriate.

 

If a conflict of interest is identified, the Contractor shall report to the Contracting Officer, the existence of the conflicting interest found. This report shall be made and the conflicting interest managed, reduced, or eliminated, at least on a temporary basis, within sixty (60) days of that identification.

 

51

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

If the failure of an investigator to comply with the conflict of interest policy has biased the design, conduct, or reporting of the BARDA-funded research, the Contractor must promptly notify the Contracting Officer of the corrective action taken or to be taken. The Contracting Officer will take appropriate action or refer the matter to the Contractor for further action, which may include directions to the Contractor on how to maintain appropriate objectivity in the funded research.

 

The Contracting Officer may at any time inquire into the Contractor’s procedures and actions regarding conflicts of interests in BARDA-funded research, including a review of all records pertinent to compliance with 45 CFR Part 94. The Contracting Officer may require submission of the records or review them on site. On the basis of this review, the Contracting Officer may decide that a particular conflict of interest will bias the objectivity of the BARDA-funded research to such an extent that further corrective action is needed or that the Contractor has not managed, reduced, or eliminated the conflict of interest. The issuance of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.

 

If the Contracting Officer determines that BARDA-funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment, has been designed, conducted, or reported by an investigator with a conflict of interest that was not disclosed or managed, the Contractor must require disclosure of the conflict of interest in each public presentation of the results of the research.

 

H.16. NEEDLE DISTRIBUTION

 

The Contractor shall not use contract funds to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

 

H.17. RESTRICTION ON ABORTIONS

 

The Contractor shall not use contract funds for any abortion.

 

H.18. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

 

The Contractor shall not use contract funds for (1) the creation of a human embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b) and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term “human embryo or embryos” includes any organism, not protected as a human subject under 45 CFR 46 as of the date of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.

 

Additionally, in accordance with a March 4, 1997 Presidential Memorandum, Federal funds may not be used for cloning of human beings.

 

H.19. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

 

The Contractor shall not use contract funds to disseminate information that is deliberately false or misleading.

 

H.20. CONFIDENTIALITY OF INFORMATION

 

[Reserved]

 

H.21. ACCESS TO DOCUMENTATION/DATA

 

The Government shall have physical and electronic access to all documentation and data generated under this contract, including: all data documenting Contractor performance; all data generated; all communications and correspondence with regulatory agencies and bodies to include all audit observations, inspection reports, milestone completion documents, and all Offeror commitments and responses. Contractor shall provide the Government with an electronic copy of all correspondence and submissions to the FDA within 5 business days of receipt. The Government shall acquire unlimited rights to all data funded or furnished without proprietary restrictions under this contract in accordance with FAR Subpart 27.4 and FAR Clause 52.227-14.

 

52

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

H.22. EPA ENERGY STAR REQUIREMENTS

 

In compliance with Executive Order 12845 (requiring Agencies to purchase energy efficient computer equipment), all microcomputers, including personal computers, monitors, and printers that are purchased using Government funds in performance of a contract shall be equipped with or meet the energy efficient low-power standby feature as defined by the EPA Energy Star program unless the equipment always meets EPA Energy Star efficiency levels. The microcomputer, as configured with all components, must be Energy Star compliant.

 

This low-power feature must already be activated when the computer equipment is delivered to the agency and be of equivalent functionality of similar power managed models. If the equipment will be used on a local area network, the vendor must provide equipment that is fully compatible with the network environment. In addition, the equipment will run commercial off-the-shelf software both before and after recovery from its energy conservation mode.

 

H.23. ACKNOWLEDGMENT OF FEDERAL FUNDING

 

Section 507 of P.L. 104-208 mandates that Contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. This requirement is in addition to the continuing requirement to provide an acknowledgment of support and disclaimer on any publication reporting the results of a contract funded activity.

 

Publication and Publicity

 

No information related to data obtained under this contract shall be released or publicized without providing BARDA with at least thirty (30) days advanced notice and an opportunity to review the proposed release or publication.

 

In addition to the requirements set forth in HHSAR Clause 352.227-70, Publications and Publicity incorporated by reference in Section I of this contract, Section 507 of P.L. 104-208 mandates that Contractors funded with Federal dollars, in whole or in part, acknowledge Federal funding when issuing statements, press releases, requests for proposals, bid solicitations and other documents. Contractors are required to state:

 

(1) The percentage and dollar amounts of the total program or project costs financed with Federal money and;

 

(2)  The percentage and dollar amount of the total costs financed by non-governmental sources. For purposes of this contract “publication” is defined as an issue of printed material offered for distribution or any communication or oral presentation of information, including any manuscript or scientific meeting abstract. Any publication containing data generated under this contract must be submitted for BARDA review no less than thirty (30) calendar days for manuscripts and fifteen (15) calendar days for abstracts

 

before submission for public presentation or publication. Contract support shall be acknowledged in all such publications substantially as follows:

 

“This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800023C.”

 

53

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Press Releases

 

Misrepresenting contract results or releasing information that is injurious to the integrity of BARDA may be construed as improper conduct. Press releases shall be considered to include the public release of information to any medium, excluding peer-reviewed scientific publications. With the exception of ad-hoc press releases required by applicable law or regulations, the Contractor shall ensure that the COR has received an advance copy of any press release related to the contract not less than two (2) business days prior to the issuance of the press release.

 

The Contractor shall acknowledge the support of the Department of Health and Human Service, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, whenever publicizing the work under this contract in any media by including an acknowledgment substantially as follows:

 

“This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800023C.”

 

H.24. PROHIBITION ON THE USE OF APPROPRIATED FUNDS FOR LOBBYING ACTIVITIES AND HHSAR 352.203-70 ANTI-LOBBYING (December 2015)

 

Pursuant to the HHS annual appropriations acts, except for normal and recognized executive- legislative relationships, the Contractor shall not use any HHS contract funds for:

 

		(a)	Publicity or propaganda purposes;

 

		(b)	The preparation, distribution, or use of any kit, pamphlet, booklet, publication, electronic communication, radio, television, or video presentation designed to support or defeat the enactment of legislation before the Congress or any State or local legislature or legislative body, except in presentation to the Congress or any state or local legislature itself; or designed to support or defeat any proposed or pending regulation, administrative action, or order issued by the executive branch of any state or local government, except in presentation to the executive branch of any state or local government itself; or

 

		(c)	Payment of salary or expenses of the Contractor, or any agent acting for the Contractor, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before the Congress or any state government, state legislature or local legislature or legislative body, other than for normal and recognized executive-legislative relationships or participation by an agency or officer of a state, local, or tribal government in policymaking and administrative processes within the executive branch of that government.

  

		(d)	The prohibitions in subSections (a), (b), and (c) above shall include any activity to advocate or promote any proposed, pending, or future federal, state, or local tax increase, or any proposed, pending, or future requirement for, or restriction on, any legal consumer product, including its sale or marketing, including, but not limited to, the advocacy or promotion of gun control.

 

54

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

H.25. PRIVACY ACT APPLICABILITY

 

Notification is hereby given that the Contractor and its employees are subject to criminal penalties for violation of the Privacy Act to the same extent as employees of the Government. The Contractor shall assure that each of its employees knows the prescribed rules of conduct and that each is aware that he or she can be subjected to criminal penalty for violation of the Act. A copy of 45 CFR Part 5b, Privacy Act Regulations, may be obtained at https://www.gpo.gov/fdsys/granule/CFR-2007- title45-vol1/CFR-2007-title45-vol1-part5b

 

The Project Officer is hereby designated as the official who is responsible for monitoring contractor compliance with the Privacy Act.

 

The Contractor shall follow the Privacy Act guidance as contained in the Privacy Act System of Records number 09-25-0200. This document may be obtained at the following link: http://oma.od.nih.gov/ms/privacy/pa-files/0200.htm

 

H.26. LABORATORY LICENSE REQUIREMENTS

 

The Contractor shall comply with all applicable requirements of Section 353 of the Public Health Service Act (Clinical Laboratory Improvement Act as amended) (42 U.S.C. 263a and 42 CFR Part 493). This requirement shall also be included in any subcontract for services under the contract.

 

H.27. QUALITY ASSURANCE (QA) AUDIT REPORTS

 

BARDA reserves the right to participate in QA audits as related to activities funded under this contract. Upon completion of the audit/site visit the Contractor shall provide a report capturing the findings, results and next steps in proceeding with the subcontractor. If action is requested of the subcontractor, detailed concerns for addressing areas of non-conformance to FDA regulations for GLP, GMP, or GCP guidelines, as identified in the audit report, must be provided to BARDA. The Contractor shall provide responses from the subcontractors to address these concerns and plans for corrective action execution.

 

		●	Contractor shall notify CO and COR of upcoming, ongoing, or recent audits/site visits of subcontractors as part of weekly communications.

		●	Contractor shall notify the COR and CO within five (5) business days of report completion.

 

H.28. BARDA AUDITS

 

Contractor shall accommodate periodic or reasonable ad hoc site visits during normal business hours by the Government with forty-eight (48) hours advance notice. If the Government, the Contractor, or other parties identifies any issues during an audit, the Contractor shall capture the issues, identify potential solutions, and provide a report to the Government.

 

		●	If issues are identified during the audit, Contractor shall submit a report to the CO and COR detailing the finding and corrective action(s) within 10 business days of the audit.

		●	COR and CO will review the report and provide a response to the Contractor with ten (10) business days.

		●	Once corrective action is completed, the Contractor will provide a final report to the CO and COR.

 

H.29. RESTRICTION ON EMPLOYMENT OF UNAUTHORIZED ALIEN WORKERS

 

The Contractor shall not use contract funds to employ workers described in Section 274A (h)(3) of the Immigration and National Act, which reads as follows:

 

“(3) Definition of unauthorized alien – As used in this Section, the term ‘unauthorized alien’ with respect to the employment of an alien at a particular time, that the alien is not at that time either an alien lawfully admitted for permanent residence, or (B) authorized to be so employed by this Act or by the Attorney General.”

 

55

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

H.30. NOTIFICATION OF CRITICAL PROGRAMMATIC CONCERNS, RISKS, OR POTENTIAL RISKS

 

If any action occurs that creates a cause for critical programmatic concern, risk, or potential risk to BARDA or the Contractor and Incident Report shall be delivered to BARDA.

 

		●	Within 48 hours of activity or incident or within 24 hours for a security related activity or incident, Contractor must notify BARDA.

		●	Additional updates due to COR and CO within 48 hours of additional developments.

		●	Contractor shall submit within 5 business days a Corrective Action Plan (if deemed necessary by either party) to address any potential issues.

 

If corrective action is deemed necessary, Contractor must address in writing, its consideration of concerns raised by BARDA within 5 business days.

 

H.31. PROTECTION OF PERSONNEL WHO WORK WITH NONHUMAN PRIMATES

 

All Contractor personnel who work with nonhuman primates or enter rooms or areas containing nonhuman primates shall comply with the procedures set forth in NIH Policy Manual 3044-2, entitled, “Protection of NIH Personnel Who Work with Nonhuman Primates,” located at the following URL: http://www1.od.nih.gov/oma/manualchapters/intramural/3044-2/

 

H.32. DISSEMINATION OF INFORMATION (May 2004)

 

Other than scientific and technical Sections for which the contractor can assert a copyright under FAR Clause 52.227-14 I no information related to data obtained under this contract shall be released or publicized without the prior written consent of the Contracting Officer. In the event that the contractor seeks to publicize data through a scientific or technical Section, the contractor shall provide BARDA, through the COR, with a minimum of thirty (30) business days to review the Section prior to publication.

 

H.33. REGISTRATION WITH THE SELECT AGENT PROGRAM FOR WORK INVOLVING THE POSSESSION, USE, AND/OR TRANSFER OF SELECT BIOLOGICAL AGENTS OR TOXINS

 

Work involving select biological agents or toxins shall not be conducted under this contract until the Contractor and any affected subcontractor(s) are granted a certificate of registration or are authorized to work with the applicable select agents.

 

For prime or subcontract awards to domestic institutions who possess, use, and/or transfer Select Agents under this contract, the institution must complete registration with the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS) or the Animal and Plant Health Inspection Services (APHIS), U.S. Department of Agriculture (USDA), as applicable, before performing work involving Select Agents, in accordance with 42 CFR 73. No Government funds can be used for work involving Select Agents, as defined in 42 CFR 73, if the final registration certificate is denied.

 

For prime or subcontract awards to foreign institutions who possess, use, and/or transfer Select Agents under this contract, the institution must provide information satisfactory to the Government that a process equivalent to that described in 42 CFR 73 (http://www.cdc.gov/od/sap/docs/42cfr73.pdf ) for U.S. institutions is in place and will be administered on behalf of all Select Agent work sponsored by these funds before using these funds for any work directly involving the Select Agents. The Contractor must provide information addressing the following key elements appropriate for the foreign institution: safety, security, training, procedures for ensuring that only approved/appropriate individuals have access to the Select Agents, and any applicable laws, regulations and policies equivalent to 42 CFR 73. The Government will assess the policies and procedures for comparability to the U.S. requirements described in 42 CFR Part 73. When requested by the contracting officer, the Contractor shall provide key information delineating any laws, regulations, policies, and procedures applicable to the foreign institution for the safe and secure possession, use, and transfer of Select Agents. This includes summaries of safety, security, and training plans, and applicable laws, regulations, and policies. For the purpose of security risk assessments, the Contractor must provide the names of all individuals at the foreign institution who will have access to the Select Agents and procedures for ensuring that only approved and appropriate individuals have access to Select Agents under the contract.

 

56

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Listings of HHS select agents and toxins, biologic agents and toxins, and overlap agents or toxins as well as information about the registration process, can be obtained on the Select Agent Program Web site at http://selectagents.gov

 

H.34. MANUFACTURING STANDARDS

 

The Good Manufacturing Practice Regulations (GMP)(21 CFR Parts 820) will be the standard to be applied for manufacturing, processing, packaging, storage and delivery of this product.

 

If at any time during the life of the contract, the Contractor fails to comply with GMP in the manufacturing, processing, packaging, storage, stability and other testing of the manufactured drug substance or product and delivery of this product and such failure results in a material adverse effect on the safety, purity or potency of the product (a material failure) as identified by the FDA, the Contractor shall have thirty (30) calendar days from the time such material failure is identified to cure such material failure. If, within the thirty (30) calendar day period, the Contractor fails to take such an action to the satisfaction of the Government Project Officer, or fails to provide a remediation plan that is acceptable to the COR, then the contract may be terminated.

 

H.35. IN-PROCESS REVIEW

 

In Process Reviews (IPR) will be conducted at the discretion of the Government to discuss the progression of the milestones. The Government reserves the right to revise the milestones and budget pending the development of the project. Deliverables such as an overall project summary report and/or slides will be required when the IPRs are conducted. The Contractor’s success in completing the required tasks under each work segment must be demonstrated through the Deliverables and Milestones specified under Section F. Those deliverables will constitute the basis for the Government’s decision, at its sole discretion, to proceed with the work segment, or institute changes to the work segment, or terminate the work segment.

 

IPRs may be scheduled at the discretion of the Government to discuss progression of the contract. The Contractor shall provide a presentation following a prescribed template which will be provided by the Government at least 30 business days prior to the IPR. Subsequently, the contractor will be requested to provide a revised/final presentation to the Contracting Officer at least 10 business days prior to the IPR.

 

H.36. LABORATORY LICENSE REQUIREMENTS 

 

The contractor shall comply with all applicable requirements of the Code of Federal Regulations Title 21, Part 58 and FDA Medical Device GMP Guidance. This requirement shall also be included in any subcontract for services under the contract.

 

H.37. CARE OF LABORATORY ANIMALS  

 

		(a)	Notice to Offerors of Requirement for Compliance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals (January 2006)

 

57

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

The Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals (PHS Policy) establishes a number of requirements for research activities involving animals. Before award may be made to an applicant organization, the organization shall file, with the Office of Laboratory Animal Welfare (OLAW), National Institutes of Health (NIH), a written Animal Welfare Assurance (Assurance) which commits the organization to comply with the provisions of the PHS Policy, the Animal Welfare Act, and the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC). In accordance with the PHS Policy, applicant organizations must establish an Institutional Animal Care & Use Committee (IACUC), qualified through the experience and expertise of its members, to oversee the institution’s animal program, facilities and procedures. Applicant organizations are required to provide verification of IACUC approval prior to release of an award involving live vertebrate animals. No award involving the use of animals shall be made unless OLAW approves the Assurance and verification of IACUC approval for the proposed animal activities has been provided to the Contracting Officer. Prior to award, the Contracting Officer will notify Contractor(s) selected for projects that involve live vertebrate animals that an Assurance and verification of IACUC approval are required. The Contracting Officer will request that OLAW negotiate an acceptable Assurance with those Contractor(s) and request verification of IACUC approval. For further information, contact OLAW at NIH, 6705 Rockledge Drive, RKL1, Suite 360, MSC 7982 Bethesda, Maryland 20892–7982 (E-mail: olaw@od.nih.gov ; Phone: 301–496–7163).

 

H.38. HUMAN SUBJECTS

 

The Contractor shall submit all human clinical protocols and informed consent documents to BARDA for review and comment prior to submission to another entity.

 

Research involving human subjects shall not be conducted under this contract until the study protocol has been approved by the Department of Health and Human Services, written notice of such approval has been provided by the CO, and the Contractor has provided to the CO a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263 (formerly Optional Form 310) certifying IRB review and approval of the protocol. The human subject certification can be met by submission of the Contractor’s self-designated form, provided that it contains the information required by the “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263 (formerly Optional Form 310).

 

When research involving Human Subjects will take place at collaborating sites or other performance sites, the Contractor shall obtain, and keep on file, a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263 (formerly Optional Form 310) certifying IRB review and approval of the research.

 

H.39. SHARING RESEARCH DATA 

 

The Contractor’s data sharing plan, due date to be determined at contract award, is hereby incorporated by reference. The Contractor agrees to adhere to its plan and shall request prior approval of the Contracting Officer for any changes in its plan.

 

BARDA endorses the sharing of final research data to serve health. This contract is expected to generate research data that must be shared with the public and other researchers.

 

BARDA recognizes that data sharing may be complicated or limited, in some cases, by institutional policies, local IRB rules, as well as local, state and Federal laws and regulations, including the Privacy Rule (see HHS-published documentation on the Health Information Privacy at http://www.hhs.gov/ocr/privacy/index.html). The rights and privacy of people who participate in BARDA-funded research must be protected at all times; thus, data intended for broader use should be free of identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects. 

 

H.40 CONTINUED BAN ON FUNDING ABORTION AND CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH, HHSAR 352.270-13 (December 2015)

 

		52.	The Contractor shall not use any funds obligated under this contract for any abortion.

 

58

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

b. The Contractor shall not use any funds obligated under this contract for the following: 

(1) The creation of a human embryo or embryos for research purposes; or 

(2) Research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury of death greater than that allowed for research on fetuses in utero under 45 CFR part 46 and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)).

 

		52.	The term “human embryo or embryos” includes any organism, not protected as a human subject under 45 CFR part 46 as of the date of the enactment of this Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes of human diploid cells.

 

		52.	The Contractor shall not use any Federal funds for the cloning of human beings.

 (End of clause)

 

H.41 PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM ASPR FUNDED RESEARCH 

 

All ASPR-funded investigators shall submit to the NIH National Library of Medicine’s (NLM) PubMed Central (PMC) an electronic version of the author’s final manuscript, upon acceptance for publication, of any peer-reviewed scientific publications resulting from research supported in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response.  ASPR defines the author’s final manuscript as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. The PMC archive will preserve permanently these manuscripts for use by the public, health care providers, educators, scientists, and ASPR. The Policy directs electronic submissions to the NIH/NLM/PMC: http://www.pubmedcentral.nih.gov.

 

H.42 BARDA SECURITY REQUIREMENTS FOR FACILITIES

 

Security plan must be provided within 60 days if required and security remediation plan (if needed) must be required within 120 days.  All security requirements must be met prior to commencing manufacturing of any product.  See Section C for a detailed list of security requirements.

 

59

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

PART II – CONTRACT CLAUSES

 

SECTION I – CONTRACT CLAUSES

 

I.1. FAR 52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)

 

This contract incorporates the following clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at: http://www.acquisition.gov/far. HHSAR clauses at http://www.hhs.gov/policies/hhsar/subpart352.html

 

General Clauses for Cost-Reimbursement Research and Development Contract

 

		a.	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

	Reg	Clause	Date	Clause Title
	FAR	52.202-1	Nov 2013	Definitions 
	FAR	52.203-3	Apr 1984	Gratuities 
	FAR	52.203-5	May 2014	Covenant Against Contingent Fees 
	FAR	52.203-6	Sep 2006	Restrictions on Subcontractor Sales to the Government 
	FAR	52.203-7	May 2014	Anti-Kickback Procedures
	FAR	52.203-8	May 2014	
Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity 

	FAR	52.203-10	May 2014	Price or Fee Adjustment for Illegal or Improper Activity 
	FAR	52.203-11	Sept 2007	
Certification and Disclosure Regarding Payments to Influence Certain Federal Transactions 

	FAR	52.203-12	Oct 2010	Limitation on Payments to Influence Certain Federal Transactions 
	FAR	52.203-13	Oct 2015	Contractor Code of Business Ethics and Conduct
	FAR	52.203-14	Oct 2015	Display of Hotline Poster(s)
	FAR	52.203-17	Apr 2014	
Contractor Employee Whistleblower Rights and Requirement To Inform Employees of Whistleblower Rights 

	FAR	52.204-1	Dec 1989	Administrative Matters Provisions and Clauses
	FAR	52.204-4	May 2011	
Printed or Copied Double-Sided on Postconsumer Fiber Content Paper 

	FAR	52.204-5	Oct 2014	Women-Owned Business (Other Than Small Business)
	FAR  	52.204-7	Oct 2016	System for Award Management
	FAR  	52.204-10	Oct 2016	
Reporting Executive Compensation and First-Tier Subcontract Awards 

	FAR	52.204-13	Oct 2016	System for Award Management Maintenance
	FAR	52.204-16	Jul 2016	Commercial and Government Entity Code Reporting
	FAR	52.204-17	Jul 2016	Ownership of Control or Offeror
	FAR	52.204-18	Jul 2015	Commercial and Government Entity Code Maintenance
	FAR	52.207-1	May 2006	Notice of Standard Competition
	FAR	52.209-5	Oct 2015	Certification Regarding Responsibility Matters
	FAR  	52.209-6	Oct 2015	
Protecting the Government’s Interests When Subcontracting With 

Contractors Debarred, Suspended, or Proposed for Debarment 

	FAR	52.209-9	Jul 2013	
Updates of Publicly Available Information Regarding Responsibility Matters 

  

60

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

   

	FAR	52.209-10	Nov 2015	Prohibition on Contracting with Inverted Domestic Corporations
	FAR	52.210-1 	Apr 2011	Market Research
	FAR	52.211-5	Aug 2000	Material Requirements
	FAR  	52.215-2	Oct 2010	Audit and Records – Negotiation
	FAR  	52.215-8	Oct 1997	Order of Precedence – Uniform Contract Format
	FAR  	52.215-10	Aug 2011	Price Reduction for Defective Cost or Pricing Data 
	FAR	52.215-11	Aug 2011	
Price Reduction for Defective Certified Cost or Pricing Data —Modifications. 

	FAR  	52.215-12	Oct 2010	Subcontractor Certified Cost or Pricing Data 
	FAR	52.215-13	Oct 2010	Subcontractor Certified Cost or Pricing Data—Modifications
	FAR	52.215-14	Oct 2010	Integrity of Unit Prices (Over the Simplified Acquisition Threshold
	FAR	52.215-15	Oct 2010	Pension Adjustments and Asset Reversions
	FAR	52.215-16	June 2003	Facilities Capital Cost of Money
	FAR	52.215-17	Oct 1997	Waiver of Facilities Capital Cost of Money
	FAR	52.215-18	Jul 2005	
Reversion or Adjustment of Plans for Postretirement Benefits (PRB) other than Pensions 

	FAR	52.215-19	Oct 1997	Notification of Ownership Changes
	FAR	52.215-20	Oct 2010	
Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data 

	FAR	52.215-21	Oct 2010	
Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data – Modifications 

	FAR	52.215-22	Oct 2009	
Limitations on Pass-Through Charges—Identification of Subcontract Effort 

	FAR	52.215-23	Oct 2009	Limitations on Pass-Through Charges
	FAR	52.216-7	Aug 2018	Allowable Cost and Payment
	FAR	52.216-8	Jun 2011	Fixed Fee
	FAR	52.219-8	Nov 2016	Utilization of Small Business Concerns 
	FAR	52.219-9	Aug 2018	Small Business Subcontracting Plan 
	FAR	52.219-10	Oct 2014	Incentive Subcontracting Program
	FAR	52.219-16	Jan 1999	Liquidated Damages – Subcontracting Plan 
	FAR	52.219-28	Jul 2013	Post-Award Small Business Program Representation
	FAR	52.222-3	Jun 2003	Convict Labor
	FAR  	52.222-21	Apr 2015	Prohibition of Segregated Facilities
	FAR	52.222-24	Feb 1999	Pre-award On-Site Equal Opportunity Compliance Evaluation
	FAR	52.222-25	Apr 1984	Affirmative Action Compliance
	FAR  	52.222-26	Sept 2016	Equal Opportunity
	FAR	52.222-35	Oct 2015	Equal Opportunity for Veterans ($150,000 or more)
	FAR	52.222-36	Jul 2014	Equal Opportunity for Workers with  Disabilities
	FAR  	52.222-37	Feb 2016	Employment Reports on Veterans 
	FAR	52.222-38	Feb 2016	Compliance with Veterans’ Employment Reporting Requirements
	FAR  	52.222-40	Dec 2010	
Notification of Employee Rights Under the National Labor Relations Act 

	FAR  	52.222-50	Mar 2015	Combating Trafficking in Persons
	FAR  	52.222-54	Oct 2015	Employment Eligibility Verification 
	FAR	52.222-59	Dec 2016	Compliance With Labor Laws (Executive Order 13673)

  

61

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

				
	FAR	52.222-60	Oct 2016	Paycheck Transparency (Executive Order 13673)
	FAR 	52.222-61	Dec 2016	Arbitration of Contractor Employee Claims (Executive Order 13673)
	FAR 	52.222-62	Jan 2017	Paid Sick Leave Under Executive Order 13706
	FAR  	52.223-6	May 2001	Drug-Free Workplace
	FAR  	52.223-18	Aug 2011	
Encouraging Contractor Policy to Ban Text Messaging While Driving 

	FAR  	52.225-13	Jun 2008	Restrictions on Certain Foreign Purchases
	FAR	52.225-25	Oct 2015	
Prohibition on Contracting with Entities Engaging in Certain Activities or Transactions Relating to Iran—Representation and Certifications 

	FAR	52.226-1	Jun 2000	
Utilization of Indian Organizations and Indian-Owned Economic Enterprises. 

	FAR  	52.227-1	Dec 2007	Authorization and Consent, Alternate 1 (APR 1984)
	FAR  	52.227-2	Dec 2007	
Notice and Assistance Regarding Patent and Copyright Infringement 

	FAR 	52.227-3	Apr 1984	Patent Indemnity
	FAR	52.227-11	May 2014	Patent Rights – Ownership by the Contractor
	FAR	52.227-14	May 2014	Rights in Data – General
	FAR	
52.227-14 

Alt. II 

	Dec 2007	Rights in Data – General – Limited Rights Notice
	FAR	52.227-15	Dec 2007	
Representation of Limited Rights Data and Restricted Computer Software 

	FAR	52.227-16	June 1987	Additional Data Requirements
	FAR	52.228-7	Mar 1996	Insurance – Liability to Third Persons
	FAR	52.230-2	Oct 2015	Cost Accounting Standards
	FAR	52.230-3	Oct 2015	Disclosure and Consistency of Cost Accounting Practices
	FAR	52.230-6	Jun 2010	Administration of Cost Accounting Standards
	FAR	52.230-7	Apr 2005	Proposal Disclosure—Cost Accounting Practice Changes
	FAR  	52.232-9	Apr 1984	Limitation on Withholding of Payments
	FAR  	52.232-17	May 2014	Interest
	FAR	52.232-20	Apr 1984	Limitation of Cost
	FAR  	52.232-23	May 2014	Assignment of Claims
	FAR  	52.232-25	Jan 2017	Prompt Payment
	FAR  	52.232-33	Jul 2013	
Payment by Electronic Funds Transfer–System for Award Management 

	FAR	52.232.39	Jun 2013	Unenforceability of Unauthorized Obligations
	FAR	52.232-40	Dec 2013	Providing Accelerated Payments to Small Business Subcontractors
	FAR  	52.233-1	May 2014	Disputes
	FAR  	52.233-3	Aug 1996	Protest After Award, Alternate 1 (Jun 1985)
	FAR  	52.233-4	Oct 2004	Applicable Law for Breach of Contract Claim
	FAR	52.242-1	Apr 1984	Notice of Intent to Disallow Costs
	FAR	52.242-3	May 2014	Penalties for Unallowable Costs
	FAR	52.242-4	Jan 1997	Certification of Final Indirect Costs
	FAR  	52.242-13	Jul 1995	Bankruptcy 
	FAR	52.243-2	Aug 1987	Changes – Cost-Reimbursement Alternate V (Apr 1984)

 

62

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	FAR	52.244-2	Oct 2010	Subcontracts, Alternate 1 (Jun 2007) 
	FAR	52.244-5	Dec 1996	Competition in Subcontracting
	FAR  	52.244-6	Aug 2018	Subcontracts for Commercial Items
	FAR 	52.245-1	Apr 2012	Government Property
	FAR	52.245-9	Apr 2012	Use and Charges
	FAR	52.246-23	Feb 1997	Limitation of Liability
	FAR	52.249-6	May 2004	Termination (Cost-Reimbursement)
	FAR	52.249-14	Apr 1984	Excusable Delays
	FAR  	52.253-1	Jan 1991	Computer Generated Forms

 

		b.	DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES:

 

	
HHSAR   

	352.203-70	Dec 2015	Anti-Lobbying 
	HHSAR	352.208-70	Dec 2015	Printing and Duplication
	HHSAR	352.211-3	Dec 2015	Paperwork Reduction Act
	HHSAR	352.219-70	Dec 2015	Mentor-Protégé Program
	HHSAR	352.219-71	Dec 2015	Mentor-Protégé Program Reporting Requirements
	HHSAR	352.222-70	Dec 2015	Contractor Cooperation in Equal Employment Opportunity Investigations
	HHSAR	352.223-70	Dec 2015	Safety and Health
	HHSAR	352.224-70	Dec 2015	Privacy Act
	HHSAR	352.224-71	Dec 2016	Confidential Information
	HHSAR  	352.227-70	Dec 2015	Publications and Publicity
	HHSAR	352.231-70	Dec 2015	Salary Rate Limitation
	HHSAR  	352.233-71	Dec 2015	Litigation and Claims
	HHSAR	352.237-75	Dec 2015	Key Personnel
	HHSAR	352.239-74	Dec 2015	Electronic and Information Technology Accessibility
	HHSAR	352.270-9	Dec 2015	Non-discrimination for Conscience

  

I.2. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

 

This contract incorporates the following clauses in full text. FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

FAR Clause 52.217-8 Option to Extend Services (Nov 1999)

 

The Government may require continued performance of any services within the limits and at the rates specified in the contract. These rates may be adjusted only as a result of revisions to prevailing labor rates provided by the Secretary of Labor. The option provision may be exercised more than once, but the total extension of performance hereunder shall not exceed 6 months. The Contracting Officer may exercise the option by written notice to the Contractor within 30 days of end of period of performance.

 

FAR Clause 52.217-9, Option to Extend the Term of the Contract (Mar 2000)

 

The Government may extend the term of this contract by written notice to the Contractor within 15 days provided that the Government gives the Contractor a preliminary written notice of its intent to extend at least 30 days before the contract expires. The preliminary notice does not commit the Government to an extension.

 

63

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

• If the Government exercises this option, the extended contract shall be considered to include this option clause.

 

• The total duration of this contract, including the exercise of any options under this clause, shall not exceed 10 years.

 

FAR Clause 52.219-28, Post-Award Small Business Program Representation (July 2013)

 

		a.	Definitions. As used in this clause--

 

Long-term contract means a contract of more than five years in duration, including options. However, the term does not include contracts that exceed five years in duration because the period of performance has been extended for a cumulative period not to exceed six months under the clause at 52.217-8, Option to Extend services, or other appropriate authority.

 

Small business concern means a concern, including its affiliates, that is independently owned and operated, not dominant in the field of operation in which it is bidding on Government contracts, and qualified as a small business under the criteria in 13 CFR part 121 and the size standard in paragraph (c) of this clause. Such a concern is “not dominant in its field of operation” when it does not exercise a controlling or major influence on a national basis in a kind of business activity in which a number of business concerns are primarily engaged. In determining whether dominance exists, consideration shall be given to all appropriate factors, including volume of business, number of employees, financial resources, competitive status or position, ownership or control of materials, processes, patents, license agreements, facilities, sales territory, and nature of business activity.

 

		b.	If the Contractor represented that it was a small business concern prior to award of this contract, the Contractor shall re-represent its size status according to paragraph (e) of this clause or, if applicable, paragraph (g) of this clause, upon the occurrence of any of the following:

 

(1) Within 30 days after execution of a novation agreement or within 30 days after modification of the contract to include this clause, if the novation agreement was executed prior to inclusion of this clause in the contract.

 

(2) Within 30 days after a merger or acquisition that does not require a novation or within 30 days after modification of the contract to include this clause, if the merger or acquisition occurred prior to inclusion of this clause in the contract.

 

(3) For long-term contracts--

 

(i)  Within 60 to 120 days prior to the end of the fifth year of the contract; and  

(ii) Within 60 to 120 days prior to the date specified in the contract for exercising any option thereafter.

 

		c.	The Contractor shall represent its size status in accordance with the size standard in effect at the time of this re-representation that corresponds to the North American Industry Classification System (NAICS) code assigned to this contract. The small business size standard corresponding to this NAICS code can be found at http://www.sba.gov/content/table-small-business-size-standards

 

		d.	The small business size standard for a Contractor providing a product which it does not manufacture itself, for a contract other than a construction or service contract, is 500 employees.

  

64

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

		e.	Except as provided in paragraph (g) of this clause, the Contractor shall make the representation required by paragraph (b) of this clause by validating or updating all its representations in the Representations and Certifications Section of the System for Award Management (SAM) and its other data in SAM, as necessary, to ensure that they reflect the Contractor’s current status. The Contractor shall notify the contracting office in writing within the timeframes specified in paragraph (b) of this clause that the data have been validated or updated, and provide the date of the validation or update.

 

		f.	If the Contractor represented that it was other than a small business concern prior to award of this contract, the Contractor may, but is not required to, take the actions required by paragraphs (e) or (g) of this clause.

 

		g.	If the Contractor does not have representations and certifications in SAM, or does not have a representation in SAM for the NAICS code applicable to this contract, the Contractor is required to complete the following representation and submit it to the contracting office, along with the contract number and the date on which the representation was completed:

 

The Contractor represents that it [X] is, [ ] is not a small business concern under NAICS Code 541714 assigned to contract number HHSO100201800023C.

 

FAR 52.204-21 Basic Safeguarding of Covered Contractor Information Systems (Jun 2016)

 

(a) Definitions. As used in this clause--

 

“Covered contractor information system” means an information system that is owned or operated by a contractor that processes, stores, or transmits Federal contract information.

 

“Federal contract information” means information, not intended for public release, that is provided by or generated for the Government under a contract to develop or deliver a product or service to the Government, but not including information provided by the Government to the public (such as on public Web sites) or simple transactional information, such as necessary to process payments.

 

“Information” means any communication or representation of knowledge such as facts, data, or opinions, in any medium or form, including textual, numerical, graphic, cartographic, narrative, or audiovisual (Committee on National Security Systems Instruction (CNSSI) 4009).

 

“Information system” means a discrete set of information resources organized for the collection, processing, maintenance, use, sharing, dissemination, or disposition of information (44 U.S.C. 3502).

 

“Safeguarding” means measures or controls that are prescribed to protect information systems.

 

(b) Safeguarding requirements and procedures. 

 

(1) The Contractor shall apply the following basic safeguarding requirements and procedures to protect covered contractor information systems. Requirements and procedures for basic safeguarding of covered contractor information systems shall include, at a minimum, the following security controls:

 

(i) Limit information system access to authorized users, processes acting on behalf of authorized users, or devices (including other information systems).

 

(ii) Limit information system access to the types of transactions and functions that authorized users are permitted to execute.

 

65

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

(iii) Verify and control/limit connections to and use of external information systems.

 

(iv) Control information posted or processed on publicly accessible information systems.

 

(v) Identify information system users, processes acting on behalf of users, or devices.

 

(vi) Authenticate (or verify) the identities of those users, processes, or devices, as a prerequisite to allowing access to organizational information systems.

 

(vii) Sanitize or destroy information system media containing Federal Contract Information before disposal or release for reuse.

 

(viii) Limit physical access to organizational information systems, equipment, and the respective operating environments to authorized individuals.

 

(ix) Escort visitors and monitor visitor activity; maintain audit logs of physical access; and control and manage physical access devices.

 

(x) Monitor, control, and protect organizational communications (i.e., information transmitted or received by organizational information systems) at the external boundaries and key internal boundaries of the information systems.

 

(xi) Implement subnetworks for publicly accessible system components that are physically or logically separated from internal networks.

 

(xii) Identify, report, and correct information and information system flaws in a timely manner.

 

(xiii) Provide protection from malicious code at appropriate locations within organizational information systems.

 

(xiv) Update malicious code protection mechanisms when new releases are available.

 

(xv) Perform periodic scans of the information system and real-time scans of files from external sources as files are downloaded, opened, or executed.

 

(2) Other requirements. This clause does not relieve the Contractor of any other specific safeguarding requirements specified by Federal agencies and departments relating to covered contractor information systems generally or other Federal safeguarding requirements for controlled unclassified information (CUI) as established by Executive Order 13556.

 

(c) Subcontracts. The Contractor shall include the substance of this clause, including this paragraph (c), in subcontracts under this contract (including subcontracts for the acquisition of commercial items, other than commercially available off-the-shelf items), in which the subcontractor may have Federal contract information residing in or transiting through its information system.

 

(End of clause)

 

66

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

 

SECTION J - LIST OF ATTACHMENTS

 

The following documents are attached and incorporated in this contract:

 

1. Statement of Work

 

Statement of Work, dated 09/02/2018 11 pages

 

2. Invoice/Financing Request Instructions for AMCG Cost-Reimbursement Type Contracts,

 

Invoice/Financing Request Instructions and Contract Financial Reporting Instructions for AMCG Cost-Reimbursement Type Contracts, 2 pages.

 

3. Sample Invoice, 1 page

 

4. Financial Report of Individual Project/Contract, 1 page

 

5. Instructions for Completing Financial Report of Individual Project/Contract, 2 pages

 

6. Inclusion Enrollment Report

 

Inclusion Enrollment Report, 5/01 (Modified OAMP: 10/01), 1 page.

 

7. Research Patient Care Costs

 

Research Patient Care Costs, 1 page.

 

8. Report of Government Owned, Contractor Held Property

 

Report of Government Owned, Contractor Held Property,1 page. Located at: http://rcb.cancer.gov/rcb-internet/forms/Govt-Owned-Prop.pdf

 

67

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment #1

 

BARDA Broad Agency Announcement (BAA) 

 

(Solicitation BAA-16-100-SOL-0001 (CBRN)

 

Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures

 

NexoBrid 

Topic Area of Interest No. (5) – 5.2, “Vesicants”

 

Contractual Statement of Work 

September 2, 2018 (r04)

 

PREAMBLE

 

Independently, and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified professional, technical, and administrative personnel, material, equipment and facilities, not otherwise provided by the Government under the terms of this contract, as needed to perform the tasks set forth below according to BAA-16-100-SOL-0001 (CBRN).

 

Overall Objectives and Scope

 

The overall objective of this contract is to advance the development of “NexoBrid” as a proposed removal agent for tissue damaged by Sulfur-Mustard. The Research and Development (R&D) effort for the NexoBrid will progress in specific stages that cover the base performance (I) segment and 4 option segments as specified in this contract.

 

SOW Table 1: Contract Option Summary

 

	Option	Description
	CLIN 0001 (base period)	Development of NexoBrid as an MCM with the Gottingen Mini-Pig Model (POC)
	CLIN 0002 (option)	Pivotal Trials in Gottingen Mini-Pigs and BLA Submission
	CLIN 0003 (option)	Proof of Concept Studies Hairless Guinea Pig Model (POC)
	CLIN 0004 (option)	Pivotal Trial in Hairless Guinea Pig
	CLIN 0005 (option)	[***]

 

 68

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

SOW Table 2: SOW Summary Table

  

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est)	CLIN
	1	Base Period	NexoBrid for the Treatment of SM Cutaneous Injury (POC)	 	0001
	1.1	Program Management	Program Management 	 	 	 	 	0001
	1.1.1	Technical and Project Management	 	0001
	1.1.1.1	Project Management and Reporting	The overall management, integration and coordination of all contract activities. Staffing, review meetings and monthly and annual reports. 	
PM designated.

Monthly technical progress reports. Annual technical progress report.

Biweekly meeting minutes.

	
PM designated.

 

Reports submitted to BARDA PO/CO.

	[***]	[***]	0001
	1.1.1.2	Integrated Product Development Plan (IPDP)	Prepare IPDP including IMS, GO/NO-GO and TLCC for BARDA PO/CO approval.	IPDP draft completed within 14 days of contract award. 	
IPDP completed within 14 days of contract award.

IMS completed.

	[***]	[***]	0001
	1.1.2	Subcontractor Management	 	0001
	1.1.2.1	Base Period Subcontractor Management Plan	Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.	Completion of subcontractor management plan.	Completion of subcontractor management plan.	[***]	[***]	0001
	1.1.3	Risk Management	 	0001
	1.1.3.1	Risk Management	Risk mitigation plan, PMBR, deviation requests as needed. 	
Complete risk mitigation plan.

 

PMBR

	
Develop Risk Mitigation Plan (timeline TBD)

 

PMBR within 90 days of award, deviation requests as required.

	[***]	[***]	0001
	1.1.4	EVMS	 	0001
	1.1.4.1	EVMS System Implementation	Elements of EVMS shall be applied to all CLINs as part of the IPDP, the Contractor shall submit a written summary of the management procedures that it will establish, maintain and use to comply with EVMS requirements	Complete EVMS plan and report.	
Develop EVMS Plan.

Complete EVMS Plan Implementation.

	[***]	[***]	0001
	1.1.4.2	EVMS Monthly Reports Begin	Prepare EVMS monthly reports after first report. 	Complete monthly reports. 	Complete monthly reports and submit to BARDA CO/PO.	[***]	[***]	0001
	1.2	Non-Clinical Toxicology	Non-Clinical PK/PD and Safety studies.	 	0001
	1.2.1	PK/PD	Pharmacokinetic (PK) and Pharmacodynamic (PD) studies.	 	 
	1.2.1.1	Bioanalytical Methods Development: Mini-Pig (Gottingen)	Adapt existing bioanalytical methods for NXB PK and immunogenicity to models. Develop/transfer and validate methods for GLP use per ICH method validation guidance.	Complete method development and validation. 	Reports submitted to BARDA. 	[***]	[***]	0001
	1.2.1.2	PK Studies: Mini-Pig (Gottingen)	Conduct pilot PK study for this model prior to POC.. [***]	Complete study. 	Study protocol / report submitted to BARDA.	[***]	[***]	0001
	1.3	Non-Clinical Pharmacology	Non-Clinical animal model development and proof of concept efficacy studies	 	0001
	1.3.1	Animal Model Development	Animal Model Development studies	 	0001

 

 69

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est)	CLIN
	1.3.1.1	SM Exposure [***] Wound Depth: Mini-Pig (Gottingen)	[***]	Complete study.	
Study protocol / report submitted to BARDA.

 

[***]

	[***]	[***]	0001
	1.3.1.2	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0001
	1.3.1.3	Statistical Analysis: Mini-Pig (Gottingen)	Provide statistical support including pharmacometric analysis for this model from PK and nonclinical data.	Provide support	Analysis submitted to BARDA as required	[***]	[***]	0001
	1.3.2	POC Studies	Proof of Concept (POC) studies to enable pivotal studies. 	 	0001
	1.3.2.1	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0001
	1.3.2.2	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0001
	1.3.2.3	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0001
	1.3.2.4	POC Efficacy Study: Mini-Pig (Gottingen)	Using the exposure and treatment scenarios as determined in earlier studies, this study will aim at determining the efficacy of NexoBrid in a non-GLP study. [***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0001
	1.5	Regulatory	Regulatory activities. 	 	0001
	1.5.1	IND	For IND / EOP2	 	0001
	1.5.1.1	FDA Meetings and Requests for Review	PIND and other RA Meetings/ requests for review at each development milestone.	Conduct meetings.	Meeting minutes to BARDA PO/CO	[***]	[***]	0001
	1.5.1.2	[***]	[***]	[***]	[***]	[***]	[***]	0001
	1.5.1.3	IND Submission	IND preparation and submission 	Prepare IND.	Submit to FDA. 	[***]	[***]	0001
	1.5.1.4	End of P2 Meeting	End of Phase 2 Meeting	Conduct meeting.	Meeting minutes to BARDA PO/CO	[***]	[***]	0001

   

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	2	CLIN 0002	Pivotal Trials in Gottingen Mini-Pigs and BLA Submission	 	0002
	2.1	Program Management	Program Management 	 	 	 	 	0002
	2.1.1	Technical and Project Management	 	0002
	2.1.1.1	Project Management and Reporting	Option project management.	Option project management.	Reports submitted to BARDA PO/CO. 	[***]	[***]	0002
	2.1.1.2	EVMS Monthly Reports Begin	Prepare EVMS monthly reports	Complete monthly reports. 	Complete monthly reports and submit to BARDA CO/PO.	[***]	[***]	0002
	2.3	Non-Clinical Pharmacology	Non-Clinical animal model pivotal studies	 	 	 	 	0002
	2.3.3	Efficacy Studies	Pivotal Efficacy Studies	 	0002
	2.3.3.1	Two Pivotal Efficacy Studies: Mini-Pig (Gottingen)	Show efficacy under the Animal Rule[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0002
	2.5	Regulatory	Regulatory activities. 	 	0002
	2.5.2	BLA	BLA submission	 	0002

 

 70

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	2.5.2.1	Regulatory - Gap Analysis	Pre-BLA gap analysis by SMEs.	Prepare gap analysis.	Submit to BARDA PO/CO.	$150,000	Q4 2021	0002
	2.5.2.2	Pre-BLA Meeting	Pre-BLA meeting	Conduct pre-BLA meeting.	Meeting minutes to BARDA PO/CO	$150,000	Q4 2022 	0002
	2.5.2.3	[***]	[***]	[***]	[***]	[***]	[***]	0002
	2.5.2.4	[***]	[***]	[***]	[***]	[***]	[***]	0002
	2.5.2.5	Preparation and Submission of BLA 	Submit BLA. Respond to FDA feedback and update BLA as needed.	Prepare BLA.	Submit to FDA	[***]	[***]	0002
	2.5.3	Post-Approval	Post-approval	 	0002
	2.5.3.1	MCI Support Under Animal Rule – Data Collection and Reporting	Create plan for this contingency. 	Prepare plan.	Submit to BARDA PO/CO.	[***]	[***]	0002

  

 71

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	3	Contract Option	CLIN 0003 Option – Proof of Concept Studies Hairless Guinea Pig Model (POC)	 	0003
	3.1	Program Management	Program Management 	 	 	 	 	0003
	3.1.1	Technical and Project Management	 	0003
	3.1.1.1	Project Management and Reporting	Option project management.	Option project management.	Reports submitted to BARDA PO/CO. 	[***]	[***]	0003
	3.1.1.2	EVMS Monthly Reports 	Prepare EVMS monthly reports	Complete monthly reports. 	Complete monthly reports and submit to BARDA CO/PO.	[***]	[***]	0003
	3.2	Non-Clinical Toxicology	Non-Clinical PK/PD and Safety studies.	 	0003
	3.2.1	PK/PD	Pharmacokinetic (PK) and Pharmacodynamic (PD) studies.	 	0003
	3.2.1.1	Bioanalytical Methods Development: Hairless guinea pig	Adapt existing development bioanalytical methods for NXB to model. Method development and Validate methods for GLP use per ICH method validation guidance.	Complete method development and validation. 	Reports submitted to BARDA. 	[***]	[***]	0003
	3.2.1.2	PK Studies: Hairless guinea pig	Conduct pilot PK study for this model. [***]	Complete study. 	Study protocol / report submitted to BARDA.	[***]	[***]	0003
	3.3	Non-Clinical Pharmacology	Non-Clinical animal model development, proof of concept efficacy studies	 	0003
	3.3.1	Animal Model Development	Animal Model Development studies	 	0003
	3.3.1.1	SM Exposure [***] Wound Depth: Hairless guinea pig	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0003
	3.3.1.2	Statistical Analysis: Hairless Guinea Pig	Provide statistical support including pharmacometric analysis for this model from PK and nonclinical data.	Provide support	Analysis submitted to BARDA as required	[***]	[***]	0003
	3.3.2	POC Studies	Proof of Concept (POC) studies to enable pivotal studies. 	 	0003
	3.3.2.1	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0003
	3.3.2.2	[***]	[***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0003
	3.3.2.3	POC Efficacy Study: Hairless guinea pig	
Using the exposure and treatment scenarios as determined in earlier studies, this study will aim at determining the efficacy of NexoBrid in a non-GLP study.

[***]

	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0003
	3.5	Regulatory	Regulatory activities. 	 	0003
	3.5.1	IND	For IND / EOP2	 	0003
	3.5.1.4	End of P2 Meeting	End of Phase 2 Meeting	Conduct meeting.	Meeting minutes to BARDA PO/CO	[***]	[***]	0003

 

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	4	Contract Option	CLIN 0004 Option – Pivotal Trials in Hairless Guinea Pig	 	0004
	4.1	Program Management	Program Management	 	0004
	4.1.1	Technical and Project Management	Technical and Project Management	 	0004

 

 72

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	4.1.1.1	Project Management and Reporting	Option project management.	Option project management.	Reports submitted to BARDA PO/CO. 	[***]	[***]	0004
	4.1.1.2	EVMS Monthly Reports 	Prepare EVMS monthly reports	Complete monthly reports. 	Complete monthly reports and submit to BARDA CO/PO.	[***]	[***]	0004
	4.3	Non-Clinical Pharmacology	Non-Clinical animal studies, pivotal trial	 	0004
	4.3.3	Efficacy Studies	Efficacy Studies	 	0004
	4.3.3.1	Pivotal Efficacy Study: Hairless guinea pig	Show efficacy under the Animal Rule, [***] test for efficacy of NXB under GLP conditions in accordance with the Animal Rule. [***]	Complete study.	Study protocol / report submitted to BARDA. 	[***]	[***]	0004
	4.5	Regulatory	Regulatory activities. 	 	0004
	4.5.2	BLA	BLA submission	 	0004
	4.5.2.1	Regulatory - Gap Analysis	Pre-BLA gap analysis by SMEs.	Prepare gap analysis.	Submit to BARDA PO/CO.	[***]	[***]	0004
	4.5.2.2	Pre-BLA Meeting	Pre-BLA meeting	Conduct pre-BLA meeting.	Meeting minutes to BARDA PO/CO	[***]	[***]	0004
	4.5.2.3	Preparation and Submission of BLA 	Submit BLA. Respond to FDA feedback and update BLA as needed (additional updates for second animal model)	Prepare BLA.	Submit to FDA	[***]	[***]	0004
	4.5.2.5	[***]	[***]	[***]	Submit to FDA	[***]	[***]	0004

  

	WBS	Title	Description	Milestone	Deliverables	Cost	Delivery Date (est.)	CLIN
	5	Contract Option	Option – Dual-Chamber Frangible Pouch Development (CLIN 0005)	 	0005
	5.1	Program Management	Program Management 	 	 	 	Q	0005
	5.1.1	Technical and Project Management	 	0005
	5.1.1.1	Project Management and Reporting	Option project management.	Option project management.	Reports submitted to BARDA PO/CO. 	[***]	[***]	0005
	5.6	CMC	CMC development	 	 	 	 	0005
	5.6.3	Packaging Development	 	0005
	5.6.3.1	Feasibility for container/closure system for efficient & ease of use in MCI	Conduct feasibility study [***]	Feasibility studies	Submit report to BARDA PO/CO.	[***]	[***]	0005
	5.6.3.2	Develop new container/closure system for efficient & ease of use in MCI	[***]	Development, batch manufacturing and stability. 	Submit report to BARDA PO/CO.	[***]	[***]	0005
	5.6.5	Analytical / Validation	 	0005
	5.6.5.1	RT Stability	[***] ICH stability study in current configuration.	Complete study.	Report to BARDA PO/CO	[***]	[***]	0005

 

 73

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		WBS 1	Base Period Contract

 

The Contractor shall provide for the following as outlined below and in the contract deliverables list (Article F.2):

 

WBS 1.1 Program Management

 

Objective / Description of Work:

 

		a.	Identification of and management to, distinct stages of the product development pathway that are gates for Go/No Go decisions for advancing to the next stage of the Integrated Product Development Plan.

		b.	Establishment of and tracking of milestones and timelines for the initiation conduct, and completion of product development activities for each stage with a budget (in direct costs) linked to each stage.

		c.	Ongoing evaluation of qualitative and quantitative criteria and accompanying data used to assess the scientific merit and technical feasibility of proceeding to the next stage of product development.

		d.	Maintaining and managing staff (in-house and contracted) to assure the necessary expertise and dedicated effort to perform the work.

		e.	Directing and overseeing subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.

		f.	Conducting performance measurement that shall include establishing an initial plan; defining measurable parameters; defining how these parameters relate to cost and schedule impacts; their approach in providing a detailed schedule that generates a critical path for the project; and a description of the cost- accounting system used or intended to be used based on budget estimates to monitor all costs related to the contract award for both prime- and sub- contractors on a real time basis.

		g.	Perform assessments of technical approaches to reduce the Total Life Cycle Cost (TLCC) for the proposed countermeasure throughout the products life cycle and identify strategic approaches to ensure the product has a sustainable commercial value to ensure long term access to the medical countermeasure.

 

Milestones/Deliverables:

 

Described in individual WBS items below (1.1.1. – 1.1.4)

 

		WBS 1.1.1	Technical and Project Management

 

		WBS 1.1.1.1	Project Management and Reporting

 

Objective / Description of Work:

 

The overall management, integration and coordination of all contract activities.

 

Staffing: A Project Manager (PM) will be designated by MediWound who is responsible for project management, communication, tracking, monitoring and reporting on status and progress, costs incurred and responsibility for effective communication with the BARDA Project Officer and Contracting Officer.

 

Contract Review Meetings: The Contractor shall participate in regular meetings to coordinate and oversee the contract effort as directed by the Contracting and Project Officers. The Contractor shall participate in teleconferences every two weeks or as required with BARDA to review technical progress.

 

Monthly and Annual Reports: The Contractor shall deliver Project Status Reports monthly, referencing the WBS, SOW, IMS, and EVM.

 

Milestones/ Deliverables:

 

PM designated.

 

Monthly technical progress reports. Annual technical progress report.

 

Biweekly meeting minutes.

 

		WBS 1.1.1.2	Integrated Product Development Plan (IPDP)

 

Objective / Description of Work:

 

MediWound shall prepare an IPDP including:

 

 74

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Integrated Master Schedule: The Integrated Master Schedule shall be incorporated into the contract and will be used to monitor performance of the contract. Contractor shall include the key milestones and Go/No Go decisions.

 

GO/ NO-GO Decisions: The Integrated Master Plan outlines key milestones with “Go/No Go” decision criteria (entrance and exit criteria for each phase of the project). The project plan should include, but not be limited to, milestones in manufacturing, non-clinical and clinical studies, and regulatory submissions.

 

TLCC: Perform assessments of technical approaches to reduce the Total Life Cycle Cost (TLCC) for the proposed countermeasure throughout the products life cycle and identify strategic approaches to ensure the product has a sustainable commercial value to ensure long term access to the medical countermeasure.

 

Milestones/ Deliverables:

 

IPDP completed within 14 days of contract award.

 

IMS completed.

 

		WBS 1.1.2	Subcontractor Management

 

		WBS 1.1.2.1	Base Period Subcontractor Management

 

Objective/Description of Work: 

 

Contractor will direct and oversee subcontractors and consultants to assure successful performance of planned activities within the cost and schedule constraints of the contract.

 

Milestones/Deliverables:

 

Completion of subcontractor management activities for the base period. Documentation of completed work in the Technical Progress Reports.

 

		WBS 1.1.3	Risk Management

 

		WBS 1.1.3.1	Base Period Risk Management

 

Objective/Description of Work: MediWound will prepare a Risk Mitigation Plan and Matrix and submit to BARDA. MediWound will maintain and update the plan as necessary throughout the term of the contract and provide updates as requested by the COR. A report on these activities will be included as part of regular quarterly project status updates to the BARDA PO/CO.

 

Performance Measurement Baseline Review (PMBR): The Contractor shall submit a plan for a PMBR to occur within 90 days of contract award.

 

Deviation Request: During contract performance, in response to a need to change IMS activities as baselined at the PMBR, the Contractor shall submit a Deviation Report. This report shall request a change in the agreed-upon IMS and timelines.

 

Milestones/Deliverables:

 

Develop Risk Mitigation Plan (timeline TBD) 

PMBR within 90 days of award 

Deviation requests as required.

 

		WBS 1.1.4	EVMS

 

		WBS 1.1.4.1	EVMS System Implementation

  

Objective/Description of Work: Subject to the requirements under HHSAR Clause 352.234-4, the Contractor shall use principles of Earned Value Management System (EVMS) in the management of this contract.

 

Elements of EVMS shall be applied to all CLINs as part of the Integrated Master Project Plan, the Contractor shall submit a written summary of the management procedures that it will establish, maintain and use to comply with EVMS requirements.

 

Milestones/Deliverables:

 

Develop EVMS Plan. 

Complete EVMS Plan Implementation.

 

 75

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		WBS 1.1.4.2	EVMS Monthly Reports

 

Objective/Description of Work:

 

Prepare EVMS reports monthly.

 

Milestones/Deliverables:

 

Prepare EVMS reports monthly after first report.

 

WBS 1.2 Non-Clinical Toxicology

 

		WBS 1.2.1	PK/PD

 

		WBS 1.2.1.1	Bioanalytical Methods Technology Transfer Development& Validation: Mini-Pig (Gottingen)

   

Objective/Description of Work:

 

Adapt existing bioanalytical methods for NXB to model. Technology transfer & Validate methods for GLP use per ICH method validation guidance.

 

Milestones/Deliverables: 

 

Complete method development transfer and validation and submit protocol and report to BARDA.

 

		WBS 1.2.1.2	PK Studies: Mini-Pig (Gottingen)

 

Objective/Description of Work:

 

Validation of the bioanalytical method in mini pig serum. Conduct PK study for this model. [***]

 

Milestones/Deliverables: 

 

Complete study and submit report to BARDA.

 

		WBS 1.3	Non-Clinical Pharmacology

 

		WBS 1.3.1	Animal Model Development

 

		WBS 1.3.1.1	SM Exposure [***] Wound Depth: Mini-Pig (Gottingen)

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables: 

 

Complete study and submit protocol and report to BARDA

 

[***]

 

		WBS 1.3.1.2	[***]

 

Milestones/Deliverables: 

 

Complete study and submit protocol and report to BARDA.

 

		WBS 1.3.1.3	Statistical Support

 

Provide statistical analysis support as needed for nonclinical studies.

 

		WBS 1.3.2	Proof of Concept Studies

 

		WBS 1.3.2.1	[***]

 

 76

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables: 

 

Complete study and submit protocol and report to BARDA

 

		WBS 1.3.2.2	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables: 

 

Complete study and submit protocol and report to BARDA

 

		WBS 1.3.2.3	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

		WBS 1.3.2.4	POC Efficacy Study: Mini-Pig (Gottingen)

  

Objective/Description of Work:

 

[***], this study will aim at determining the efficacy of NexoBrid in a non-GLP study.

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

WBS 1.4 Clinical (Reserved)

 

WBS 1.5 Regulatory

 

		WBS 1.5.1	IND

 

		WBS 1.5.1.1	FDA Meetings and Requests for Review

  

Objective/Description of Work:

 

Under the Animal Rule, FDA will grant review requests for study protocols and reports, as well as at significant milestones.

 

Milestones/Deliverables:

 

PIND and other RA Meetings/ requests for review at each development milestone. Submit meeting minutes to BARDA PO/CO.

 

		WBS 1.5.1.2	[***]

  

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables: 

 

Submit application to FDA.

 

		WBS 1.5.1.3	Submit IND

  

Objective/Description of Work:

 

MediWound will submit an IND when required by FDA for further development under the Animal Rule.

 

 77

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Milestones/Deliverables:

 

Submit IND to FDA.

 

		WBS 1.5.1.4	End of Phase 2 Meeting

 

Objective/Description of Work:

 

Conduct EOP2 meeting with FDA.

 

Milestones/Deliverables:

 

Conduct meeting, submit minutes to BARDA PO/CO.

 

		WBS 2	Option Period Statement of Work – Pivotal Trials in Gottingen Mini-Pigs (CLIN 0002)

 

WBS 2.1 Program Management

 

		WBS 2.1.1	Technical and Project Management

 

		WBS 2.1.1.1	Option Project Management

  

WBS 2.2 Reserved

 

WBS 2.3 Non-Clinical Studies

 

		WBS 2.3.1	Reserved

 

		WBS 2.3.2	Reserved

 

		WBS 2.3.3	Efficacy Studies

 

		WBS 2.3.3.1	Two Pivotal Efficacy Studies: Mini-Pig (Gottingen)

 

Objective/Description of Work:

 

Show efficacy under the Animal Rule, [***], test for efficacy of NXB under GLP conditions in accordance with the Animal Rule.

 

Note; The size of the pivotal trials is subject to sample size calculations that will be done based on the efficacy studies results in CLIN 1.

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

WBS 2.4 Reserved

 

WBS 2.5 Regulatory

 

		WBS 2.5.1	Reserved

 

		WBS 2.5.2	BLA

  

		WBS 2.5.2.1	Regulatory Gap Analysis

 

Objective/Description of Work:

 

As part of the BLA preparation, a gap analysis will be prepared to ensure that the data available are adequate, complete and meet FDA requirements, MediWound will perform a gap analysis by subject matter experts.

 

 78

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Milestones/Deliverables:

 

Submit gap analysis to BARDA PO/CO.

 

		WBS 2.5.2.2	Pre-BLA Meeting

 

Objective/Description of Work:

 

Prior to BLA submission, MediWound plans a pre-BLA meeting with the FDA.

 

Milestones/Deliverables:

 

Submit meeting minutes to BARDA PO/CO.

 

		WBS 2.5.2.3	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Submit request to FDA.

 

		WBS 2.5.2.4	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Submit application to FDA.

 

		WBS 2.5.2.5	Preparation and Submission of BLA

  

Objective/Description of Work:

 

MediWound plans on submitting BLA for NexoBrid approval when development is complete. MediWound will work closely with regulatory consultants to prepare CTD modules, file compilation and submission of electronic CTD. Following BLA submission MediWound will prepare responses to FDA comments as applicable.

 

Milestones/Deliverables:

 

Submission of BLA to FDA.

 

		WBS 2.5.3	Post-Approval

 

		WBS 2.5.3.1	MCI Support Under Animal Rule – Data Collection and Reporting Plan

  

Objective/Description of Work:

 

Under the Animal Rule, “some safety concerns may not become apparent until the drug is used in the general population during an actual event. Examples include the potential for drug-drug interactions and adverse interactions between the drug and a disease (preexisting or agent-induced). Such adverse interactions reinforce the critical need for post-marketing studies.”

 

In accordance with this guidance, MediWound will prepare a plan to determine what data could be feasibly collected under an MCI.

 

Milestones/Deliverables:

 

Submission of plan to BARDA.

 

 79

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

WBS 3        Option Period Statement of Work - Proof of Concept Studies - Hairless Guinea Pig Model (CLIN 0003)

 

WBS 3.1 Program Management

 

Option project management.

 

WBS 3.2 Non-Clinical Toxicology

 

		WBS 3.2.1	PK/PD

 

		WBS 3.2.1.1	Bioanalytical Methods Development: Hairless guinea pig

 

Objective/Description of Work:

 

Adapt existing bioanalytical methods for NXB to model. Validate methods for GLP use per ICH method validation guidance.

 

Milestones/Deliverables:

 

Complete method development and validation and submit protocol and report to BARDA.

 

		WBS 3.2.1.2	PK Studies: Hairless guinea pig

 

Objective/Description of Work:

 

Conduct PK study for this model. [***]

 

Milestones/Deliverables:

 

Complete study and submit report to BARDA.

 

WBS 3.3 Non-Clinical Pharmacology

 

		WBS 3.3.1	Animal Model Development

 

		WBS 3.3.1.1	SM Exposure [***] Wound Depth: Hairless guinea pig

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

		WBS 3.3.1.2	Statistical Support

 

Provide statistical analysis support as needed for nonclinical studies.

 

		WBS 3.3.2	Proof of Concept Studies

 

		WBS 3.3.2.1	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA.

 

 80

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		WBS 3.3.2.2	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

		WBS 3.3.2.3	POC Efficacy Study: Hairless guinea pig

 

Objective/Description of Work:

 

Using the exposure and treatment scenarios as determined in earlier studies, this study will aim at determining the efficacy of NexoBrid in a non-GLP study.

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA.

 

WBS 3.4 Reserved

 

WBS 3.5 Regulatory

 

		WBS 3.5.1	IND

 

		WBS 3.5.1.1	Reserved

 

		WBS 3.5.1.2	Reserved

 

		WBS 3.5.1.3	Reserved

 

		WBS 3.5.1.4	End of Phase 2 Meeting

 

Objective/Description of Work:

 

Conduct EOP2 meeting with FDA.

 

Milestones/Deliverables:

 

Conduct meeting, submit minutes to BARDA PO/CO.

 

WBS 4        Option Period Statement of Work - Pivotal Trial in Hairless Guinea Pig (CLIN 0004)

 

WBS 4.1 Program Management

 

Option project management.

 

WBS 4.2 Reserved

 

WBS 4.3 Non-Clinical Pharmacology

 

		WBS 4.3.1	Reserved

 

		WBS 4.3.2	Reserved

 

		WBS 4.3.3	Efficacy Studies

 

		WBS 4.3.3.1	Pivotal Efficacy Study: Hairless guinea pig

 

Objective/Description of Work:

 

Show efficacy under the Animal Rule, [***] of NXB under GLP conditions in accordance with the Animal Rule.

 

 81

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Note; The size of the pivotal trials is subject to sample size calculations that will be done based on the efficacy studies results in CLIN 3.

 

Milestones/Deliverables:

 

Complete study and submit protocol and report to BARDA

 

WBS 4.4 Reserved

 

WBS 4.5 Regulatory

 

		WBS 4.5.1	Reserved

 

		WBS 4.5.2	BLA

 

		WBS 4.5.2.1	Regulatory Gap Analysis

 

Objective/Description of Work:

 

As part of the BLA preparation, a gap analysis will be prepared to ensure that the data available are adequate, complete and meet FDA requirements, MediWound will perform a gap analysis by subject matter experts.

 

Milestones/Deliverables:

 

Submit gap analysis to BARDA PO/CO.

 

		WBS 4.5.2.2	Pre-BLA Meeting

 

Objective/Description of Work:

 

Prior to BLA submission, MediWound plans a pre-BLA meeting with the FDA.

 

Milestones/Deliverables:

 

Submit meeting minutes to BARDA PO/CO.

 

		WBS 4.5.2.3	Preparation and Submission of BLA

 

Objective/Description of Work:

 

MediWound plans on submitting BLA for NexoBrid approval when development is complete. MediWound will work closely with regulatory consultants to prepare CTD modules, file compilation and submission of electronic CTD. Following BLA submission MediWound will prepare responses to FDA comments as applicable. This task is to include the additional data generated for the hairless guinea pig animal model.

 

Milestones/Deliverables:

 

Submission of BLA to FDA.

 

		WBS 4.5.2.4	Reserved

 

		WBS 4.5.2.5	[***]

 

Objective/Description of Work:

 

[***]

 

Milestones/Deliverables:

 

Submit request to FDA.

 

 82

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		WBS 5	Option Period Statement of Work – [***] (CLIN0004)

 

WBS 5.1 Technical and Project Management

 

Option Management

 

WBS 5.2 Reserved

 

WBS 5.3 Reserved

 

WBS 5.4 Reserved

 

WBS 5.5 Reserved

 

WBS 5.6 CMC

 

		WBS 5.6.1	Reserved

 

		WBS 5.6.2	Reserved

 

		WBS 5.6.3	Packaging Development

 

		WBS 5.6.3.1	Feasibility for new container/closure system for efficient & ease of use in MCI

 

Objective/Description of Work:

 

Conduct feasibility [***] for finished product container/closure packaging.

 

Milestones/Deliverables:

 

Complete study and submit feasibility study report to BARDA.

 

		WBS 5.6.3.2	Develop new container/closure system for efficient & ease of use in MCI

 

Objective/Description of Work:

 

Develop new dual-chamber container/closure system frangible pouch for finished product container/closure packaging.

 

Milestones/Deliverables:

 

Complete development, batch manufacturing and stability and submit report to BARDA.

 

		WBS 5.6.4	Reserved

 

		WBS 5.6.5	Analytical / Validation

 

		WBS 5.6.5.1	RT Stability

 

Objective/Description of Work:

 

[***] ICH stability study in current configuration.

 

Milestones/Deliverables:

 

Submit report to BARDA. 

 

ATTACHMENT #2 

INVOICE/FINANCING REQUEST INSTRUCTIONS - FOR COST-REIMBURSEMENT TYPE CONTRACTS 

Format: Payment requests shall be submitted on the Contractor’s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include a cover letter with the payment request.

 

 83

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Number of Copies: Payment requests shall be submitted in the quantity specified in the Invoice Submission Instructions in SECTION G of the Contract Schedule. 

Frequency: Payment requests shall not be submitted more frequently than once every two weeks in accordance with the Allowable Cost and Payment Clause incorporated into this contract. Small business concerns may submit invoices/financing requests more frequently than every two weeks when authorized by the Contracting Officer. 

Cost Incurrence Period: Costs incurred must be within the contract performance period or covered by pre-contract cost provisions. 

Billing of Costs Incurred: If billed costs include (1) costs of a prior billing period, but not previously billed, or (2) costs incurred during the contract period and claimed after the contract period has expired, the Contractor shall site the amount(s) and month(s) in which it incurred such costs. 

Contractor’s Fiscal Year: Payment requests shall be prepared in such a manner that the Government can identify costs claimed with the Contractor’s fiscal year. 

Currency: All government contracts are expressed in United States dollars. When the Government pays in a currency other than United States dollars, billings shall be expressed, and payment by the Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract may not exceed the United States dollars authorized. 

Costs Requiring Prior Approval: Costs requiring the Contracting Officer’s approval, including those set forth in an Advance Understanding in the contract, shall be identified and reference the Contracting Officer’s Authorization (COA) Number. In addition, the Contractor shall show any cost set forth in an Advance Understanding as a separate line item on the payment request. 

Invoice/Financing Request Identification: Each payment request shall be identified as either: 

(a)           Interim Invoice/Contract Financing Request: These are interim payment requests submitted during the contract performance period. 

(b)          Completion Invoice: The completion invoice shall be submitted promptly upon completion of the work, but no later than one year from the contract completion date, or within 120 days after settlement of the final indirect cost rates covering the year in which the contract is physically complete (whichever date is later). The Contractor shall submit the completion invoice when all costs have been assigned to the contract and it completes all performance provisions. 

(c)           Final Invoice: A final invoice may be required after the amounts owed have been settled between the Government and the Contractor (e.g., resolution of all suspensions and audit exceptions). 

Preparation and Itemization of the Invoice/Financing Request: The Contractor shall furnish the information set forth in the instructions below. The instructions are keyed to the entries on the Sample Invoice/Financing Request. 

(a)           Designated Billing Office Name and Address: Enter the designated billing office name and address, as identified in the Invoice Submission Instructions in SECTION G of the Contract Schedule. 

(b)           Contractor’s Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number: Show the Contractor’s name and address exactly as they appear in the contract, along with the name, title, phone number, and e-mail address of the person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer, to whom payment is to be sent. Provide the Contractor’s Vendor Identification Number (VIN), and Data Universal Numbering System (DUNS) number or DUNS+4. The DUNS number must identify the Contractor’s name and address exactly as stated on the face page of the contract. When an approved assignment has been made by the Contractor, or a different payee has been designated, provide the same information for the payee as is required for the Contractor (i.e., name, address, point of contact, VIN, and DUNS). 

(c)           Invoice/Financing Request Number: Insert the appropriate serial number of the payment request. Include numbering in format of year_month #. 

(d)           Date Invoice/Financing Request Prepared: Insert the date the payment request is prepared. 

(e)           Contract Number and Order Number (if applicable): Insert the contract number and order number (if applicable). 

(f)            Effective Date: Insert the effective date of the contract or if billing under an order, the effective date of the order. 

(g)           Total Estimated Cost of Contract/Order: Insert the total estimated cost of the contract, exclusive of fixed-fee. If billing under an order, insert the total estimated cost of the order, exclusive of fixed-fee. For incrementally funded contracts/orders, enter the amount currently obligated and available for payment. 

(h)           Total Fixed-Fee: Insert the total fixed-fee (where applicable) or the portion of the fixed-fee applicable to a particular invoice as defined in the contract. 

(i)            Two-Way/Three-Way Match: Identify whether payment is to be made using a two-way or three-way match. To determine required payment method, refer to the Invoice Submission Instructions in SECTION G of the Contract Schedule. 

(j)            Office of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission Instructions in SECTION G of the Contract Schedule. 

(k)           Central Point of Distribution: Insert the Central Point of Distribution, as identified in the Invoice Submission Instructions in SECTION G of the Contract Schedule. 

(l)            Billing Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred and for which reimbursement is claimed. 

 

 84

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

(m)           Amount Billed - Current Period: Insert the amount claimed for the current billing period by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item. 

(n)           Amount Billed - Cumulative: Insert the cumulative amounts claimed by major cost element, including any adjustments and fixed-fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include a separate breakdown (by major cost element) for each line item. 

(o)           Direct Costs: Insert the major cost elements. For each element, consider the application of the paragraph entitled “Costs Requiring Prior Approval” on page 1 of these instructions. 

(1)       Direct Labor: Include salaries and wages paid (or accrued) for direct performance of the contract. List individuals by name, title/position, hourly/annual rate, level of effort (actual hours or % of effort), breakdown by task performed by personnel, and amount claimed.

(2)       Fringe Benefits: List any fringe benefits applicable to direct labor and billed as a direct cost. Do not include in this category fringe benefits that are included in indirect costs. 

(3)       Accountable Personal Property: Include any property having a unit acquisition cost of $5,000 or more, with a life expectancy of more than two years, and sensitive property regardless of cost see the HHS Contractor’s Guide for Control of Government Property (http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&cad=rja&uact=8&ved=0CB4QFjAA&url=http%3A%2F%2Fncioa.cancer.gov%2Foa-internet%2Freference%2FAppendix_Q_HHS_Contracting_Guide-508.pdf&ei=NRraVO6WGsqAygTz7oL4Cw&usg=AFQjCNG-0KqILRbM1IgEntH08pUZhXTV4A&sig2=XUvZkNK95EJ7uvFs0A83ig)(e.g. personal computers). Note this is not permitted for reimbursement without pre-authorization from the CO. 

On a separate sheet of paper attached to the payment request, list each item for which reimbursement is requested. Include reference to the following (as applicable): 

- Item number for the specific piece of equipment listed in the Property Schedule, and 

- COA number, if the equipment is not covered by the Property Schedule. 

The Contracting Officer may require the Contractor to provide further itemization of property having specific limitations set forth in the contract. 

(4)       Materials and Supplies: Include all consumable material and supplies regardless of amount. Detailed line-item breakdown (e.g. receipts, quotes, etc.) is required. 

(5)       Premium Pay: List remuneration in excess of the basic hourly rate. 

(6)       Consultant Fee: List fees paid to consultants. Identify consultant by name or category as set forth in the contract or COA, as well as the effort (i.e., number of hours, days, etc.) and rate billed. 

(7)       Travel: Include domestic and foreign travel. Foreign travel is travel outside of Canada, the United States and its territories and possessions. However, for an organization located outside Canada, the United States and its territories and possessions, foreign travel means travel outside that country. Foreign travel must be billed separately from domestic travel. 

(8)       Subcontract Costs: List subcontractor(s) by name and amount billed. Provide subcontract invoices/receipts as backup documentation. If subcontract is of the cost-reimbursement variety, detailed breakdown will be required. Regardless, include backup documentation (e.g. subcontractor invoices, quotes, etc.). 

(9)       Other: Include all other direct costs not fitting into an aforementioned category. If over $1,000, list cost elements and dollar amounts separately. If the contract contains restrictions on any cost element, that cost element must be listed separately. 

(p)           Cost of Money (COM): Cite the COM factor and base in effect during the time the cost was incurred and for which reimbursement is claimed, if applicable. 

(q)           Indirect Costs: Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost category. 

(r)           Fixed-Fee: Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be claimed as provided for by the contract. 

(s)           Total Amounts Claimed: Insert the total amounts claimed for the current and cumulative periods. 

(t)           Adjustments: Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals subject to appeal. 

(u)           Grand Totals 

(v)           Certification of Salary Rate Limitation: If required by the contract (see Invoice Submission Instructions in the Contract Schedule), the Contractor shall include the following certification at the bottom of the payment request: 

“I hereby certify that the salaries billed in this payment request are in compliance with the HHS Salary Rate Limitation Provisions in Section H of the contract.” 

**Note the Contracting Officer may require the Contractor to submit detailed support for costs claimed on payment requests. Every cost must be determined to be allocable, reasonable, and allowable per FAR Part 31.

 

 85

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment 3-SAMPLE INVOICE/PAYMENT REQUEST AND CONTRACT FINANCIAL REPORT 

	
(a)       Designated Billing Office Name and Address:

 

DHHS/OS/ASPR/AMCG

Attn: Contracting Officer

US DEPT OF HEALTH & HUMAN SERVICES

ASST SEC OF PREPAREDNESS & RESPONSE

ACQ MGMT, CONTRACTS, & GRANTS

O’NEILL HOUSE OFFICE BUILDING

Washington DC 20515

 

(b)       Contractor’s Name, Address, Point of Contact, VIN, and DUNS or DUNS+4 Number:

 

ABC CORPORATION

100 Main Street

Anywhere, USA Zip Code

 

Name, Title, Phone Number, and E-mail Address of person to notify in the event of an improper invoice or, in the case of payment by method other than Electronic Funds Transfer, to whom payment is to be sent.

 

VIN: 

DUNS or DUNS+4: 

 

	
(c)       Invoice/Financing Request No.:

 

(d)       Date Invoice Prepared:

 

(e)       Contract No. and Order No. (if applicable): ___________________

 

 

(f)       Effective Date:

 

(g)       Total Estimated Cost of Contract/Order:

 

(h)       Total Fixed-Fee (if applicable):

(i)        ☐Two-Way Match: 

  ☐Three-Way Match: 

 

(j)        Office of Acquisitions:

 

(k)       Central Point of Distribution:

	(l) This invoice/financing request represents reimbursable costs for the period from ______ to 
	
Expenditure Category*

A

	Cumulative Percentage of Effort/Hrs.	Amount Billed	
Cost at

Completion

F

	
Contract

Amount

G

	
Variance

H

	
Negotiated

B

	
Actual

C

	
(m)

Current

D

	
(n) Cumulative

E

	(o) Direct Costs:	 	 	 	 	 	 	 
	 (1) Direct Labor 	 	 	 	 	 	 	 
	 (2) Fringe Benefits	 	 	 	 	 	 	 
	 (3) Accountable Property	 	 	 	 	 	 	 
	 (4) Materials & Supplies	 	 	 	 	 	 	 
	 (5) Premium Pay	 	 	 	 	 	 	 
	 (6) Consultant Fees 	 	 	 	 	 	 	 
	 (7) Travel 	 	 	 	 	 	 	 
	 (8) Subcontracts 	 	 	 	 	 	 	 
	 (9) Other	 	 	 	 	 	 	 
	Total Direct Costs	 	 	 	 	 	 	 
	(p) Cost of Money	 	 	 	 	 	 	 
	(q) Indirect Costs	 	 	 	 	 	 	 
	(r) Fixed Fee	 	 	 	 	 	 	 
	(s) Total Amount Claimed	 	 	 	 	 	 	 
	(t) Adjustments	 	 	 	 	 	 	 
	(u) Grand Totals	 	 	 	 	 	 	 
	I certify that all payments are for appropriate purposes and in accordance with the contract.	 
	 	 	 	 	 	 	 	 	 	 	 	 
	 	(Name of Official)	 	(Title)	 	 	 	 	 
	
 

* Attach details as specified in the contract

 

 86

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

  

Attachment 4

	
 

 

FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT

	Project Task:	
Contract No.:

 

	Date of Report:	
0990-0134

0990-0131

	
Note: Complete this Form in Accordance with

Accompanying Instructions.

	
Reporting Period:

 

 

	
Contractor Name and Address:

 

 

 

 

	Expenditure Category	
Percentage of Effort/Hours

 

	Cumulative Incurred Cost at End of Prior Period	Incurred Cost--Current Period	Cumulative Cost to Date (D + E)	Estimated Cost to Complete	Estimated Cost at Completion (F + G) 	Negotiated Contract Amount	Variance (Over or Under) (I - H)
	Negotiated	Actual
	A	B	C	D	E	F	G	H	I	J
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 

 

 87

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment 5 

INSTRUCTIONS FOR COMPLETING 

“FINANCIAL REPORT OF INDIVIDUAL PROJECT/CONTRACT” 

 

GENERAL INFORMATION 

Purpose. This Quarterly Financial Report is designed to: (1) provide a management tool for use by the Government in monitoring the application of financial and personnel resources to the BARDA funded contracts; (2) provide contractors with financial and personnel management data which is usable in their management processes; (3) promptly indicate potential areas of contract underruns or overruns by making possible comparisons of actual performance and projections with prior estimates on individual elements of cost and personnel; and (4) obtain contractor’s analyses of cause and effect of significant variations between actual and prior estimates of financial and personnel performance.

 

REPORTING REQUIREMENTS

 

Scope. The specific cost and personnel elements to be reported shall be established by mutual agreement prior to award. The Government may require the contractor to provide detailed documentation to support any element(s) on one or more financial reports.

 

Number of Copies and Mailing Address. An original and two (2) copies of the report(s) shall be sent to the contracting officer at the address shown on the face page of the contract, no later than 30 working days after the end of the period reported. However, the contract may provide for one of the copies to be sent directly to the Contracting Officer’s Representative.

 

REPORTING STATISTICS

 

A modification which extends the period of performance of an existing contract will not require reporting on a separate quarterly report, except where it is determined by the contracting officer that separate reporting is necessary. Furthermore, when incrementally funded contracts are involved, each separate allotment is not considered a separate contract entity (only a funding action). Therefore, the statistics under incrementally funded contracts should be reported cumulatively from the inception of the contract through completion.

 

Definitions and Instructions for Completing the Quarterly Report. For the purpose of establishing expenditure categories in Column A, the following definitions and instructions will be utilized. Each contract will specify the categories to be reported.

 

		(1)	Key Personnel. Include key personnel regardless of annual salary rates. All such individuals should be listed by names and job titles on a separate line including those whose salary is not directly charged to the contract but whose effort is directly associated with the contract. The listing must be kept up to date.

 

		(2)	Personnel--Other. List as one amount unless otherwise required by the contract.

 

		(3)	Fringe Benefits. Include allowances and services provided by the contractor to employees as compensation in addition to regular salaries and wages. If a fringe benefit rate(s) has been established, identify the base, rate, and amount billed for each category. If a rate has not been established, the various fringe benefit costs may be required to be shown separately. Fringe benefits which are included in the indirect cost rate should not be shown here.

  

		(4)	Accountable Personal Property. Include nonexpendable personal property with an acquisition cost of $1,000 or more and with an expected useful life of two or more years, and sensitive items regardless of cost. Form HHS 565, “Report of Accountable Property,” must accompany the contractor’s public voucher (SF 1034/SF 1035) or this report if not previously submitted. See “Contractor’s Guide for Control of Government Property.”

 

		(5)	Supplies. Include the cost of supplies and material and equipment charged directly to the contract, but excludes the cost of nonexpendable equipment as defined in (4) above.

 

		(6)	Inpatient Care. Include costs associated with a subject while occupying a bed in a patient care setting. It normally includes both routine and ancillary costs.

 

		(7)	Outpatient Care. Include costs associated with a subject while not occupying a bed. It normally includes ancillary costs only.

 

		(8)	Travel. Include all direct costs of travel, including transportation, subsistence and miscellaneous expenses. Travel for staff and consultants shall be shown separately. Identify foreign and domestic travel separately. If required by the contract, the following information shall be submitted: (i) Name of traveler and purpose of trip; (ii) Place of departure, destination and return, including time and dates; and (iii) Total cost of trip.

 

 88

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

		(9)	Consultant Fee. Include fees paid to consultant(s). Identify each consultant with effort expended, billing rate, and amount billed.

 

		(10)	Premium Pay. Include the amount of salaries and wages over and above the basic rate of pay.

 

		(11)	Subcontracts. List each subcontract by name and amount billed.

 

		(12)	Other Costs. Include any expenditure categories for which the Government does not require individual line item reporting. It may include some of the above categories.

 

		(13)	Overhead/Indirect Costs. Identify the cost base, indirect cost rate, and amount billed for each indirect cost category.

 

		(14)	General and Administrative Expense. Cite the rate and the base. In the case of nonprofit organizations, this item will usually be included in the indirect cost.

 

		(15)	Fee. Cite the fee earned, if any.

 

		(16)	Total Costs to the Government.

 

PREPARATION INSTRUCTIONS 

 

These instructions are keyed to the Columns on the Quarterly Report.

 

Column A--Expenditure Category. Enter the expenditure categories required by the contract.

 

Column B--Percentage of Effort/Hours Negotiated. Enter the percentage of effort or number of hours agreed to during contract negotiations for each labor category listed in Column A.

 

Column C--Percentage of Effort/Hours-Actual. Enter the cumulative percentage of effort or number of hours worked by each employee or group of employees listed in Column A.

 

Column D--Cumulative Incurred Cost at End of Prior Period. Enter the cumulative incurred costs up to the end of the prior reporting period. This column will be blank at the time of the submission of the initial report. 

 

Column E--Incurred Cost-Current Period. Enter the costs which were incurred during the current period.

 

Column F--Cumulative Incurred Cost to Date. Enter the combined total of Columns D and E.

 

Column G--Estimated Cost to Complete. Make entries only when the contractor estimates that a particular expenditure category will vary from the amount negotiated. Realistic estimates are essential.

 

Column H--Estimated Costs at Completion. Complete only if an entry is made in Column G.

 

Column I--Negotiated Contract Amount. Enter in this column the costs agreed to during contract negotiations for all expenditure categories listed in Column A.

 

Column J--Variance (Over or Under). Complete only if an entry is made in Column H. When entries have been made in Column H, this column should show the difference between the estimated costs at completion (Column H) and negotiated costs (Column I). When a line item varies by plus or minus 10 percent, i.e., the percentage arrived at by dividing Column J by Column I, an explanation of the variance should be submitted. In the case of an overrun (net negative variance), this submission shall not be deemed as notice under the Limitation of Cost (Funds) Clause of the contract.

  

Modifications. List any modification in the amount negotiated for an item since the preceding report in the appropriate cost category. 

Expenditures Not Negotiated. List any expenditure for an item for which no amount was negotiated (e.g., at the discretion of the contractor in performance of its contract) in the appropriate cost category and complete all columns except for I. Column J will of course show a 100 percent variance and will be explained along with those identified under J above.

 

 89

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment 6 

INCLUSION ENROLLMENT REPORT

  

This report format should NOT be used for data collection from study participants

	 	 	 	 	 	 
	
Study Title:

 

	Total Enrollment:	Protocol Number:
	Contract Number:	 
	PART A.  TOTAL ENROLLMENT REPORT: Number of Subjects Enrolled to Date (Cumulative) by Ethnicity and Race
	
 

Ethnic Category

	Sex/Gender
	 	Females	Males	Unknown or

Not Reported	Total
	Hispanic or Latino	 	 	 	 
	Not Hispanic or Latino	 	 	 	 
	Unknown (Individuals not reporting ethnicity)	 	 	 	 
	Ethnic Category:  Total of All Subjects*	 	 	 	 
	Racial Categories	 
	American Indian/Alaska Native	 	 	 	 
	Asian	 	 	 	 
	Native Hawaiian or Other Pacific Islander	 	 	 	 
	Black or African American	 	 	 	 
	White	 	 	 	 
	More than one race	 	 	 	 
	Unknown or not reported	 	 	 	 
	Racial Categories:  Total of All Subjects*	 	 	 	 
	 
	PART B.  HISPANIC ENROLLMENT REPORT: Number of Hispanics or Latinos Enrolled to Date (Cumulative)
	Racial Categories	Females	Males	Unknown or

Not Reported	Total
	American Indian or Alaska Native	 	 	 	 
	Asian	 	 	 	 
	Native Hawaiian or Other Pacific Islander	 	 	 	 
	Black or African American	 	 	 	 
	White	 	 	 	 
	More Than One Race	 	 	 	 
	Unknown or not reported	 	 	 	 
	Racial Categories:  Total of Hispanics or Latinos**	 	 	 	 
	
*These totals must agree

**These totals must agree

	 	 	 	 

 

 

 90

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment 7 - Research Patient Care Costs

 

Research Patient Care Costs

 

(a)        Research patient care costs are the costs of routine and ancillary services provided to patients participating in research programs described in this contract.

(b)        Research patient care costs shall be computed in a manner consistent with the principles and procedures used by the Medicare Program for determining the part of Medicare reimbursement based on reasonable costs. The Diagnostic Related Group (DRG) prospective reimbursement method used to determine the remaining portion of Medicare reimbursement shall not be used to determine research patient care costs. Research patient care rates or amounts shall be established by the Secretary of HHS or his/her duly authorized representative.

(c)        Prior to submitting an invoice for research patient care costs under this contract, the contractor must make every reasonable effort to obtain third party payment, where third party payors (including Government agencies) are authorized or are under a legal obligation to pay all or a portion of the charges incurred under this contract for research patient care.

(d)        The contractor must maintain adequate procedures to identify those research patients participating in this contract who are eligible for third party reimbursement.

(e)        Only those charges not recoverable from third party payors or patients and which are consistent with the terms and conditions of the contract are chargeable to this contract.

 

 91

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

Attachment 8 - Report of Government Owned, Contractor Held Property

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	REPORT OF GOVERNMENT OWNED, CONTRACTOR HELD PROPERTY
	CONTRACTOR:	CONTRACT NUMBER:
	ADDRESS:	REPORT DATE:
	ADDRESS1:	 
	ADDRESS2:	FISCAL YEAR:
	CITY:	 
	STATE:
	ZIP:	 	 	 
	CLASSIFICATION	BEGINNING OF 

PERIOD	ADJUSTMENTS	END OF PERIOD
	 	#ITEMS	VALUE	GFP 

ADDED	CAP 

ADDED	DELETIONS	#ITEMS	VALUE
	LAND >=$25K	 	 	 	 	 	 	 
	LAND <$25K	 	 	 	 	 	 	 
	OTHER REAL >=$25K	 	 	 	 	 	 	 
	OTHER REAL <$25K	 	 	 	 	 	 	 
	
PROPERTY UNDER CONST

>=$25K

	 	 	 	 	 	 	 
	
PROPERTY UNDER CONST

<$25K

	 	 	 	 	 	 	 
	PLANT EQUIP >=$25K	 	 	 	 	 	 	 
	PLANT EQUIP <$25K	 	 	 	 	 	 	 
	SPECIAL TOOLING >=$25K	 	 	 	 	 	 	 
	SPECIAL TOOLING <$25K	 	 	 	 	 	 	 
	SPECIAL TEST EQUIP >=$25K	 	 	 	 	 	 	 
	SPECIAL TEST EQUIP <$25K	 	 	 	 	 	 	 
	AGENCY PECULIAR >=$25K	 	 	 	 	 	 	 
	AGENCY PECULIAR <$25K	 	 	 	 	 	 	 
	
MATERIAL >=$25K (CUMULATIVE)

	 	 	 	 	 
	
PROPERTY UNDER MFR >=$25K

	 	 	 	 	 	 	 
	
PROPERTY UNDER MFR <$25K

	 	 	 	 	 	 	 
	SIGNED BY:	 
	
 

SIGNATURE

 

	 	
 

DATE SIGNED:

	 
	
 

NAME PRINTED

 

	 	
 

Email

	 
	
 

TITLE

 

	 	
 

TELEPHONE

	 

 

Report of Government Owned, Contractor Held Property (Rev 10/2014)

 

 92

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Confidential Treatment Requested by Mediwound Ltd.

 

End of Contract No. HHSO100201800023C

 

 

 93

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.Exhibit 4.20

Addendum to Unprotected Sublease Contract dated March 18th, 2018

 made and signed in Tel Aviv on February 3rd, 2019

	Between:	
CLAL LIFE SCIENCES Limited Partnership (registered partnership 55-020837-5)

At 132 Derech Menachem Begin street, Azrieli Center, Triangular Tower, Tel Aviv

(hereinafter – the "Lessor")

on the one hand

	And:	
MEDIWOUND LTD (public company 512894940)

At 42 Hayarkon street Yavne

(hereinafter – the "Lessee")

on the other hand

 

	Whereas	
on 18.03.2018, an unprotected sublease contract was signed between the Lessor and the Lessee (the "Lease Agreement") in relation to the leasehold as defined in the Lease Agreement, which is located at parcel 3 on block 4939 in Yavne Industrial Zone including the structure built on it (the "Original Leasehold"); 

 

	Whereas	
The Original Leasehold included the entire property (as defined in the Lease Agreement), except for the premises which were leased to CURETECH LTD. ("Curetech") at the same time, which are marked on the sketch hereby attached to this addendum as Appendix A, as well as 10 parking spaces which were leased to Curetech at the same time (the premises which were leased to Curetech Ltd. as specified in Appendix A and the said parking spaces will be hereinafter jointly called – the "Rest of The Property ");

 

	And Whereas	
the lease of Curetech ended on 31.12.2018 and the Lessee turned to the Lessor requesting to hire the Rest of The Property as well, commencing on 1.1.2019, in its condition as-is, so that the Lessee will hire the property as a whole, without exception, and the Lessor granted the request of the Lessee, all in accordance with and subject to the terms of this addendum as specified below;

Now, therefore, it is declared, stipulated and agreed between the parties as follows:

 

	1.	

General

 

		1.1.	
The introduction to this addendum becomes an integral part hereof.

 

		1.2.	
The captions of the addendum articles are for orientation and convenience purposes only, they are not part of the addendum and they will not be used for its interpretation.

 

 

		1.3.	
This addendum becomes an integral part of the Lease Agreement and unless provided otherwise, all of its terms will be construed as defined in the Lease Agreement.

 

		1.4.	
This addendum will come into force only after the parties sign it.

 

		1.5.	
All provisions of the Lease Agreement which were not explicitly changed in accordance with the contents of this addendum, will continue binding the parties, mutatis mutandis. 

 

	2.	

The transaction 

 

		2.1	
Commencing on January 1st, 2019 (the "Effective Date"), the Lessee hires from the Lessor, and the Lessor rents to the Lessee, within an unprotected sublease, the Rest of The Property as well, in accordance with the provisions of this addendum.

 

		2.2	
The Rest of The Property was delivered to the Lessee on the Effective Date in its condition as-is, and the Lessee confirms that it has been given the option to see and to examine the Rest of The Property within a reasonable lessee's examination, as well as any detail which can influence its decision to hire the Rest of The Property, and that it found the Rest of The Property suitable for its goal and needs, and that it waives any claim regarding a discrepancy and/or a fault in the Rest of The Property, except for a discrepancy or hidden defects which were known to the Lessor prior to the signing of this Agreement and which were not disclosed by it. 

 

		2.3	
 The lease period in respect of the Rest of The Property will begin on the Effective Date and it will end at the completion of the Lease period or the option period (as far as it is fulfilled), as these periods are defined in the Lease Agreement. 

 

The original leasehold jointly with the Rest of The Property will be referred to hereinafter as the "Updated Leasehold".

 

		2.4	
Without derogating from the generality of the above stated, and for the avoidance of doubt, it is clarified that commencing on the Effective Date, the Lessee shall be the exclusive lessee and possessor of the Updated Leasehold, i.e., of the property as a whole, without exception, and the provisions of the Lease Agreement relating to the Leasehold, will relate to it commencing on the Effective Date for the Updated Leasehold, mutatis mutandis and as one piece.  

 

	3.	
The rent

 

Despite anything stated in the Lease Agreement:

 

		3.1	
The rent for the Updated Leasehold in respect of the period lasting from 1.1.2019 until 30.10.2019, will be in the amount of NIS 116,000 in respect of each month of lease. 

 

		3.2	
The rent for the Updated Leasehold in respect of the period lasting from 1.11.2019 until 30.10.2022, will be in the amount of NIS 119,000 in respect of each month of lease. 

 

- 2 -

 

		3.3	
The rent for the Updated Leasehold in respect of the option period (as much as it is extended) (i.e. in respect of the period lasting from 1.11.2022 until 30.10.2025), will be in the amount of NIS 125,500 in respect of each month of lease. 

 

		3.4	
For the avoidance of doubt, the rent as stated above will be paid in addition to VAT by its lawful rate, as well as linkage differentials in accordance with the provisions of the Lease Agreement. 

 

	4.	
The rest of the provisions of the Lease agreement which were not explicitly changed in this addendum, will continue to apply mutatis mutandis only, and with respect to the Updated Leasehold, i.e., the property as a whole, without exception. 

 

In WITNESS WHEREOF the parties have signed

at the place and on the date mentioned at the top of this contract:

          

	 

/s/ Ofer Gonen /s/ Assaf Segal   

	 /s/ Gal Cohen /s/ Sharon Malka
	Clal Life Sciences Limited Partnership          	Mediwound Ltd.

 

	
I hereby certify that the above signatures are the signatures of the Messrs.:

	
I hereby certify that the above signatures are the signatures of the Messrs.:

	
Ofer Gonen and Assaf Segal

and that these signatures legally bind the Lessor

	
Gal Cohen and Sharon Malka

and that these signatures legally bind the Lessee

	 	 
	
    /s/ Shiran Manor

   Shiran Manor, Adv.

	
   /s/ Yaron Meyer

  Yaron Meyer, Adv.

- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]